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SUMMARY 
Resistance to endocrine therapy in breast cancer is associated with poor prognosis. Cell 
models of acquired tamoxifen resistance have implicated altered growth factor receptor 
signalling, especially the ErbB family of receptor tyrosine kinases, in development of the 
accompanying aggressive phenotype. Microarray analysis of an in vitro wtMCF-7 based 
model of acquired tamoxifen resistance (‘Tam-R’) identified upregulation of CD44, a 
transmembrane glycoprotein, known to interact with ErbB receptors and influence breast 
cancer progression. We investigated the hypothesis that CD44 overexpression in Tam-R cells 
can modulate ErbB activity and promote an adverse phenotype. CD44 gene overexpression 
was validated by RT-PCR and its protein expression determined by Western blotting and 
immunocytochemistry. CD44 contribution to intracellular signalling and phenotype of Tam-R 
cells (migration, invasion and growth), both endogenous and in response to hyaluronan (HA), 
was determined using Western blotting, immunocytochemistry and functional assays 
including wound healing, Boyden chamber migration, Matrigel™ invasion and growth assays 
in the presence  or absence of siRNA-mediated CD44 knockdown. Interactions between 
CD44 and ErbB receptors were investigated using immunofluorescence and 
immunoprecipitation. CD44 was overexpressed at gene and protein level in Tam-R versus 
wtMCF-7 cells and whilst this did not influence the endogenous phenotype of Tam-R cells, it 
enhanced their sensitivity to HA as evidenced by HA-induced MAPK, EGFR and HER2 
activation and increased migration. HA-induced migration was attenuated following 
treatment with the MAPK inhibitor PD098059, gefitinib as well as trastuzumab. CD44 was 
found to associate with HER2 and HER3 at the cell surface whilst HA stimulation appeared 
to modulate ErbB dimerisation patterns. Our data suggest that CD44 overexpression 
sensitises tamoxifen-resistant cells to HA thereby modulating ErbB dimerisation and 
enhancing migration. These observations may have importance in vivo where the tumour 
microenvironment can provide a rich source of HA to promote the progression of tamoxifen-
resistant tumours. 
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Introduction 
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1.1 EPIDEMIOLOGY OF BREAST CANCER 
Breast cancer is now a major worldwide public health problem and its incidence varies 
widely within regions and countries but is highest in the more developed regions of the 
world, in urban populations and in Caucasian women (Porter 2009). More recently, there 
has been a trend of increasing incidence in Central Europe, Eastern Europe and Asia 
where traditionally the incidence has been comparatively low (Hery, Ferlay et al. 2008). 
Although the reasons for this are not yet fully understood, a number of factors have been 
suggested to play a role. Some of the reasons cited for an increase in the incidence of 
postmenopausal breast cancer in the economically developed countries include 
reproductive risk factors (such as delay in childbearing and nulliparity), weight gain, 
alcohol consumption and higher use of hormone-replacement therapy (Hesketh, Lu et al. 
2005; Kamangar, Dores et al. 2006).  
 
In the United Kingdom (UK), breast cancer is now the most commonly occurring female 
cancer and in 2010 there were 49,961 new cases of breast cancer. Of these, 49,564 (99%) 
occurred in women and 397 in men (less than 1%) resulting in a female: male ratio of 
125:1. females and this amounts to an Age-Standardised (AS) incidence rate of 125.9 per 
100,000 women (Office for National Statistics, June 2010; Welsh Cancer Intelligence and 
Surveillance Unit, 2012; Information and Statistics Division National Health Service 
(NHS) Scotland, 2012 and Northern Ireland Cancer Registry, 2012). There has been an 
overall increase in breast cancer incidence rates in the UK since the mid-1970s including 
a sharp rise in the late-1980s due to the introduction of the national screening programme, 
but since the mid-2000s, the incidence has been very stable. The recent stable trend is 
likely to be due to the reduced use of hormone-replacement therapy (HRT) which has 
been shown to increase the risk in some women (Beral 2003; Farquhar, Marjoribanks et 
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al. 2009). Overall, breast cancer is the second most common cause of cancer related 
deaths in women after lung cancer accounting for 11,556 female cancer deaths in 2010. 
However, the mortality from breast cancer in the developed nations is on the decline, 
especially in the UK (Autier, Boniol et al. 2010). It is believed that the advent of national 
screening, specialisation of care and improved therapy are responsible for this decline 
(Sant, Francisci et al. 2006). There has been a significant improvement in the clinical 
management of breast cancer through the development of endocrine therapy.  
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1.2 OESTROGENS AND BREAST CANCER 
1.2.1 Historical Context 
The first link between breast cancer and hormones was made by Albert Schinzinger who 
presented his theory at the 18
th
 Congress of German Surgeons in 1889 (Love and Philips 
2002). He observed that the outcome for breast cancer was better in older women and 
argued that oophorectomy would make younger women prematurely old, thereby causing 
atrophy of the breast and of any cancer (Schinzinger 1889). The next major development 
happened when George Thomas Beatson performed bilateral oophorectomies on two 
women with breast cancer (Beatson 1896). This influenced an English surgeon, Stanley 
Boyd, to try surgical oophorectomy as a treatment for breast cancer. He did not believe in 
the effect of thyroid extract and used oophorectomy on its own and published a paper 
about his first five patients in 1897 (Boyd 1897). Progress in this area was greatly 
influenced by the discovery of oestrogen in ‘follicular fluid’ by Allen and Doisy in 1923 
(Allen and Doisy 1983). In 1935, Professor Antoine Lacassagne postulated that if 
oestrogen secreted by the ovary was responsible for breast cancer then it should be 
possible to develop an agent to suppress this effect and he was hopeful that such an agent 
would be available soon (Lacassagne 1936). In 1962, Jensen proposed the oestrogen 
receptor (ER) as a mechanism of oestrogen action specific to target tissues (Jensen 1962).  
 
1.2.2 Oestrogens: Structure and Function 
An understanding of endocrine therapy in breast cancer needs a detailed knowledge of 
oestrogens, their receptors and the mechanism of action on breast tissue. Oestrogens 
(derived from the Greek: ‘estrus’ = sexual desire and ‘gen’ = generate) are a group of 
naturally occurring steroidal compounds which are primarily secreted by the ovaries in 
adult females and derived from cholesterol synthesis via androgen precursors (Figure 
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1.1). The three major naturally occurring oestrogens in women are oestrone (E1), 
oestradiol (E2), and oestriol (E3).  
 
Oestradiol (Figure 1.2A) is the most common form of oestrogen in humans. Luteinising 
hormone (LH) and follicle stimulating hormone (FSH) influence the ovarian follicles to 
secrete oestrogens, primarily E2 (Owen 1975). However, oestrone (E1) is the 
predominant oestrogen in postmenopausal women and breast cancer incidence is highest 
in this age group. During the menstrual cycle and pregnancy, oestrogens stimulate growth 
and development of mammary glands and this observation led scientists in the earlier 
decades to investigate the potential role of oestrogens in the development of breast cancer 
(Bulbrook 1972). There is now evidence of the link between oestrogens and the 
development and progression of human breast cancer (MacMahon 2006; Russo and 
Russo 2006). Although the exact mechanisms are less well understood, binding of 
oestrogen to its specific nuclear receptor alpha (ERα) and subsequent stimulation of 
breast cell proliferation, through its action on growth factor production, is the most 
widely accepted mechanism. Other suggested mechanisms include a direct genotoxic 
effect by increasing mutation rates through a cytochrome P450-mediated metabolic 
activation and induction of chromosome abnormality or aneuploidy (Kulendran, Salhab et 
al. 2009). The exact role of exogenous oestrogen and the risk of breast cancer is an issue 
of ongoing research. A recent Cochrane review looked at 19 trials involving 41,904 
women and concluded that in healthy women, combined continuous HRT (containing 
oestrogen and progesterone) significantly increased the risk of breast cancer whereas 
long-term oestrogen-only HRT did not significantly increase the risk of breast 
cancer.(Farquhar, Marjoribanks et al. 2009).  
 
6 
 
Figure 1.1 Pathway of reproductive hormone synthesis
Oestrogens (derived from the Greek: ‘estrus’ = sexual desire and ‘gen’ = generate) are a
group of naturally occurring steroidal compounds which are primarily secreted by the
ovaries in adult females and derived from cholesterol synthesis via androgen precursors.
Oestradiol (E2) is the most commonly occurring oestrogen. Aromatase is an enzyme that is
a member of the cytochrome P450 superfamily and is responsible for aromatisation of
androgens into oestrogens. Adapted from Tsilchorozidou et al. 2004.
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Corticosterone
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1.2.3 Oestrogen Receptor (ER) 
It is now clear that oestrogen action is primarily mediated through oestrogen receptors 
(ER), which are members of a large superfamily of nuclear receptors that function as 
ligand-activated transcription factors (Evans 1988; Beato 1989). These receptor proteins 
share a common structural and functional organisation, with several distinct domains 
(Katzenellenbogen 1996). There are two main types of ER: ER alpha (ERα) and ER beta 
(ERβ). Whilst ERα has traditionally been considered to be the main receptor involved in 
breast cancer there is now evidence to indicate that ERβ is also implicated but its exact 
role needs to be investigated further (Hartman, Strom et al. 2009). The basic domain 
structure of ERα (from here onwards referred to as ‘ER’) is shown in Figure 1.2B 
(Kumar, Zakharov et al. 2011). The N-terminal domains A and B contain transcription 
activation function (AF-1) activity. Domain C is one of the two highly conserved domains 
seen in this family of receptors which binds to DNA, called the DNA-binding domain or 
DBD (Schwabe, Chapman et al. 1993). Domain D separates the DBD from the hormone 
binding zone or ligand-binding domain (LBD) (Tanenbaum, Wang et al. 1998). Domain 
E or LBD is encoded within a domain of 250 amino acids and also contains AF-2 activity, 
the ligand–activated transcription activation zone.  
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Oestradiol (E2)
Figure 1.2 Structure of oestradiol and schematic structure of the oestrogen receptor
Oestradiol or E2 has the chemical formula C18H24O2 (A) and its actions are mediated via the
oestrogen receptor (ER) which has two main forms: ERα and ERβ. ERα is the main type
(B) and is made up of 595 amino acids and contains several domains including the N-
teminal domain (NTD), DNA-binding domain (DBD) and a ligand-binding domain (LBD).
It has two areas with transcription activation function, namely, AF-1 and AF-2. Adapted
from Kumar et al. 2011, Howell et al. 2005.
A
B
ERα
NH2 COOH
1                                        180              263    302                                                        552 595
NTD (A/B)            DBD (C)  (D)                      LBD (E)                  (F)
AF1                                                                              AF2
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1.2.4 ER Signalling 
ER signalling occurs through two general mechanisms, namely, genomic and non-
genomic (Figure 1.3). These mechanisms are described below:  
 
1.2.4.1 Genomic ER signalling 
Genomic ER signalling proceeds via ER binding to DNA in either a direct (referred to as 
the ‘classical’ mechanism) or an indirect (‘non-classical’ mechanism) manner and 
together they are known as the ‘nuclear-initiated steroid signalling’ (NISS) pathway.  
 
1. ‘Classical’ ER signalling: In the absence of oestrogen, ERs are mainly found in an 
inactive monomeric state bound to heat shock proteins in the nucleus of the cell. 
When oestradiol diffuses through the cell membrane into the nucleus and, binds to the 
LBD on the ER, it triggers receptor conformational change, phosphorylation and 
finally dimerisation (Gruber, Tschugguel et al. 2002). The ligand-receptor complex 
binds to oestrogen responsive elements (EREs) present in the promoter regions of ER 
target genes to form a complex with other transcription factors (which may act as co-
activators or co-repressors) leading to activation or suppression of gene expression.  
 
2. ‘Non-classical’ ER signalling: ER activation of genes lacking ERE sequence such as 
cyclin D1 and insulin-like growth factor 1 receptor (IGF-1R) is explained by this 
mechanism whereby ER interacts with other transcription factors rather than directly 
binding to DNA itself (Eeckhoute, Carroll et al. 2006; Maor, Mayer et al. 2006). The 
promoter elements include AP-1 sites, cyclic AMP response elements (CREs) and Sp-
1 sites and these directly bind to the transcription factors Jun/Fos, Jun/ATF-2 and Sp-
1 respectively (Sabbah, Courilleau et al. 1999; Kushner, Agard et al. 2000; Saville, 
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Wormke et al. 2000). ER interaction with these transcription factors facilitates their 
binding to DNA and, thus, indirectly promotes transcription.  
 
Oestrogen action through either of these mechanisms results in the upregulation of 
genes regulating cell proliferation and survival and the downregulation of genes with 
anti-proliferative or pro-apoptotic activity ultimately leading to stimulation of growth 
and inhibition of apoptosis (Frasor, Danes et al. 2003). Two distinct transactivation 
domains in the ER mediate gene upregulation: AF-1, which is hormone independent, 
is regulated by phosphorylation and located in the amino-terminal A/B region, and 
AF-2, which is fully hormone dependent and located in the carboxy-terminal E region 
(Tora, White et al. 1989). For ER transcriptional activity to occur, AF-1 and/or AF-2 
must be activated and either can be dominant although often there is a synergism 
between the two (Metivier, Penot et al. 2001; Osborne, Schiff et al. 2001). Oestrogen 
causes conformational ER changes which uncover AF-2 allowing for modulation by 
co-activators and co-repressors which respectively enhance or reduce transcription. 
Instead, AF-1 is activated by phosphorylation via kinases which are downstream of 
growth factor receptors such as the epidermal growth factor receptor (EGFR), human 
epidermal growth factor receptor 2 (HER2) and IGF-1R (Zilli, Grassadonia et al. 
2009). Both the ER and its associated regulatory proteins can be modulated by 
phosphorylation at various sites and this process involves numerous cellular kinases 
and introduces a further range of regulatory influences on the process of ER mediated 
transcription. The kinases implicated in this include Akt (a serine/threonine-specific 
protein kinase), mitogen activated protein kinase (MAPK) and MEK1 (kinase 
associated with MAPK) amongst others. For example, ER can be phosphorylated at 
AF-1 by MAPK (ERK1/2) which are downstream of the HER2 pathway at the serine-
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118 position (directly by ERK1/2) and serine-167 by ribosomal S6 kinase activated 
via ERK1/2 (Kato, Endoh et al. 1995; Joel, Smith et al. 1998).    
 
1.2.4.2 Non-genomic ER signalling 
Oestrogens are known to cause rapid activation of intracellular signalling molecules 
(within minutes) following cellular exposure and these actions cannot be explained in 
terms of trasnscriptional activation but have been postulated to occur through ERs located 
at the plasma membrane and localised to caveolae (Kim, Lee et al. 1999). As such, this 
pathway has been referred to as the ‘membrane-initiated steroid signalling’ (MISS) 
pathway. Association of ERs with caveolin-1 likely provides a scaffolding platform for 
complexing with several other signalling molecules including G-proteins and Src 
(Okamoto, Schlegel et al. 1998). Oestrogen directly binds to these cell surface ERs 
resulting in G-protein activation which consequently stimulates various kinases including 
MAPK, protein kinase C and phospholipase C (Razandi, Pedram et al. 2003). Oestrogen 
induced activation of MAPK occurs through transactivation of EGFR (Filardo, Quinn et 
al. 2000). This can lead to activation of other growth factors and cytoplasmic kinases 
which can then phosphorylate ER and its coregulators. 
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Figure 1.3 Mechanisms of oestrogen receptor (ER) signalling
ER signalling can proceed via genomic (classical and non-classical) and non-genomic
pathways. The classical genomic pathway (1) involves binding of the ligand-receptor
complex to EREs, whereas the non-classical genomic pathway (2) involves ER interaction
with transcription factors such as Fos, Jun without directly binding to DNA. The non-
genomic pathway (3) involves ER interaction with growth factor receptors which trigger
activation of kinases such as MAPK and Akt leading to gene activation via phosphorylation.
Adapted from Ring et al. 2004 and Nicholson et al. 2005.
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1.3 ER-TARGETED THERAPY IN BREAST CANCER  
ER is expressed in up to 75% of breast cancers and given its role in breast cancer 
proliferation it represents a potential target (Nadji, Gomez-Fernandez et al. 2005). As 
such, ER antagonists have been developed starting with tamoxifen. Tamoxifen was 
discovered by Arthur Walpole at AstraZeneca (Macclesfield, England) and was found to 
possess the properties of a selective oestrogen receptor modulator (SERM).  
 
The main categories of ER-targeted drugs that have a clinical role in the management of 
ER-positive breast cancer are discussed below: 
 
1. Selective oestrogen receptor modulators (SERMs): These agents act by inhibiting 
oestrogen binding to ER. They bind to the LBD of the ER and owing to their 
structural difference compared to ER, they induce a unique conformational change in 
the LBD which prevents the co-activator binding to AF-2 thereby inhibiting the 
transactivation function (Singh and Kumar 2005). This has no effect on the AF-1 
domain which is free to promote gene transcription thereby explaining the partial 
agonist action noted with SERMs. Tamoxifen was the first SERM in clinical use but 
others have now been developed such as toremifene, raloxifene and arzoxifene. 
However, these agents have not proved to be more efficacious than tamoxifen and 
exhibit a high level of cross-resistance with tamoxifen.  
 
Tamoxifen is a non-steroidal triphenylethylene derivative which binds to ER leading 
to conformational changes which are distinctly different to oestrogen. Oestrogen 
binds to the hydrophobic pocket of the LBD and it is sealed inside by helix 12 
resulting in AF-2 activation. In contrast, tamoxifen prevents helix 12 from sealing the 
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binding pocket (Shiau, Barstad et al. 1998). This prevents AF-2 activation due to an 
inability to bind co-activators. In genes where transcription is driven by AF-1, 
tamoxifen is found to have an agonistic effect (McDonnell, Clemm et al. 1995). Thus, 
depending on the predominance of AF-1 or AF-2 activated genes in a tissue, 
tamoxifen can exert either an agonistic or antagonistic role respectively. The tissue 
specificity of tamoxifen also depends on the expression levels of co-activators and co-
repressors in a given tissue. For example, in breast tissue tamoxifen recruits a co-
repressor complex and thus acts as an antagonist (Shang and Brown 2002).  
 
The clinical efficacy of tamoxifen in the treatment of ER-positive breast cancer is 
now well established. Current indications for tamoxifen include primary treatment of 
advanced breast cancer, standard adjuvant therapy for premenopausal patients, 
adjuvant therapy in postmenopausal patients including patients not eligible for 
aromatase inhibitors (AIs) and as part of a sequence strategy prior to switch-over to 
AIs (Mao, Yang et al. 2012; Rao and Cobleigh 2012). It is also indicated as 
preventative therapy for both high-risk premenopausal and postmenopausal patients 
and has better efficacy than raloxifene (Cuzick, DeCensi et al. 2011). This is 
discussed in detail later. 
 
2. Selective oestrogen receptor downregulators (SERDs): The search for agents with 
pure oestrogen antagonism and little or no agonistic effect has led to the development 
of the novel agent fulvestrant which has nearly the same affinity for ER as oestradiol 
(Howell and Abram 2005). Fulvestrant binds to ER monomers and inhibits 
dimerisation, inactivates AF-1 and AF-2 function, reduces ER translocation to nucleus 
and, also, accelerates ER degradation (Carlson 2005). The exact clinical role and dose 
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of fulvestrant is currently evolving. The phase III COmparisoN of Faslodex In 
Recurrent or Metastatic breast cancer (CONFIRM) study showed an improvement in 
progression-free survival (PFS) for fulvestrant 500 milligrams versus 250 milligrams 
in postmenopausal patients who had progressed on prior endocrine therapy, and, 
pooled evidence from other clinical trials have also demonstrated evidence of better 
efficacy when used at a higher dose (Howell and Sapunar 2011). ‘Fulvestrant fIRst-
line Study comparing endocrine Treatments’ (FIRST) was a phase II, randomised trial 
comparing fulvestrant (500 milligrams) with anastrozole (1 milligram) as initial 
endocrine for postmenopausal women with ER-positive advanced breast cancer 
(Robertson, Lindemann et al. 2012). It was noted that fulvestrant was associated with 
a 34% reduction in risk of progression with the median time to progression (TTP) 
being 23.4 months for fulvestrant and 13.1 months for anastrozole (p-value = 0.01). 
More importantly, overall response to subsequent endocrine therapy was comparable 
between the treatment groups. 
 
3. Aromatase inhibitors (AIs): This group of drugs inhibits the activity of the 
cytochrome P450 aromatase enzyme (Figure 1.1) responsible for production of 
oestrogen from androgens in peripheral tissues of postmenopausal women (Smith and 
Dowsett 2003). Type I steroidal drugs, such as formestane and exemestane, are 
androgen substrate analogues which bind competitively but irreversibly to the enzyme 
and are essentially ‘inactivators’. In contrast, Type II non-steroidal inhibitors, such as 
anastrozole and letrozole, are triazoles which bind reversibly to the enzyme and fit 
into the substrate binding site resulting in very good potency and specificity (Miller 
2003). The clinically relevant third generation AIs include the steroidal AI, 
16 
 
exemestane, and the non-steroidal AIs, anastrozole and letrozole (di Salle, Ornati et 
al. 1992; Yates, Dowsett et al. 1996; Bhatnagar 2007).  
 
In premenopausal patients with ER-positive breast cancer, tamoxifen at a dose of 20 
milligrams per day for 5 to 10 years is currently considered standard therapy as discussed 
in the European Society of Medical Oncology (ESMO) guidelines (Colleoni, Gelber et al. 
2006; Senkus, Kyriakides et al. 2013). In the subgroup of patients who become 
postmenopausal following 5 years of tamoxifen, letrozole for 5 years has been noted to 
improve disease-free survival (DFS) significantly (Goss, Ingle et al. 2003). Patients in 
whom tamoxifen is contraindicated can be treated using gonadotrophin-releasing 
hormone (GnRH) agonist, either alone or in combination with an AI (Cuzick, Ambroisine 
et al. 2007). 
 
There is currently huge debate about the optimal adjuvant therapy in postmenopausal 
patients with ER-positive breast cancer especially with regard to the duration and type of 
endocrine agent. Both AIs (steroidal and non-steroidal) and tamoxifen have been shown 
to be efficacious in this setting. The optimal duration of adjuvant tamoxifen therapy has 
been investigated as part of several clinical trials. Recent evidence from the ‘Adjuvant 
Tamoxifen: Longer Against Shorter’ (ATLAS) trial shows that adjuvant tamoxifen 
therapy for 10 years as opposed to 5 years leads to significant reduction in recurrence and 
mortality, particularly after the 10
th
 year (Davies, Pan et al. 2013). Results of the 
‘adjuvant Tamoxifen Treatment offer more?’ (aTTom) trial show that in ER-positive 
disease, continuing tamoxifen for 10 years instead of 5 years produces further reductions 
in recurrence, from year 7 onward, and breast cancer mortality after year 10 (Gray, Rea et 
al. 2013). A meta-analysis of randomised trials comparing 5 years of adjuvant tamoxifen 
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versus no tamoxifen performed by the Early Breast Cancer Trialists' Collaborative Group 
(EBCTCG) which included 20 trials and 21,457 patients showed that adjuvant tamoxifen 
safely reduces 15 year risks of breast cancer recurrence and death (Davies, Godwin et al. 
2011). Multiple randomised trials have now also proven the efficacy of AIs in the 
adjuvant therapy of early breast cancer including the landmark ‘Anastrozole, Tamoxifen 
Alone or in Combination’ (ATAC) trial which demonstrated improved DFS and time to 
recurrence in the anastrozole group over the tamoxifen group in ER-positive early breast 
cancer (Cuzick, Sestak et al. 2010). A meta-analysis of randomised trials of AIs compared 
with tamoxifen either as initial monotherapy (cohort 1) or after 2 to 3 years of tamoxifen 
(cohort 2) was published in 2010 (Dowsett, Cuzick et al. 2010). In cohort 1, at 5 years, AI 
therapy was associated with an absolute 2.9% decrease in recurrence (p-value < 0.00001) 
and a absolute 1.1% decrease in breast cancer mortality (p-value = 0.1). In cohort 2, at 3 
years from treatment divergence, AI therapy was associated with an absolute 3.1% 
decrease in recurrence (p-value < 0.00001) and an absolute 0.7% decrease in breast 
cancer mortality (p-value = 0.02). The authors concluded that “AIs produce significantly 
lower recurrence rates compared with tamoxifen, either as initial monotherapy or after 2 
to 3 years of tamoxifen”. Another meta-analysis examined 9 randomised trials (28,632 
women) and examined the role of AIs as an alternative to tamoxifen in the form of 
monotherapy (instead of tamoxifen), sequenced therapy (tamoxifen switched to an AI) 
and extended therapy (following 5 years of adjuvant tamoxifen) (Josefsson and Leinster 
2010). They found that DFS was significantly improved for monotherapy (p-value = 
0.002) and sequenced therapy (p-value < 0.00001). Of note, overall survival was 
prolonged for patients who switched from tamoxifen to AI therapy (p-value = 0.001) but 
no such difference in survival was noted for monotherapy (p-value = 0.39) or extended 
therapy (p-value = 0.67). Current evidence thus supports the use of AIs upfront (both 
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non-steroidal AIs and exemestane), switch over following 2 to 3 years of tamoxifen (non-
steroidal AIs and exemestane) or as part of an extended adjuvant therapy regime 
following 5 years of tamoxifen (letrozole and anastrozole) (Senkus, Kyriakides et al. 
2013).  
 
Optimal endocrine therapy in postmenopausal women with advanced ER-positive breast 
cancer is also currently being debated particularly since trials have shown conflicting 
outcomes. A recent meta-analysis examined the evidence AIs versus tamoxifen as initial 
endocrine therapy in this group of patients (Xu, Liu et al. 2011). 6 trials consisting of 
2560 patients were collectively analysed and a significantly improved overall response 
rate (ORR) and the clinical benefit rate (CBR) in favour of AIs (p-value = 0.002 and 
0.0009 respectively) was noted. No significant difference was noted in overall survival 
(OS) between the two groups (p-value = 0.10).  
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1.4 RESISTANCE TO TAMOXIFEN THERAPY 
Although there has been a significant improvement in outcomes in breast cancer through 
the use of endocrine therapy, de novo and acquired resistance to endocrine agents is a 
major limiting factor. In the adjuvant setting, nearly 25% of newly detected breast cancers 
are ER-negative and are unlikely to respond to tamoxifen therapy thus demonstrating de 
novo resistance (Nadji, Gomez-Fernandez et al. 2005). Among the remaining 75% of ER-
positive breast cancer patients, recent meta-analysis data from the EBCTCG suggests that 
approximately 33% patients (approximately 25% overall) will develop recurrence by 15 
years despite 5 years of adjuvant therapy with tamoxifen thus exhibiting acquired 
resistance (Davies, Godwin et al. 2011). Taken together, this indicates that nearly 50% 
patients in the adjuvant setting are affected by resistance to tamoxifen therapy. In the 
setting of metastatic breast cancer, recent meta-analysis evidence also shows that 
tamoxifen when used as first-line therapy produces initial clinical benefit in nearly 50% 
of patients and, even in the patients who do display an early response, eventual relapse 
due to acquired resistance is extremely common (Ring and Dowsett 2004; Xu, Liu et al. 
2011). Even more worryingly, in both the laboratory and clinical setting, tamoxifen 
resistant cell lines and tumours exhibit more aggressive behaviour. We have previously 
demonstrated that upon acquisition of tamoxifen resistance, ER-positive MCF-7 cells 
display an aggressive phenotype accompanied by higher invasiveness and motility in 
vitro (Hiscox, Morgan et al. 2004). Therefore, defining the mechanisms of tamoxifen 
resistance has recently become an area of international research interest with a view to 
improving outcomes.  
 
The exact mechanisms for tamoxifen resistance are, as yet, not fully understood although 
several key pathways and their related mechanisms have been described.  
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1.4.1 ER Expression 
Lack of ER expression is the best negative predictor for benefit from tamoxifen. 
Alterations in ER expression or activity is, therefore, likely to be important in the 
development of resistance. In fact, lack of ER expression is the most important 
mechanism for de novo tamoxifen resistance and most ER-negative tumours do not 
respond to tamoxifen (Campbell, Blamey et al. 1981; Stewart, King et al. 1982; Ring and 
Dowsett 2004). Gutierrez et al. showed that ER expression is lost in only 17% of tumours 
with acquired tamoxifen resistance (Gutierrez, Detre et al. 2005). Also, up to 20% 
patients who relapse on tamoxifen respond to AIs or fulvestrant (Howell, Robertson et al. 
2002). Loss of ER expression thus appears to be less important in the setting of acquired 
resistance. Although mutations in ERα which cause functional loss of ER activity have 
been noted in vitro, Roodi et al. showed that only 1% primary breast cancers have point 
mutations in the ER gene (Roodi, Bailey et al. 1995). This suggests that ER mutations are 
unlikely to be an important mechanism of resistance. There is conflicting evidence 
regarding the role of ERβ in tamoxifen resistance and further work is needed to elucidate 
this further.  Post-translational or transcriptional modifications of ER via splice variants 
or alteration of messenger RNA (mRNA) stability have also been implicated in resistance 
(Adams, Furneaux et al. 2007; Shi, Dong et al. 2009). 
 
1.4.2 Co-repressor and Co-activator Expression 
Co-regulator proteins play an important role in the transcriptional machinery of ER and 
alteration in their expression is now considered to be an important pathway for 
development of resistance. In an in vitro wtMCF-7 model, Shou et al. demonstrated that 
tamoxifen has an agonistic action in breast cancer cells that overexpressed ‘Amplified In 
Breast Cancer 1’ (AIB1), an ER co-activator, and this resulted in de novo resistance 
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(Shou, Massarweh et al. 2004). Osborne et al. showed that high AIB1 expression, as 
determined by Western blotting, correlated well with poor DFS in patients treated with 
tamoxifen (Osborne, Bardou et al. 2003). Experimental studies have also implicated 
another co-activator, SRC-1, and this has been linked to AI resistance in a metastatic 
setting (McBryan, Theissen et al. 2012). Downregulation or decreased activity of co-
repressors can also contribute to resistance. Lavinsky et al. have noted that decreased 
levels of the co-repressor N-CoR are linked with acquired tamoxifen resistance in a 
mouse model of human breast cancer (Lavinsky, Jepsen et al. 1998). Increased activity of 
various transcriptional factors involved in ER signalling such as AP-1 and NFkappaB has 
also been implicated in development of resistance (Zhou, Yau et al. 2007).  
 
1.4.3 Cell cycle and Apoptosis Regulators 
Both positive and negative cell cycle regulators appear to have an impact on tamoxifen 
sensitivity and resistance, in particular, positive regulators such as cyclins E1 and D1 
(Butt, McNeil et al. 2005; Chu, Hengst et al. 2008). Possible mechanisms include 
activation of cyclin dependent kinases which are critical for the G1 phase and minimising 
the role of negative cell cycle regulators such as p21 and p27. Regulators of apoptosis 
including bcl-XL, bcl2 and caspase 9 can affect tamoxifen induced apoptosis and thus 
affect its efficacy (Kumar, Mandal et al. 1996). 
 
It is worthwhile mentioning here that resistance to AIs is also an emerging problem with 
the now widespread use in both metastatic and adjuvant settings (Miller and Larionov 
2012). Unlike resistance to tamoxifen, mechanisms underlying resistance to AIs are less 
clearly understood. Data from athymic mice have pointed to a role of HER2/MAPK and 
their interaction with ER as a probable mechanism (Brodie, Macedo et al. 2010; Sabnis 
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and Brodie 2010). As with tamoxifen resistance, it is probable that multiple mechanisms 
exist and complex interplay between these various mechanisms underlies resistance. 
 
1.4.4 Cross-talk with Receptor Tyrosine Kinases (RTKs) 
ER signalling is intimately associated with growth factors and signalling pathways in a 
bi-directional fashion especially receptor tyrosine kinases (RTKs) which are high affinity 
cell surface receptors for various growth factors, hormones and cytokines. Cross-talk 
between these pathways can promote resistance as can the ability of growth factor 
signalling to provide a growth stimulus independent of ER. For example, ERα can 
transactivate IGFR, HER2 and EGFR via phosphorylation and, conversely, kinases such 
as MAPK (ERK 1/2) which are downstream of HER2 can phosphorylate ER at AF-1 
(Ring and Dowsett 2004).  
 
The ErbB family of growth factor receptors in particular have been implicated in the 
development of tamoxifen resistance. The evidence supporting the role of ErbB family in 
tamoxifen resistance and the currently available agents targeting these receptors are 
discussed in detail in Section 1.5. The evidence implicating other RTKs in tamoxifen 
resistance is less compelling compared to the ErbB family and this is discussed further in 
this section. 
 
There is accumulating evidence of synergistic interactions between IGF-1R, ER and 
EGFR/HER2. Knowlden et al. have noted IGF-1R and EGFR cross-talk in two in vitro 
models of acquired tamoxifen resistance (Knowlden, Hutcheson et al. 2005). Haluska et 
al. showed that enhanced EGFR and HER2 signalling can overcome the effects of the 
IGF-1R inhibitor in vitro and Lu et al. noted that in a HER2 overexpressing cell line, 
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increased IGF-1R signalling inhibits the action of trastuzumab (Lu, Zi et al. 2001; 
Haluska, Carboni et al. 2008). Using their MCF7/IGF-1R cell model which overexpresses 
IGF-1R, Zhang et al. showed that the IGF-1/IGF-1R may play a causal role in tamoxifen 
resistance via MAPK/ERK and PI3K-Akt signalling (Zhang, Moerkens et al. 2011). Hou 
et al. noted synergistic effect of tamoxifen and the IGF-1R inhibitor BMS-754807 in a 
murine xenograft model of ER-positive breast cancer (Hou, Huang et al. 2011). 
Interestingly, Drury et al. did not find any evidence for gain in IGF-1R levels in tumours 
of patients with acquired tamoxifen resistance (Drury, Detre et al. 2011). Indeed, Fagan et 
al. have noted the presence of IGF-1R downregulation in tamoxifen-treated xenografts 
and found that the IGF-1R specific antibody dalotuzumab did not enhance the effect of 
tamoxifen (Fagan, Uselman et al. 2012). IGF-1R directed agents have been assessed as 
part of clinical trials in breast cancer. A randomised phase II trial which included 156 
patients with advanced hormone receptor positive breast cancer did not find any 
additional benefit of ganitumab, a monoclonal antibody which blocks IGF-1R, when 
combined with hormonal therapy (Robertson, Ferrero et al. 2013). Soria et al. noted 
promising response of AVE1642, a monoclonal antibody with specificity towards IGF-
1R, in their subset of patients with breast cancer amongst other solid tumours (Soria, 
Massard et al. 2013).  
 
Growing evidence points to a role of the vascular endothelial growth factor (VEGF) 
receptor in tamoxifen resistance. Tamoxifen has been noted to induce VEGF both in 
preclinical models and clinical specimens. For example, VEGF can be induced by 
tamoxifen in smooth muscle cells obtained from human saphenous vein (Bausero, Ben-
Mahdi et al. 2000). Banerjee et al. noted a 38% rise in serum VEGF levels following 12 
weeks of neoadjuvant tamoxifen treatment in patients with operable ER-positive breast 
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cancer (Banerjee, Pancholi et al. 2008). Elevated VEGF and VEGFR levels have been 
linked to tamoxifen insensitivity and resistance. Qu et al. showed that induction of VEGF 
expression in implanted xenografts to clinically relevant levels in a doxycycline regulated 
manner led to tamoxifen-resistant tumour growth and lung metastases (Qu, Van Ginkel et 
al. 2008). Using multivariate analysis, Foekens et al. noted that elevated VEGF level was 
an independent prognostic factor for poor response to tamoxifen in patients with 
advanced breast cancer (Foekens, Peters et al. 2001). Using immunohistochemical 
analysis of tumour specimens from 564 patients with premenopausal breast cancer 
randomly assigned to 2 years of tamoxifen or no treatment, Ryden et al. noted that 
patients with ER-positive and low VEGFR2 tumours showed improved recurrence-free 
survival (p-value = 0.001) following adjuvant tamoxifen but tamoxifen was not effective 
in patients with high VEGFR2 tumours (Ryden, Jirstrom et al. 2005). Linderholm et al. 
noted that elevated VEGFR2 levels correlated with early tamoxifen resistance whereas 
high VEGF levels predicted late recurrences on tamoxifen therapy (Linderholm, Hellborg 
et al. 2011). Sanchez et al. noted that patients with elevated VEGF levels had better 
outcomes when treated with 5 years of tamoxifen instead of two years (Sanchez, 
Sundqvist et al. 2010). Drugs targeting VEGF/VEGFR have been noted to be effective in 
preclinical models and in the clinical setting. Small molecule TKIs have shown promise 
in the setting of tamoxifen resistance in preclinical models but they have not been 
specifically assessed in clinical trials in this setting. Patel et al. demonstrated that brivanib 
alaninate, a VEGFR2 inhibitor, can reduce tumour volumes when used in tamoxifen 
resistant xenografts namely MCF7-Tam (Patel, Sengupta et al. 2010). Coxon et al. 
reported that the combination of motesanib (AMG 706), a highly selective small molecule 
angiokinase inhibitor with activity against VEGF receptors 1,2 and 3, and tamoxifen in an 
MCF-7 based athymic mice model led to significantly greater reduction in xenograft 
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growth than either drug alone (Coxon, Bush et al. 2009). A recent systematic review 
noted that phase III trials of sunitinib (SU11248, Sutent®) have not shown any significant 
benefit (Mackey, Kerbel et al. 2012). This review also noted that randomised phase II 
trials of sorafenib (Nexavar®) have shown significant benefit when used along with first 
and second line chemotherapy. Other TKIs with activity against VEGF receptors which 
are currently under development against breast cancer include motesanib (AMG706), 
pazopanib (Votrient®), regorafenib (BAY73-4506), cediranib (AZD 2171, Recentin®) 
and axitinib (Inlyta, AG013736) (Taylor, Chia et al. 2010; Martin, Roche et al. 2011; 
Rugo, Stopeck et al. 2011; Wilhelm, Dumas et al. 2011; Cristofanilli, Johnston et al. 
2013; Hyams, Chan et al. 2013; Johnston, Gomez et al. 2013). Monoclonal antibodies 
against VEGF receptors have also been developed and include the VEGF-A specific 
antibody bevacizumab (Avastin®) and ranibizumab (Lucentis®) which is derived from 
an antibody fragment with higher VEGF-A specificity as compared to bevacizumab 
(Braghiroli, Sabbaga et al. 2012). A Cochrane review of the benefit of bevacizumab in 
patients with hormone receptor refractory or resistant metastatic breast cancer (MBC) 
concluded that the benefit of adding bevacizumab to first or second line chemotherapy is 
at best modest as there is no improvement in OS although there was a significant 
improvement in progression-free survival and ORR (Wagner, Thomssen et al. 2012). 
Many of the small molecule tyrosine kinase agents that are effective against VEGF 
receptors also show cross activity against the platelet-derived growth factor receptor 
(PDGF) which has also been implicated in resistance to endocrine agents (Weigel, 
Ghazoui et al. 2012; Weigel, Banerjee et al. 2013).   
 
Other RTKs that have been implicated in tamoxifen resistance include the hepatocyte 
growth factor (HGF) receptor family (c-Met family) and the fibroblast growth factor 
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receptor (FGFR) family. Activation of Ron RTK, a member of the c-Met family, has been 
shown to confer tamoxifen resistance in murine and human breast cancer cell lines 
(McClaine, Marshall et al. 2010). Various agents which are active against the HGF/c-Met 
axis are currently being investigated in clinical trials in breast cancer (Blumenschein, 
Mills et al. 2012). The role of the FGFR family in tamoxifen resistance is currently not 
clear. Turner et al. demonstrated that FGFR1 overexpressing cell lines demonstrate 
tamoxifen resistance and siRNA mediated FGFR1 knockdown restores tamoxifen 
sensitivity (Turner, Pearson et al. 2010). Tomlinson et al. have shown that MCF-7 cells 
cultured with FGF-1 exhibit reduced tamoxifen sensitivity in vitro (Tomlinson, Knowles 
et al. 2012). They also observed that FGFR3 is overexpressed in tamoxifen-resistant 
tumours and FGFR3 overexpression in MCF-7 cells leads to reduced tamoxifen 
sensitivity.  
 
Signalling elements such as MAPK and phosphoinositide 3-kinase -Akt pathway (PI3K-
Akt) which are known to play key roles in RTK signalling are also upregulated in models 
of tamoxifen resistance suggesting that effects of EGFR and HER2 in the setting of 
tamoxifen resistance may be mediated through RTK downstream signalling pathways. 
Cytoplasmic proteins such as Bcar and Cas, which are linked to growth factor receptors, 
may also be involved in tamoxifen resistance. Van der Flier et al. measured Bcar1/p-
130Cas protein levels in 937 primary breast carcinomas and concluded that levels of 
Bcar1/p-130Cas protein correlated well with de novo resistance to tamoxifen (van der 
Flier, Brinkman et al. 2000). The PI3K-Akt pathway has also been shown to be 
upregulated in acquired tamoxifen resistance by our group (Jordan, Gee et al. 2004). 
There is evidence from clinical trials indicating benefit of targeting this pathway using 
mTOR inhibitors in endocrine resistant breast cancer. A randomised phase II trial of 
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everolimus, an mTOR inhibitor, in combination with tamoxifen versus tamoxifen alone in 
patients with ER-positive, HER2-negative MBC with prior AI exposure showed that the 
combination of tamoxifen and everolimus increased the CBR, TTP and OS compared to 
tamoxifen alone (Bachelot, Bourgier et al. 2012). The BOLERO-2 trial was an 
international, randomised, double-blinded phase III study comparing combination of 
everolimus and exemestane versus exemestane alone in postmenopausal women with ER-
positive, HER2-negative advanced breast cancer with disease refractory to letrozole or 
anastrozole (Beaver and Park 2012). The median PFS was 10.6 months for the 
combination versus 4.1 months for exemestane alone (p-value < 0.001) thus suggesting 
that addition of everolimus to exemestane is a potential treatment option in this patient 
subgroup. Schiff et al. have also shown that increased phosphorylated JNK and Jun levels 
(kinases activated by cellular stresses) and AP-1 activity is noted in breast tumours that 
convert to a tamoxifen-resistant phenotype (Schiff, Reddy et al. 2000).  
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1.5 ERBB RECEPTORS AND TAMOXIFEN RESISTANCE  
In particular, the ErbB family of RTKs have been implicated in promoting de novo and 
acquired resistance in breast cancer. In humans, the ErbB family includes a group of four 
structurally related receptor tyrosine kinases namely EGFR (Epidermal growth factor 
receptor or ErbB1/HER1), HER2 (Human epidermal growth factor receptor 2 or 
ErbB2/neu), HER3 (Human epidermal growth factor receptor 3 or ErbB3) and HER4 
(Human epidermal growth factor receptor 4 or ErbB4) (Hynes and Lane 2005). Typically 
they have an extracellular region which binds to ligands, a membrane linked region and a 
cytoplasmic domain which contains tyrosine kinase activity. ErbB receptors can be 
activated by a variety of ligands which typically are members of the EGF family of 
growth factors (Yarden and Sliwkowski 2001). ErbB receptors can exist as both 
monomers, homodimers or heterodimers  and although HER2 has no identified ligand, it 
is the preferred receptor for dimerisation with other ErbB receptors and, this initiates the 
most potent signal transduction pathway in the entire ErbB family (Rubin and Yarden 
2001). Ligand binding to these receptors leads to the formation of homo- / heterodimers 
and induces the formation of receptor homo- / heterodimers, tyrosine kinase domain 
activation and consequent phosphorylation on specific tyrosine targets within the 
cytoplasmic domain (Schlessinger 2004). These phosphorylated residues then serve as 
attachment sites for various proteins thus leading to activation of important downstream 
signalling pathways. Two of the most important pathways that are activated, certainly as 
far as breast cancer is concerned, are the MAPK pathway and the PI3K-Akt axis which 
also involves the ‘mammalian target of rapamycin’ (mTOR) receptor downstream to the 
PI3K-Akt pathway. Another important group of effectors are the STAT (signal transducer 
and activator of transcription) proteins especially STAT3 which has been implicated in 
breast cancer (Yu and Jove 2004). Interestingly, STAT3 has been shown to be activated 
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via EGF and Src kinases in breast cancer cell lines (Garcia, Yu et al. 1997; Yu and Jove 
2004). Src kinase itself is also activated via the ErbB pathway and this has been 
demonstrated in breast cancer cell lines. 
ErbB receptors have also been implicated in the pathogenesis of both de novo and 
acquired tamoxifen resistance in experimental studies along with promotion of an 
aggressive phenotype. Firstly, ErbB overexpression has been demonstrated in models of 
tamoxifen resistance by various authors. Long et al. demonstrated higher expression of 
EGFR in the acquired tamoxifen-resistant cell line (ZR-75-9al 8 microM) as compared to 
the endocrine-sensitive parent cell line, ZR-75-1 (Long, McKibben et al. 1992). Li et al. 
have also demonstrated elevated EGFR levels in their wtMCF-7 derived model of 
acquired tamoxifen resistance called MCF7/TAM (Li, Zhang et al. 2013). A recent study 
by Jin et al. has shown that EGFR upregulation in acquired tamoxifen resistance occurs 
via direct binding of HOXB7, an ERα responsive homeobox gene, to the EGFR promoter 
thus providing a mechanistic clue (Jin, Kong et al. 2011). Block et al. developed a panel 
of tamoxifen resistant cell lines and showed increased EGFR and HER2 expression in 
their T47D-TR cells whilst their MCF-7-TR cells only showed HER2 overexpression 
(Block, Grundker et al. 2012). Liu et al. noted that HER3 also contributes to HER2-
mediated tamoxifen resistance and suggested that HER3 may be a clinically relevant 
therapeutic target in addition to HER2 in the setting of tamoxifen resistance (Liu, 
Ordonez-Ercan et al. 2007). The role of HER4 is less clear with studies  suggesting that 
loss of HER4 expression may be associated with tamoxifen resistance (Naresh, Thor et al. 
2008). Secondly, transfection studies indicate that experimentally induced ErbB 
overexpression can directly lead to tamoxifen resistance in previously tamoxifen sensitive 
cell lines. For example, Benz et al. reported that when wtMCF-7 cells were transfected 
with full length HER2 cDNA, the HER2 overexpressing clones were hormone dependant 
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but resistant to tamoxifen (Benz, Scott et al. 1992). Thirdly, ErbB overexpression in 
acquired tamoxifen-resistant cell lines and induced ErbB overexpression via transfection 
and resultant tamoxifen resistance in previously tamoxifen sensitive cell lines have been 
directly to the development of an aggressive phenotype. Knowlden et al. have observed 
that elevated levels of EGFR-HER2 heterodimers regulate an autocrine growth pathway 
in our tamoxifen-resistant wtMCF-7 derived ‘Tam-R’ cells (Knowlden, Hutcheson et al. 
2003). Thrane et al. have recently showed that in a model of wtMCF-7 derived tamoxifen 
resistance, EGFR along with ERα sustain the higher growth rates noted in these cells 
(Thrane, Lykkesfeldt et al. 2013). Several transfection studies have shown that increased 
EGFR and HER2 expression in breast cancer cell lines exhibiting de novo hormone 
sensitivity has been shown to promote hormone independent proliferation (van Agthoven, 
van Agthoven et al. 1992; Miller, el-Ashry et al. 1994). For example, Liu et al. 
transfected the ER-positive wtMCF-7 cell line with a HER2 expression vector and found 
that transfected clones had a growth advantage in an oestrogen depleted state in vitro and 
the clones with higher HER2 expression could form transient tumours in ovariectomised 
mice as well as mice receiving tamoxifen (Liu, el-Ashry et al. 1995). 
Evidence from several clinical studies also support the critical role of the ErbB family in 
tamoxifen resistance. Wright et al. initially noted that in their series of 221 breast cancer 
patients with known ER and EGFR status, expression of EGFR and HER2 protein 
appeared to have additive effects in lowering the possibility of response to endocrine 
agents. Interestingly, none of the eight patients with EGFR-positive, HER2-positive 
breast cancer responded to endocrine therapy but this needs to be interpreted cautiously 
due to the low sample size (Wright, Nicholson et al. 1992). Nicholson et al. studied the 
protein expression of EGFR, HER2 and Ki67 (proliferation marker) using 
immunocytochemistry in a series 105 breast cancers who received endocrine therapy. 
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They found that EGFR expression correlated with higher rates of cell proliferation (as 
determined by Ki67 expression) and insensitivity to hormonal agents, whereas, HER2 
expression only had weak correlation with hormone insensitivity and did not influence 
proliferation (Nicholson, McClelland et al. 1993). De Placido et al. reported that HER2 
levels were highly predictive of poor response to adjuvant tamoxifen in patients with 
early breast cancer (De Placido, De Laurentiis et al. 2003). Dowsett et al. reported that a 
proportion of patients who developed tamoxifen resistance switched from a HER2-
negative status prior to endocrine therapy to a HER2-positive status at the time of relapse 
(Ring and Dowsett 2004).  Giltnane et al. investigated the relationship between EGFR 
expression, measured using a new fluorescence-based method of protein expression in 
situ called automated quantitative analysis, and tamoxifen response using a tissue 
microarray constructed from a cohort of 564 patients enrolled in a randomised trial for 
adjuvant tamoxifen treatment in early breast cancer (Giltnane, Ryden et al. 2007). They 
noted a significant beneficial effect of tamoxifen in the group with low EGFR expression 
(p-value = 0.013) in contrast to no effect in the group with low EGFR expression (p-value 
= 0.7) by using a Cox model. Larsen et al. explored the role of activated ErbB receptors 
and their influence on outcome of patients treated with endocrine therapy and found that 
HER2 was associated with a worse outcome to endocrine therapy (Larsen, Bjerre et al. 
2012).  
Major advances have been made in therapeutic targeting of ErbB receptors especially as 
part of clinical trials in the last few years and this is discussed in detail below. The current 
status of anti-ErbB agents in relation to endocrine therapy and resistance to hormonal 
agents is also discussed with particular emphasis on tamoxifen resistance. 
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1.5.1 Therapeutic Targeting of ErbB  
There are now several anti-ErbB agents that are in routine use, being used as part of 
clinical trials or in development as therapeutic agents for breast cancer. They can be 
divided into two broad categories: anti-receptor monoclonal antibodies and small 
molecule TKIs.  
 
1.5.1.1 Monoclonal Antibodies 
Various monoclonal antibodies with specificity against ErbB family receptors have been 
developed with varying degrees of clinical success. The currently available anti-ErbB 
monoclonal antibodies are as follows: 
 
1. Trastuzumab (Herceptin®): Trastuzumab is an intravenous humanised monoclonal 
antibody which targets the extracellular domain of HER2 with high affinity resulting 
in inhibition of downstream signalling. Slamon et al. originally demonstrated in the 
H0684g trial that addition of trastuzumab increases the clinical benefit of first-line 
chemotherapy in patients with MBC which overexpresses HER2 (Slamon, Leyland-
Jones et al. 2001). Vogel et al. subsequently demonstrated that trastuzumab was also 
effective as a single-agent in this setting (Vogel, Cobleigh et al. 2002). Trastuzumab 
is now widely used in the management of HER2-positive MBC either alone or in 
combination with chemotherapy and hormonal therapy. A recent meta-analysis by 
Harris et al. showed that the addition of trastuzumab improved OS, PFS and ORR in 
HER2-positive MBC (Harris, Ward et al. 2011). A recent Cochrane review which 
included 8 trials with 11991 patients concluded that trastuzumab improves DFS and 
OS in patients with early and locally advanced HER2-positive breast cancer (Moja, 
Tagliabue et al. 2012). Current meta-analysis evidence also clearly supports the 
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efficacy of trastuzumab when used as adjuvant therapy in HER2-positive breast 
cancer and supports the use of trastuzumab in the neo-adjuvant setting along with 
chemotherapy as it offers substantial benefit in terms of pathological complete 
response (Valachis, Mauri et al. 2011; Yin, Jiang et al. 2011). Whilst trastuzumab is 
indicated only in patients who were HER2-positive at initial presentation, Heitz et al. 
noted that 11.5% of tumours switch receptor status from HER2-negative to positive 
following development of recurrence, thus, providing a rationale for anti-HER2 
therapy in selected patients who were originally HER2-negative (Heitz, Barinoff et al. 
2013).  There is growing evidence for the benefit of concurrent use of trastuzumab 
with hormone therapy. A retrospective review of 897 patients with ER-positive, 
HER2-positive stage I – III breast cancer revealed that addition of hormonal therapy, 
either tamoxifen or AI, conferred a survival benefit when added to chemotherapy and 
trastuzumab (Hayashi, Niikura et al. 2013). Koeberle et al. recently published early 
evidence suggesting that a combination of letrozole and trastuzumab is beneficial in 
ER-positive, HER2-positive patients who have progressed on AI and trastuzumab 
monotherapy alone (Koeberle, Ruhstaller et al. 2011). There is also evidence to 
suggest that combining trastuzumab with hormonal therapy may reverse trastuzumab 
resistance. For example, Chen et al. noted that addition of tamoxifen improves 
herceptin sensitivity in the ER-positive, Trastuzumab resistant BT/HeR cells in vitro 
thus providing a rationale for tamoxifen and trastuzumab combination therapy in this 
setting (Chen, Wang et al. 2008). Conversely, trastuzumab may be able to overcome 
resistance to hormonal therapy. Using xenograft studies utilising ER-positive cells 
stably transfected with aromatase gene (MCF7-Ca) and cells with acquired letrozole 
resistance (LTLT-Ca), Sabnis et al. showed that trastuzuamb can reverse letrozole 
resistance (Sabnis, Schayowitz et al. 2009).  
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2. Pertuzumab (Perjeta®): Pertuzumab is a novel intravenous recombinant humanised 
monoclonal antibody that exerts its action via inhibition of HER2 dimerisation. It is 
the first in a new class of therapeutic agents called HER2 dimerisation inhibitors 
(Zagouri, Sergentanis et al. 2013). In June 2012, pertuzumab was approved by the 
United States Food and Drug Administration (FDA) for use with trastuzumab and 
docetaxel in patients with metastatic HER2-positive breast cancer (Blumenthal, Scher 
et al. 2013). This was primarily based on the results of the landmark phase III 
randomised, double-blind, placebo-controlled CLinical Evaluation Of PertuzumAb 
and TRAstuzumab (CLEOPATRA) trial which included 808 patients with HER2-
positive MBC (Baselga, Cortes et al. 2012). The trial reported that when pertuzumab 
was used as first line therapy along with trastuzumab and docetaxel in patients with 
MBC, the median PFS was significantly higher in the pertuzumab group compared to 
the control group (p-value < 0.001) with no increase in cardiac toxicity. Previous 
preclinical studies and earlier phase trials had shown evidence of improved activity 
when pertuzumab was combined with trastuzumab. For example, Scheuer et al. 
demonstrated enhanced anti-tumour activity with pertuzumab when used along with 
traztuzumab in HER2-positive xenograft models and a previous phase II trial showed 
that the combination of pertuzumab and trastuzumab was active and safe in patients 
with metastatic HER2-positive disease which progressed on trastuzumab therapy 
(Scheuer, Friess et al. 2009; Baselga, Gelmon et al. 2010).  
 
 
3. Cetuximab (Erbitux®): Cetuximab is an intravenous chimeric (mouse/human) 
monoclonal antibody with specificity towards EGFR. Uberall et al. showed that 
cetuximab enhanced the anti-proliferative effect of trastuzumab in the EGFR and 
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HER2 overexpressing SK-BR-3 cell line (Uberall, Krizova et al. 2011). Although 
currently licensed for use in colorectal and head and neck cancer, cetuximab is 
currently being investigated in trials for breast cancer. For example, a recent phase II 
randomised trial showed that addition of cetuximab to cisplatin doubled the ORR and 
PFS in patients with triple negative MBC (Baselga, Gomez et al. 2013). 
 
4. Panitumumab (Vectibix®): Panitumumab is a solely human monoclonal antibody 
which targets EGFR and is used as treatment of advanced colorectal cancer (Yang, Jia 
et al. 2001). It is currently in the developmental phase as an agent for breast cancer. 
 
 1.5.1.2 Tyrosine Kinase Inhibitors (TKIs) 
Synthetic small molecule inhibitors with activity against the tyrosine kinase domain of the 
ErbB receptors have been developed and examined in several clinical trials as agents 
against breast cancer. The currently available anti-ErbB TKIs are as follows: 
 
1. Gefitinib (ZD1839 / Iressa®): Gefitinib was the first agent with selective activity 
against the tyrosine kinase domain of EGFR and acts by binding to the ATP-binding 
site thereby inhibiting the anti-apoptotic Ras signalling cascade. Although currently in 
routine use for the treatment of non-small cell lung carcinomas, gefitinib is not yet 
licensed for the treatment of breast cancer and is currently only indicated for use as 
part of trials. There has been significant interest in the role of gefitinib in the setting 
of ER-positive breast cancer and in particular hormone-resistant breast cancer. In a 
wtMCF-7 based cell model of ER-positive breast cancer, Gee et al. demonstrated that 
gefitinib increased the anti-proliferative capacity of tamoxifen and prevented the 
development of tamoxifen resistance via inhibition of EGFR signalling (Gee, Harper 
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et al. 2003). In a wtMCF-7 based murine xenograft model which does not overexpress 
ErbB receptors, Massarweh et al. showed that gefitinib improved the anti-tumour 
effect of tamoxifen and delayed acquisition of acquired resistance thereby providing a 
rationale for combined use of tamoxifen and gefitinib (Shou, Massarweh et al. 2004). 
Using a model of ER/HER2-positive breast cancer exhibiting de novo tamoxifen 
resistance (MCF-7/HER2-18), Shou et al. showed that gefitinib is able to eliminate 
ER-HER2 cross-talk and restore tamoxifen sensitivity (Shou, Massarweh et al. 2004). 
Block et al. also showed that gefitinib is able to restore tamoxifen sensitivity using a 
model of acquired tamoxifen resistance, namely T47D-TR (Block, Grundker et al. 
2012). Hiscox et al. demonstrated that gefitinib is able to inhibit the enhanced 
invasive and motile phenotype that is noted in vitro following the development of 
acquired tamoxifen resistance (Hiscox, Morgan et al. 2004). Several trials have 
investigated the role of gefitinib in breast cancer including gefitinib monotherapy. 
Green et al. reported that gefitinib at a dose of 500 milligram per day had a low CBR 
in hormone-resistant (CBR 0%) and ER-negative (CBR 7.7%) advanced breast cancer 
in a multicentre phase II trial (Green, Francis et al. 2009). In another phase II trial, 
gefitinib (500 milligram/day) was shown to be well tolerated with a CBR of 53.6% in 
tamoxifen-resistant breast cancer and 11.5% in ER-negative breast cancer 
(Gutteridge, Agrawal et al. 2010). Use of gefitinib in combination with anti hormonal 
agents has also been investigated. In a randomised phase II trial including 93 patients, 
Cristofanilli et al. reported that the combination of anastrozole and gefitinib is 
associated with a marked improvement in PFS (14.7 versus 8.4 months) as opposed to 
anastrozole combined with placebo (Cristofanilli, Valero et al. 2010). However, in a 
randomised phase II trial which included postmenopausal women with hormone 
receptor positive MBC, Carlson et al. did not note any benefit of the combination of 
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anastrozole and gefitinib over anastrozole or gefitinib monotherapy (Carlson, O'Neill 
et al. 2012). Osborne et al. reported the results of a randomised phase II trial assessing 
tamoxifen plus placebo or gefitinib in ER-positive MBC (Osborne, Neven et al. 
2011). They noted an improved PFS in patients receiving a combination of gefitinib 
and tamoxifen except patients who progressed or recurred following prior AI therapy. 
Other trials have assessed the role of gefitinib in other settings. A recent prospective, 
single arm phase I/II trial of gefitinib, trastuzumab and docetaxel in patients with 
advanced HER2-positive MBC found that this combination was well tolerated and 
clinically effective as demonstrated by complete and partial response rates of 18 and 
46% respectively and a stable disease rate of 29% (Somlo, Martel et al. 2012).  
Massarweh et al. reported the results of a small (15 patients) phase II neoadjuvant trial 
of gefitinib, anastrozole and fulvestrant in newly diagnosed patients with ER-positive 
breast cancer and noted that this combination consistently reduced proliferation as 
assessed via Ki-67 levels (Massarweh, Tham et al. 2011).  
 
2. Lapatinib (Tyverb®): Lapatinib is an orally active TKI which targets EGFR and 
HER2. Konecny et al. noted significant anti-proliferative effect of lapatinib alone and 
in combination with trastuzumab on HER2 overexpressing breast cancer cell lines as 
well as xenografts in athymic mice (Konecny, Pegram et al. 2006). In an in vivo 
model of HER2 overexpressing breast cancer, Scaltriti et al. noted complete tumour 
remissions following 10 days of treatment with lapatinib and trastuzumab (Scaltriti, 
Verma et al. 2009). A Phase I dose escalation and pharmacokinetic study of lapatinib 
in combination with trastuzumab in patients with heavily pre-treated MBC showed 
that this combination was well tolerated and clinically active (Storniolo, Pegram et al. 
2008). Following these and other preclinical and early clinical evidence of 
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effectiveness and safety of this drug in breast cancer models, several trials have 
investigated the use of lapatinib in various clinical settings. A meta-analysis of Phase 
III trials by Amir et al. showed that lapatinib was only clinically effective against 
patients with HER2-positive disease and not HER2-negative disease irrespective of 
EGFR status (Amir, Ocana et al. 2010). Berghoff et al. reported that although 
lapatinib did not improve OS in patients with HER2-positive MBC who progressed 
on trastuzumab, it was noted to significantly improve OS (p-value = 0.022) in the 
subset of patient with bone metastases (Berghoff, Bago-Horvath et al. 2013). The 
Phase III EGF104900 trial showed a significant 4.5 month median OS benefit of 
lapatinib and trastuzumab combination over lapatinib monotherapy in patients with 
heavily pre-treated HER2-positive MBC (Blackwell, Burstein et al. 2012). A meta-
analysis of HER2 targeted agents in MBC by Harris et al. noted that addition of 
lapatinib to standard chemotherapy / AI therapy improved TTP, OS, PFS and ORR 
(Harris, Ward et al. 2011).  
 
The role of lapatinib in the setting of ER-positive disease and endocrine resistance has 
also been investigated. Leary et al. investigated the effect of lapatinib in two in vitro 
models of acquired endocrine resistance: a model of long-term oestrogen deprivation 
and a model of tamoxifen resistance following long-term tamoxifen treatment (Leary, 
Drury et al. 2010). Both models showed modest upregulation of HER2 and lapatinib 
was able to restore hormone sensitivity in both models. Chu et al showed that 
lapatinib when combined with tamoxifen showed significant decrease in tumour 
volume in an acquired tamoxifen-resistant athymic mouse xenograft model (Chu, 
Blackwell et al. 2005). A systematic review by Fleeman et al. noted that when used as 
first-line therapy for hormone receptor positive MBC which overexpresses HER2, 
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both lapatinib plus AI and trastuzumab plus AI were clinically more effective than AI 
monotherapy (Fleeman, Bagust et al. 2011). A clinical trial comparing lapatinib 
combined with letrozole versus letrozole and placebo in patients with postmenopausal 
ER-positive MBC showed that the combination of lapatinib and letrozole significantly 
improves PFS (p-value = 0.019) and CBR (p-value = 0.003) in patients with ER-
positive, HER2-positive MBC (Johnston, Pippen et al. 2009). A recent systematic 
review which included results of 18 studies noted that lapatinib plus letrozole was 
clearly superior to letrozole alone in terms of PFS, TTP and ORR (Riemsma, Forbes 
et al. 2012).  
 
3. Erlotinib (Tarceva®): It is a reversible TKI with specific activity against EGFR and 
acts via reversibly binding to the ATP-binding site on the receptor (Raymond, Faivre 
et al. 2000). It has been shown to have anti-tumour activity in several preclinical 
studies. Zhang et al. demonstrated that erlotinib can inhibit tumour proliferation and 
metastasis in an EGFR driven xenograft model of inflammatory breast cancer (Zhang, 
LaFortune et al. 2009). Saxena et al. showed that erlotinib can inhibit the invasive and 
migratory phenotype induced by leptin and IGF1-R via EGFR transactivation in 
breast cancer cell lines namely, MDA-MB-468 and MDA-MB-231(Saxena, 
Taliaferro-Smith et al. 2008). Erlotinib is currently in trial phase for use as an agent 
against breast cancer. A multicentre Phase II trial of erlotinib monotherapy and 
another Phase II trial of erlotinib and bevacizumab combination therapy did not show 
any significant clinical benefit in the setting of advanced breast cancer (Dickler, Rugo 
et al. 2008; Dickler, Cobleigh et al. 2009). However, Twelves et al. reported 
encouraging ORR and an acceptable toxicity profile of the combination of erlotinib 
with capecitabine and docetaxel in MBC (Twelves, Trigo et al. 2008). Britten et al. 
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demonstrated preliminary clinical efficacy of the combination of erlotinib and 
trastuzumab in HER2-positive MBC in a Phase I/II trial (Britten, Finn et al. 2009). 
Interestingly, Montagna et al. have reported that metronomic chemotherapy along 
with erlotinib and bevacizumab is clinically effective against HER2-negative MBC 
(Montagna, Cancello et al. 2012). 
 
Even in the setting of ER-positive disease, there is some early evidence for this drug. 
Erlotinib was able to inhibit the pro-migratory effect of leptin and IGFR-1 via EGFR 
transactivation in ER-positive wtMCF-7 cells (Saxena, Taliaferro-Smith et al. 2008). 
Khajah et al. showed that erlotinib was able to significantly inhibit proliferation and 
invasion of endocrine resistant pII cells which were established through stable 
transfection of wtMCF7 cells with ER-directed shRHA plasmid (Khajah, Al Saleh et 
al. 2012).  
 
4. Vandetanib (Caprelsa™): Vandetanib is an oral multi TKI which has inhibitory 
effect primarily on VEGFR and amongst the ErbB family on EGFR (Carlomagno, 
Vitagliano et al. 2002). Sarkar et al. reported that vandetanib enhances the anti-
proliferative and apoptotic effects of paclitaxel on breast carcinoma cells (Sarkar, 
Mazumdar et al. 2011). Mi et al. demonstrated that vandetanib could reverse 
multidrug resistance in a P-glycoprotein expressing breast cancer cell line (Mi and 
Lou 2007). In a multicentre phase II trial of vandetanib monotherapy, Miller et al. 
showed that the drug was well tolerated but did not show any definite clinical benefit 
in advanced MBC (Miller, Trigo et al. 2005). In patients with pre-treated advanced 
breast cancer, combination of vandetanib plus docetaxel was well tolerated but there 
was no additional clinical benefit when compared with docetaxel plus placebo (Boer, 
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Lang et al. 2012). Vandetanib is currently still in the development phase as a 
therapeutic agent for breast cancer. 
 
5. Neratinib (HKI-272): Neratinib is an oral TKI with irreversible activity against 
EGFR, HER2 and HER4 (Wissner and Mansour 2008). In preclinical studies it has 
been shown to have potent activity against breast cancer cell lines which overexpress 
HER2 (Rabindran, Discafani et al. 2004). It has also been shown to be effective in the 
setting of de novo and acquired trastuzumab resistance in breast cancer cell lines as 
well as in a xenograft model (Canonici, Gijsen et al. 2013). Chow et al. reported that 
the combination of neratinib and paclitaxel showed a higher response rate compared 
to neratinib alone in a Phase I/II study (Chow, Xu et al. 2013). Martin et al. reported 
the results of a Phase II study comparing neratinib monotherapy versus lapatininb plus 
capecitabine chemotherapy in patients with advanced HER2-positive breast cancer 
where neratinib was shown to be a safe and effective single agent in this setting 
(Martin, Bonneterre et al. 2013). Neratinib is currently in the clinical trial phase as an 
agent against breast cancer and is currently being investigated in Phase III trials 
(Canonici, Gijsen et al. 2013). 
 
6. Canertinib (CI-1033): Canertinib is a pan-ErbB TKI that binds to the intracellular 
domains of the ErbB receptors and has irreversible activity against EGFR, HER2 and 
HER4 (Smaill, Rewcastle et al. 2000). It is still in the early development phase as a 
breast cancer drug (www.selleckchem.com). 
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1.6 CD44 
CD44 (Cluster of Differentiation 44) is a transmembrane glycoprotein that was first 
described as a lymphocyte homing receptor (Gallatin, Weissman et al. 1983) and later 
found to be a member of the cartilage link protein family (Goldstein, Zhou et al. 1989; 
Stamenkovic, Amiot et al. 1989). It has various isoforms and exhibits functional 
heterogeneity in terms of its role in physiological processes including acting as an 
adhesion molecule for lymphocyte homing, influencing extracellular matrix remodelling 
during embryogenesis and triggering release of cytokines via adhesion to macrophages. 
CD44, along with a select few other markers including CD24, is also a widely used 
marker of breast cancer stem cells (CSCs). CD44, therefore, continues to be the subject of 
intensive research.  
 
1.6.1 CD44 Structure 
The CD44 gene is located on the short arm of human chromosome 11 and contains up to 
20 exons (Screaton, Bell et al. 1992). Exons 1 to 17 encode the extracellular domain of 
the CD44 protein, exon 18 encodes the transmembrane domain and exons 19 and 20 are 
responsible for the cytoplasmic domain of the protein (Figure 1.4A). Exons 6 to 15 are 
variably inserted into the gene via alternative splicing of mRNA to produce a number of 
CD44 isoforms. The resultant CD44 molecule is a single chain glycoprotein which has a 
globular extracellular domain, a short transmembrane domain and a cytoplasmic domain 
(Figure 1.4B).  
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Figure 1.4 CD44 gene and protein structure
The CD44 gene is located on the short arm of human chromosome 11 and contains up to 20
exons (A). Exons 1 to 17 encode the extracellular domain of the CD44 protein, exon 18
encodes the transmembrane domain and exons 19 and 20 are responsible for the
cytoplasmic domain of the protein. Exons 6 to 15 are variably inserted into the gene via
alternative splicing of mRNA to produce a number of CD44 isoforms. The resultant CD44
molecule (B) is a single chain glycoprotein which has a globular extracellular domain, a
short transmembrane domain and a cytoplasmic domain. Adapted from Zoller 2011.
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The extracellular domain undergoes post-translational modifications via N-glycosylation 
and O-glycosylation and has binding sites for various matrix proteins including 
fibronectin, laminin and collagen (Goldstein, Zhou et al. 1989; Jalkanen and Jalkanen 
1992; Ishii, Ford et al. 1993). CD44 isoforms arise through exon splicing of the CD44 
gene and result in elongation of the extracellular region of the molecule through insertion 
of exon products within a region near the transmembrane domain. This heavily 
glycosylated polypeptide stalk-like variable portion of the molecule is thought to be 
responsible for the variation in structure and function between CD44 isoforms (Screaton, 
Bell et al. 1993). 
 
The relatively well-conserved and short transmembrane domain is responsible for CD44 
dimerisation and cross-linking thus allowing CD44 to be incorporated into glycolipid 
enriched membrane microdomains (GEM’s) enabling close association with different cell 
signalling molecules (Foger, Marhaba et al. 2001). 
 
The cytoplasmic domain does not vary significantly amongst the isoforms and allows 
CD44 to associate with cytoplasmic proteins such as ankyrin, ezrin, radixin and moesin 
thereby accounting for many of the effects of CD44 on signal transduction and cell 
migration (Mori, Kitano et al. 2008; Fehon, McClatchey et al. 2010). 
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The smallest CD44 isoform, termed CD44 standard (CD44s), lacks any of the variant 
exons and is the most widely present of all CD44 isoforms (Isacke and Yarwood 2002). 
Originally seen in brain cells, leucocytes and red blood cells, it is now known that most 
vertebrate cells express CD44s in the membrane (Telen, Rogers et al. 1987; Lucas, Green 
et al. 1989; Naor, Wallach-Dayan et al. 2008). The actual size of CD44s varies between 
different cells and tissues due to differences in the extent of glycosylation. The CD44 
variants, which are named based on expression of the variant exons: v1 to v10, are less 
widely expressed in normal tissues, some only in malignant cell lines, and are known to 
have functions distinct from CD44s (Ruiz, Schwarzler et al. 1995; Borland, Ross et al. 
1998). The variant isoforms have additional binding sites for other molecules near the 
transmembrane domain at the polypeptide stalk such as the heparin sulphate site on 
CD44v3 (Bennett, Jackson et al. 1995). The functional relevance of CD44 standard and 
the variant isoforms is discussed in Section 1.6.3.  
 
1.6.2 Hyaluronan, the CD44 Ligand 
The major ligand for CD44 is hyaluronan (HA), a large glycosaminoglycan which is a 
linear polymer containing between 2,000 to 25,000 disaccharides of glucuronic acid and 
N-acetylglucosamine with a molecular weight between 10
2
 to 10
4
 kDa. HA is synthesised 
at the inner aspect of the plasma membrane by three related hyaluronan synthases (HAS1, 
HAS2 and HAS3), extruded into the peri-cellular space and eventually degraded by one 
of many hylauronidases (Weigel, Hascall et al. 1997). HA is present in most mammalian 
tissues and plays a crucial structural role in extracellular tissue due to its hydrodynamic 
characteristics and by interacting with other extracellular matrix components. HA 
interacts closely with matrix proteoglycans such as versican and aggrecan and the 
negative charge on the chondroitin sulphates on these proteoglycans forces HA to form a 
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thick gel-like coat on the cellular surface (Evanko, Tammi et al. 2007). The interaction 
between HA and the chondroitin sulphates also regulates the properties of the matrix and 
an increase in the proportion of proteoglycans leads to a matrix that is stiffer and less 
permeable (Heldin, Suzuki et al. 1995). HA and other matrix proteoglycans can also play 
a role in proliferation and migration in various cell types and influence cell adhesion 
(Evanko, Tammi et al. 2007). HA also plays a role in tumour progression including breast 
cancer. Using a mouse mammary tumour virus (MMTV-Neu) transgenic model of 
spontaneous breast cancer, Koyama et al. demonstrated that stromal HA overproduction 
stimulates tumour growth through angiogenesis (Koyama, Hibi et al. 2007). Ghatak et al. 
showed that in the TA3/St breast cancer cell line, endogenous HA is necessary for the 
constitutively high levels of HER2 thereby demonstrating that hyaluronan can have an 
impact on cell signalling via its effect on RTKs (Ghatak, Misra et al. 2005).  
 
HA is also known to bind to the “Hyaluronan Mediated Motility Receptor” (HMMR) 
which is more commonly referred to as RHAMM and has been given the designation 
CD168 (Turley 1982). RHAMM is predominantly an intracellular cytoplasmic protein 
that is implicated in tumour progression by promoting genomic instability through its 
association with ‘Breast Cancer 1’ or BRCA1 (human caretaker gene whose mutations 
lead to an increased risk of breast cancer) and the BRCA1-associated ring domain protein 
1. It is transported to the extracellular space from the cytoplasm via unconventional 
cytoplasmic protein export mechanisms. Once in the extracellular microenvironment, 
RHAMM can interact with CD44 and this is considered to enhance CD44-mediated 
signalling through MAPK (Hamilton, Fard et al. 2007). It is thought to contribute to 
cancer progression by enhancing and activating the oncogenic properties of CD44 
(Maxwell, McCarthy et al. 2008). 
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1.6.3 Role of CD44 in Cellular Signalling and Function 
CD44 is known to interact extensively with HA in the stromal microenvironment. The 
binding site for HA lies in the extracellular domain of CD44 and growing evidence points 
to HA-CD44 interactions as a mechanism of eliciting intracellular signalling pathways 
that result in cytoskeleton modulation (Underhill and Toole 1979; Aruffo, Stamenkovic et 
al. 1990; Toole and Slomiany 2008). Using human melanoma cells transfected with 
CD44, Bartolazzi et al. showed that changes in glycosylation of CD44 have a direct effect 
on its interaction with hyaluronic acid thereby providing an important mechanism for 
regulation of CD44 function (Bartolazzi, Nocks et al. 1996). Zohar et al. demonstrated 
that CD44 was localised primarily at the leading edge of migrating fibroblasts and CD44-
negative mouse fibroblasts displayed impaired migration (Zohar, Suzuki et al. 2000). 
CD44 binding to HA also triggers its metabolism and CD44 may thus mediate hyaluronan 
homeostasis (Kaya, Rodriguez et al. 1997). These and other experimental studies suggest 
a role of CD44 in regulation of adhesion of cells to the matrix as well as migration 
through the stroma. CD44 proteins have been found to act as platforms for growth factors 
and matrix metalloproteinases (MMP’s) including MMP9 and MMP7 (Ponta, Sherman et 
al. 2003).  
 
As well as exogenous matrix proteins and growth factors, CD44 has also been shown to 
interact with RTKs and influence their signalling behaviour. CD44 functions as a co-
receptor for activation of Met, a tyrosine kinase, and it appears that the v6 splice variant is 
a key requirement for this activation. Orian-Rousseau et al. demonstrated that a CD44 
isoform containing exon v6 sequences is necessary for Met activation by its ligand 
hepatocyte growth factor (HGF) in many established cell lines including primary 
keratinocytes (Orian-Rousseau, Chen et al. 2002). Met plays a critical role in embryonic 
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development and wound healing and aberrant signalling in cancer promotes tumour 
progression through proliferation, angiogenesis and metastasis and CD44 appears to play 
a part in these functions (Steffan, Coleman et al. 2011). CD44 can also function as a co-
receptor for the ErbB family of RTKs which are known to be involved in signal 
transduction controlling normal cell growth and differentiation. CD44 is known to 
directly associate with members of the ErbB family. Using co-immunoprecipitation and 
fluorescence resonance energy transfer (FRET) analysis, Gorlewicz et al. demonstrated 
that CD44 co-immunoprecipitates with both HER2 and HER3 in adult rat skeletal muscle 
Schwann cells (Gorlewicz, Wlodarczyk et al. 2009). CD44 and ErbB association has been 
noted to have important implications in terms of cell signalling and function. Using 
patient matched oral and dermal fibroblasts, Meran et al. showed that CD44 and EGFR 
interaction directly activates MAPK leading to cellular proliferation in these fibroblasts 
(Meran, Luo et al. 2011). Yu et al. have demonstrated that HER4 can be associated with 
various CD44 isoforms and this complex can play a role in regulation of female 
reproductive organ remodelling (Yu, Woessner et al. 2002).  
 
CD44 can interact with proteins that attach to the actin cytoskeleton and evidence points 
to the Band 4.1 superfamily of proteins (ERM proteins and Merlin) as being most 
relevant in this context. The ERM protein family consists of three proteins namely, ezrin, 
radixin and moesin which cross-link actin filaments to the plasma membrane and are 
involved in many cellular functions such as migration and regulation of cell shape 
(Tsukita and Yonemura 1997). Tsukita et al. showed that in cultured fibroblasts CD44 is 
precisely co-localised with ERM family members which act as a link between the 
cytoplasmic domain of CD44 and the cytoskeleton (Tsukita, Oishi et al. 1994). ERM 
proteins appear to be necessary for CD44 signal transduction through Met to Ras and 
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MAPK, a process that is closely linked to activity of Merlin (‘Moesin-Ezrin-Radixin-
Like-ProteiN’), another member of the same superfamily, which also attaches to CD44 
but does not link with actin (Ponta, Sherman et al. 2003). Thus, the interaction between 
CD44, ERM proteins and Merlin can influence signal transduction as well as cell shape 
and motility.  
 
A schematic representation of the interaction between CD44, HA and ErbB receptors and 
the consequent influence on cell signalling and function is shown in Figure 1.5. 
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Figure 1.5 Schematic representation of CD44 interaction with HA and ErbB receptors
and effect on downstream signalling and cell function
CD44 interacts with ligands such as HA and with receptor tyrosine kinases such as the ErbB
family which leads to activation of several downstream signalling pathways with resultant
changes in cellular phenotype. CD44 can interact with ErbB either directly via disulphide
bonds or dimerisation (1), via intracellular intermediates such as Src and PI3K (2) or via
extracellular intermediates such as HB-EGF and MMP7 (3). Adapted from Ponta et al.
2003, Zoller et al. 2011.
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1.6.4 Physiological and Pathological Roles of CD44 
Both CD44 standard and the variant isoforms have a wide range of functional 
implications in various physiological and non-malignant pathological processes. CD44 
was initially recognised as a protein involved in lymphocyte homing and is now known to 
aid lymphocyte rolling, activation and homing to gut-associated lymphoid tissue (Berg, 
Goldstein et al. 1989). CD44 has several other roles in the immune-haematopoietic 
system including aiding pro-thymocyte homing from the bone marrow to the thymus 
(Spangrude and Scollay 1990; Wu, Antica et al. 1991). CD44 is known to play a role in 
embryogenesis especially in limb bud development and chondrogenesis (Knudson 2003). 
During limb bud development, a reduction in the matrix HA content and cross-bridging of 
mesodermal cells is essential, and CD44 plays a role in both reduced production of peri-
cellular HA coats and HA-mediated cross-bridging of mesodermal cells (Culty, Nguyen 
et al. 1992). During chondrogenesis, CD44-mediated hyaluronan turnover is crucial in 
cartilage formation from mesenchymal cells (Nicoll, Barak et al. 2002).  
 
There has been an increasing understanding of the role of CD44 in inflammatory and 
autoimmune processes following the observation that its expression is upregulated during 
inflammation in haematopoietic and parenchymal cells (Foster, Arkonac et al. 1998). 
CD44 is implicated in the pathology of rheumatoid arthritis (RA) and is known to induce 
interleukin-6 (IL-6) and vascular cell adhesion molecule-1 (VCAM-1) in synovial cells as 
well as induce apoptosis in these cells (Fujii, Tanaka et al. 1999; Fujii, Tanaka et al. 1999; 
Fujii, Fujii et al. 2001). Other inflammatory diseases suggested to involve CD44 include 
inflammatory colitis (CD44v7), atherosclerosis and asthma (Jain, He et al. 1996). CD44 
has been noted to be involved in the interaction between pathogens and the host cell and 
there is evidence that bacteria such as Streptococcus pyogenes attach to cells via 
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interactions between their hyaluronan-rich cell wall and CD44 on the host cell surface 
(Cywes, Stamenkovic et al. 2000). There is evidence to suggest that CD44 can initiate 
signalling events that can alter host cell immunity and make them more susceptible to 
bacterial infections. Jung et al. demonstrated that Met activation by Listeria 
monocytogenes is dependent on CD44v6 which promotes bacterial invasion into target 
cells (Jung, Matzke et al. 2009). Cwyes et al. showed that Group A Streptococci 
colonisation of the oropharynx in wild-type mice which could be blocked by 
administration of CD44 monoclonal antibody, and no colonisation was seen in transgenic 
mice deficient in CD44 (Cywes, Stamenkovic et al. 2000).   
 
1.6.5 Role of CD44 in Cancer Biology 
The first clear link between CD44 and cancer emerged when Gunthert et al. found that a 
CD44 variant protein conferred metastatic ability to a non-metastatic rat pancreatic 
carcinoma cell line (Gunthert, Hofmann et al. 1991). In an attempt to identify and clone 
genes responsible for metastasis, they generated monoclonal antibodies recognising 
antigenic determinants on a cell line from a metastasising variant of a spontaneous rat 
pancreatic adenocarcinoma (BSp73ASML). The antibodies were then used to screen a 
bacterial complementary DNA (cDNA) expression library and one of the cDNA clones 
was found to code for a variant form of CD44 (CD44v4-7), which when transfected into 
the non-metastasising BSp73AS cell line conferred metastasising potential to this cell 
line. Similar observations were made in the highly metastatic 13762 NF mammary 
carcinoma cell line as well by this group (Gunthert, Hofmann et al. 1991).  
 
The ability of CD44 to promote a metastatic phenotype has been demonstrated in human 
melanoma through experimental inhibition of CD44 function using in vivo administration 
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of GKW.A2, a monoclonal antibody specific for human CD44. Use of GKW.A2 has been 
shown to inhibit the growth and metastatic potential of tumour cells in the SMMU-2 
human melanoma cell line (Guo, Ma et al. 1994). Hernandez et al. also noted that CD44 
silencing in a human melanoma cell line (SK-mel-131) caused a reduction in cell 
proliferation and migration in vitro as well as decrease in cell adhesion to vitronectin, 
fibronectin and hyaluronan (Hernandez, Miquel-Serra et al. 2012). Kim et al. observed 
that HA-induced CD44 and EGFR interaction augments the motile behaviour of a human 
melanoma cell line (B16F10) via activation of protein kinase C signalling (Kim, Lee et al. 
2008).  
 
CD44 is overexpressed in several malignant tumours where it may contribute to further 
genetic aberrations. Overexpression of CD44 gene in colorectal neoplasms seems to be an 
early event often seen prior to gene alterations (for example, K-ras and p53) indicating 
that CD44 is likely to be involved in cell activation and proliferation following APC 
(Adenomatous polyposis coli) gene mutation or alteration of DNA methylation (Kim, 
Yang et al. 1994). A number of CD44 variants have been found to be overexpressed in 
colonic adenocarcinomas (Higashikawa, Yokozaki et al. 1996). Yamaguchi et al. noted 
that patients whose tumours expressed CD44v8-10 had a significantly greater relative risk 
of death and a higher recurrence rate compared with those whose tumours were CD44v8-
10 negative and multivariate analysis confirmed CD44v8-10 expression to be an 
independent prognostic marker (Yamaguchi, Urano et al. 1996). Huang et al. 
demonstrated that CD44v6 plays a role in promoting liver metastasis in colorectal cancer 
through an osteopontin mediated mechanism that leads to increased adhesion with 
endothelial cells and weakened intercellular communication (Huang, Pan et al. 2012). In 
an in vitro model of CD44 overexpressing colon cancer cells (SW480), Cho et al. have 
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demonstrated a clear epithelial to mesenchymal transition (EMT) and CD44-mediated 
inhibition of membrane associated E-cadherin and β-catenin (cell-cell adhesion proteins) 
complex resulting in increased cell invasion and migration (Cho, Park et al. 2012). Du et 
al. showed that a single CD44-positive cell from a primary colorectal cancer specimen 
could form a sphere in vitro with stem cell properties which subsequently could generate 
a xenograft tumour resembling the original tumour. They also demonstrated that 
knockdown of CD44 prevented clonal formation and inhibited tumourigenicity in their 
xenograft model (Du, Wang et al. 2008). In primary gastric malignancies, CD44v9 
expression correlates with tumour recurrence and increased mortality (Mayer, Jauch et al. 
1993) whilst expression of CD44 variant isoforms (v3, v6, and v10 containing isoforms) 
in head and neck squamous cell carcinomas are associated with advanced disease (Wang 
and Bourguignon 2011). Altered CD44 expression functions as a marker of poor 
prognosis in most haematological malignancies (Hertweck, Erdfelder et al. 2011). For 
example, in acute lymphoblastic leukaemia, total CD44 and CD44v6 function as 
prognostic markers whereas in Hodgkin’s lymphoma, CD44v10 displays strong 
prognostic relevance. CD44 is also implicated in other malignancies such as pancreatic 
adenocarcinoma. Zoller et al. have shown that in a rat pancreatic adenocarcinoma cell 
line, CD44v6 promotes motility and apoptosis resistance through activation of signalling 
pathways involving FAK (Focal adhesion kinase), PI3K-Akt, and MAPK activation 
(Jung, Gross et al. 2011).  
 
Interestingly, and in contrast to these studies, there are reports that CD44 expression 
correlates with improved prognosis in some malignancies. For example, overexpression 
of CD44 standard is associated with reduction in metastatic potential in prostatic cancer 
55 
 
whilst loss of CD44, both standard and variant isoforms, appears to be a marker of poor 
prognosis (Gao, Lou et al. 1997; De Marzo, Bradshaw et al. 1998).  
 
1.6.6 CD44 and Breast Cancer 
As mentioned previously, the initial link between CD44 and breast carcinoma was noted 
by Gunthert and colleagues in the 13762NF rat mammary carcinoma cell line where 
expression of CD44 variants conferred metastatic potential (Gunthert, Hofmann et al. 
1991). Studies using experimental breast cancer models suggest that CD44 (standard and 
variant isoforms) may act, both directly and indirectly, as a regulator of their 
aggressiveness. Such activities appear to arise through the ability of CD44 to promote 
degradation of the extracellular matrix, cell migration, angiogenesis and metastasis 
(Trochon, Mabilat et al. 1996). CD44v3-mediated activation of Rho (protein involved in 
termination of transcription) and PI3K-Akt pathways appear to contribute to breast cancer 
cell growth and invasion whilst Rho kinase (ROK) mediated binding of ankyrin to the 
CD44v3, CD44v8 and CD44v10 isoforms contributes to increased migration. Moreover, 
in the MDA-MB-231 breast cell line, CD44 interaction with ROK plays a pivotal role in 
promoting Akt signalling and cytokine production during breast cancer progression 
(Bourguignon 2001; Bourguignon, Singleton et al. 2003).  
 
Additional evidence implicating CD44 in breast cancer arises from studies on human 
breast cancer tissue. CD44s, CD44v3 and CD44v6 are all known to be upregulated in in-
situ and invasive ductal carcinoma of the breast and this happens prior to HA 
upregulation during the process of cancer progression (Auvinen, Tammi et al. 2005). 
There is no definitive evidence that CD44s is linked to an adverse outcome in breast 
cancer; rather, CD44s expression has been reported as a favourable prognostic factor in 
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patients with node-negative breast cancer (Diaz, Zhou et al. 2005). Moreover, CD44s is 
expressed at a higher level in tubular carcinoma of the breast, which rarely metastasises, 
as compared to micropapillary carcinoma which is more aggressive with significantly 
higher metastatic potential (Gong, Sun et al. 2005). In contrast, the presence of CD44 
variants, in particular CD44v3 and CD44v6, correlates with adverse features in breast 
carcinomas. CD44v3 expression has been linked to lymph node metastases, whilst, 
CD44v6 expression has been associated with increased tumour grade and has been shown 
to be an independent prognostic factor in breast carcinomas (Kaufmann, Heider et al. 
1995; Sinn, Heider et al. 1995; Rys, Kruczak et al. 2003). However, it should be noted 
that the role of CD44 in breast cancer is not yet fully elucidated and there are still 
conflicting data suggesting that it may represent a positive prognostic element. For 
example, a study by Jansen et al. failed to find a relationship between CD44v6 and breast 
cancer prognosis in a cohort of 338 patients, whilst, loss of CD44s expression was 
suggested to promote lung metastasis in a mouse model of mammary carcinoma (Jansen, 
Joosten-Achjanie et al. 1998; Lopez, Camenisch et al. 2005). 
 
Of particular interest has been the discovery that CD44 is a reliable marker of breast 
cancer stem cells (CSCs). CSCs are a subgroup of tumour cells that grow on serial 
transplantation in xenogenic models, have self renewal ability and tumours derived from 
CSCs can replicate the heterogeneity seen in parental tumours thereby establishing the 
differentiation ability of these cells. They are also highly resistant to apoptosis. Several 
malignancies of haematopoietic and epithelial origin are known to express CD44 in their 
CSCs. The presence of CSCs in breast cancer is now considered highly likely and there 
have been several studies indicating their presence (Pece, Tosoni et al. 2010; Ali, Dawson 
et al. 2011). CD44 and CD24 were first used by Al-Hajj et al. to prospectively isolate 
57 
 
CSCs from patients with breast cancer using specific cell surface markers and they 
showed that these CD44-positive, CD24 low/negative cells (CD44
+
/ CD24
low/-
) were able 
to form tumours in NOD/SCID mice and the subsequent xenografts using these cells 
exhibited the phenotypic diversity representative of the original tumours (Al-Hajj, Wicha 
et al. 2003). Since then CD44 has been used as a reliable marker of breast CSCs in 
various studies in conjunction with CD24 (CD44
+
/ CD24
low/-
).  
 
CD44 has also been implicated in chemotherapy resistance in breast cancer. Cain et al. 
used surface proteomic signatures in wtMCF-7 and the multidrug-resistant NCI/ADR-
RES cell lines to show that CD44 was an independent surface biomarker of drug 
resistance (Cain, Hauptschein et al. 2011). CD44 activation has been shown to activate 
MDR1/P-glycoprotein (multidrug resistance gene) and the anti-apoptotic gene bcl-XL via 
beta catenin signalling in an in vitro model of breast cancer resulting in chemoresistance 
(Bourguignon, Xia et al. 2009). There is evidence that CD44-ErbB interplay may 
contribute to chemoresistance. For example, in the multidrug-resistant MCF-7/Adr human 
breast carcinoma cell line, Misra et al. showed that CD44-HA interaction contributes to 
drug resistance by formation of a complex with HER2 thereby activating PI3K which 
then activates Akt and anti-apoptotic events in these cells (Misra, Ghatak et al. 2005). 
Current evidence points to a role of CD44 in breast cancer stem cells in promoting 
resistance. For example, Phuc et al. showed that CD44 downregulation using siRNA 
increases sensitivity of breast CSCs to the chemotherapeutic agent doxorubicin (Van 
Phuc, Nhan et al. 2011). CSCs are known to have multidrug resistance and one of the 
main mechanisms appears to be the high levels of ATP-binding cassette (ABC) 
transporter proteins, particularly ABCG2 which confers a high ability to eliminate drugs 
through efflux pumping mechanisms (Hirschmann-Jax, Foster et al. 2004). This and other 
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mechanisms allow CSCs to have intrinsic resistance to not just chemotherapy but 
radiation therapy as well. For example, Philips et al. demonstrated that CD44
+
/CD24
−
 
enriched cells isolated from wtMCF-7 and MDA-MB-231 cell lines exhibited more 
resistance to radiation treatment than corresponding non CD44
+
/CD24
−
 cells (Phillips, 
McBride et al. 2006).  
 
It has been recently hypothesised that breast CSCs which express high levels of CD44 
may play a role, atleast partly, in endocrine resistance in breast cancer (O'Brien, Howell 
et al. 2009). Evidence supporting this hypothesis includes the observations that breast 
CSCs are ERα low or negative and ER expression is the most consistent marker for 
indicating response to endocrine therapy and, therefore, breast CSCs are unlikely to be 
endocrine sensitive. Many of the mechanisms that are implicated in the aggressive 
behaviour of the breast CSCs are also pathways that are known to interact with CD44. For 
example, Farnie et al. showed that the EGFR pathway was activated in DCIS and 
treatment with gefitinib, an EGFR inhibitor, resulted in a clear reduction in 
mammosphere formation efficiency (Farnie, Clarke et al. 2007). Duru et al. demonstrated 
that a HER2-mediated prosurvival signalling network accounts for the aggressive 
phenotype noted in breast CSCs (Duru, Fan et al. 2012).  
 
59 
 
1.7 EXPERIMENTAL HYPOTHESES 
Resistance to tamoxifen therapy in breast cancer is associated with poor prognosis 
clinically and development of an aggressive phenotype in vitro. Preliminary data from our 
group using an in vitro model of acquired tamoxifen resistance (‘Tam-R’ cells), have 
shown that these cells overexpress CD44 gene transcripts. These cells also utilise ErbB 
receptors known to interact with CD44. Based on these observations and the current 
evidence indicating a role of ErbB family receptors in tamoxifen resistance, we 
formulated the following hypotheses to be investigated in this MD project: 
 
1. CD44 is overexpressed at both gene and protein level in the Tam-R model of in vitro 
acquired tamoxifen-resistant breast cancer 
2. CD44 overexpression is responsible for promoting the aggressive phenotypic features 
noted in the Tam-R cells 
3. CD44 overexpression sensitises the Tam-R cells to the stromal factor HA which is 
normally found within the tumour microenvironment 
4. CD44 interacts with  ErbB receptors in Tam-R cells thereby influencing Tam-R cell 
phenotype 
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1.8 THESIS AIMS AND OBJECTIVES 
The goal of hypothesis testing during this project would be met through the following 
aims and objectives using the Tam-R model of acquired resistance:  
 
1) Validate CD44 gene overexpression by RT-PCR and characterise CD44 expression at 
the protein level using Western blotting and immunocytochemistry 
2) Investigate the role of CD44 as a mediator of the adverse phenotype noted in these 
cells using functional assays (migration, invasion and growth) 
3) Determine whether increased CD44 expression augments their sensitivity to 
exogenous HA using Western blotting, immunocytochemistry and functional assays 
(migration and growth) 
4) Explore the interaction between CD44 and members of the ErbB family using 
Western blotting, immunocytochemistry, immunofluorescence and 
immunoprecipitation 
 
 
 
  
 
 
 
 
 
 
 
 
 
Chapter Two 
 
Materials and Methods 
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2.1 MATERIALS 
Table 2.1 is a list of all the materials and equipment used during the course of this study 
along with their relevant suppliers. 
 
Table 2.1 List of materials and equipment used and their suppliers 
Material / Equipment 
 
Supplier 
Acetic acid Fisher Scientific UK Ltd, Loughborough, UK 
Acrylamide / bis-acrylamide 
(30% v/v) 
Sigma-Aldrich, Poole, Dorset, UK 
Adobe Photoshop 6 Adobe Systems Europe Ltd, UK 
Agarose Bioline Ltd, London, UK 
Alexa Fluor® 488 fluorescent dye Invitrogen, Paisley, UK 
Ammonium persulphate (APS) Sigma-Aldrich, Poole, Dorset, UK 
Amphotericin B (Fungizone®) Invitrogen, Paisley, UK 
Antibiotics  
(Penicillin and Streptomycin) 
Invitrogen, Paisley, UK 
Anti-mouse horseradish peroxidise-
linked IgG (Source: sheep)  
Amersham, Little Chalfont, UK 
Anti-rabbit horseradish peroxidase-
linked IgG (Source: donkey) 
Amersham, Little Chalfont, UK 
Aprotinin Sigma-Aldrich, Poole, Dorset, UK 
Bio-Rad Dc Protein Assay:  
Reagents A, B and S 
Bio-Rad Laboratories Ltd, UK 
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Bio-Rad Mini-Protean® 3 apparatus Bio-Rad Laboratories Ltd, UK 
Bovine Serum Albumin (BSA) Sigma-Aldrich, Poole, Dorset, UK 
Bromophenol Blue (BPB) BDH Chemicals Ltd, Poole, Dorset, UK 
Cecil CE2041 spectrophotometer Cecil Instruments, Cambridge, UK 
Cell Culture Medium: RPMI 1640 
and Phenol red-free RPMI 1640 
Invitrogen, Paisley, UK 
Cell Scrapers Greiner Bio-One Ltd, Gloucestershire, UK 
Chemiluminescent Supersignal® 
West HRP Substrate (Dura and 
Femto) 
Pierce and Warriner Ltd, Cheshire, UK  
Corning Transwell® inserts  Fisher Scientific UK Ltd, Loughborough, UK 
Cotton swabs Johnson & Johnson, Maidenhead, UK 
Coulter Counter counting cups and 
lids 
Sarstedt AG and Co, Nümbrecht, Germany 
Coulter™ Multisizer II  Beckman Coulter Ltd, High Wycombe, UK 
Crystal violet Sigma-Aldrich, Poole, Dorset, UK 
Denley BA852 Autoclave  
 
Thermoquest Ltd, Basingstoke, UK 
DharmaFECT® 1 lipid transfection 
reagent 
Thermo Scientific Dharmacon Ltd, UK 
Disposable cuvettes Fisher Scientific UK Ltd, Loughborough, UK 
Di-thiothreitol (DTT) Sigma-Aldrich, Poole, Dorset, UK 
dNTP’s (dGTP, dCTP, dATP, dTTP) Amersham, Little Chalfont, UK 
Ethidium bromide Sigma-Aldrich, Poole, Dorset, UK 
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Ethylene diamine tetraacetic acid  
(EDTA) 
Sigma-Aldrich, Poole, Dorset, UK 
EZView
TM 
Red agarose beads  Sigma-Aldrich, Poole, Dorset, UK 
Fibronectin (1μg/ml) Sigma-Aldrich, Poole, Dorset, UK 
Filter Paper Whatman, Maidstone, UK 
Foetal Calf Serum (FCS) Invitrogen, Paisley, UK 
Fotodyne 3-3002 
UV transilluminator 
Fotodyne Inc, USA 
General Laboratory Glass and Plastic 
utilities  
Fisher Scientific UK Ltd, Loughborough, UK 
Glass coverslips BDH Chemicals Ltd, Poole, Dorset, UK 
Glass slides Fisher Scientific UK Ltd, Loughborough, UK 
Glutamine Invitrogen, Paisley, UK 
Glycine Sigma-Aldrich, Poole, Dorset, UK 
GS690 Imaging densitometer  Bio-Rad Laboratories Ltd., UK 
Hamamatsu C4742-96 digital camera  Hamamatsu Photonics Ltd, Hertfordshire, UK 
Hydrochloric acid (HCl) Fisher Scientific UK Ltd, Loughborough, UK 
Hyperladder
TM
 IV (100-1000bp) Bioline Ltd, London, UK 
IEC Micromax RF Microcentrifuge  Thermo Electron Corporation, Hampshire, UK 
Isoton® II azide-free balanced 
electrolyte solution 
Beckman Coulter Ltd, High Wycombe, UK 
Jouan C312 centrifuge  Thermo Fischer Scientific Inc, MA, USA 
Kodak MXB Autoradiography film 
(blue sensitive; 18cm x 24cm) 
Genetic Research Instrumentation (GRI), 
Rayne, UK 
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Labonco Purifier PCR Enclosure  GRI, Rayne, UK 
Laminar flow cabinet Bioquell UK Ltd, Andover, UK 
Leica DM-IRE2 fluorescence 
microscope  
Leica Microsystems Imaging Solutions Ltd, 
Cambridge, UK 
Leupeptin Sigma-Aldrich, Poole, Dorset, UK 
Lower Buffer for SDS-PAGE Gels 
(TRIS 1.5M, pH 8.8) 
Bio-Rad laboratories Ltd, Herts, UK 
Magnesium chloride (MgCl2) Sigma-Aldrich, Poole, Dorset, UK 
Marvel Skimmed Milk Powder Premier International Foods, Lincs, UK 
Matrigel™ Basement Membrane BD Biosciences, Oxford, UK 
Microcentrifuge Tubes Elkay Laboratory Products, Basingstoke, UK 
Molecular Analyst™ Version 1.5  Bio-Rad laboratories Ltd, Herts, UK 
Moloney Murine Leukaemia Virus 
(MMLV) reverse transcriptase 
Invitrogen, Paisley, UK 
N,N,N’,N’-tetramethylethlyene-
diamine (TEMED) 
Sigma-Aldrich, Poole, Dorset, UK 
Nikon Eclipse TE200 phase-contrast 
microscope 
Nikon UK Ltd, Kingston-upon-Thames, UK 
Nitrocellulose transfer Membrane 
(Protran® 0.45µm pore size) 
Schleicher and Schuell, Dassell, Germany 
Olympus BH-2 microscope  Olympus Corporation, UK 
ON-TARGETplus
®
 siRNA Control 
Reagent 
Thermo Scientific Dharmacon Ltd 
PCR oligonucleotide primers Invitrogen, Paisley, UK 
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pH calibration buffer tablets (pH4, 7 
and 10) 
Fisher Scientific UK Ltd, Loughborough, UK 
Phenylarsine oxide  Sigma-Aldrich, Poole, Dorset, UK 
Phenylmethylsulfonyl fluoride 
(PMSF) 
Sigma-Aldrich, Poole, Dorset, UK 
Pipette Tips Greiner Bio-One Ltd, Gloucestershire, UK 
Polaroid GelCam camera  GRI, Rayne, UK 
Polyoxyethylene-sorbitan 
monolaurate (Tween-20) 
Sigma-Aldrich, Poole, Dorset, UK 
Ponceau S solution (0.1% w/v in 5% 
acetic acid) 
Sigma-Aldrich, Poole, Dorset, UK 
Potassium chloride (KCl) Sigma-Aldrich, Poole, Dorset, UK 
PowerMAC G5 computer  Apple Computer Inc, California, USA 
Powerpac Basic power pack Bio-Rad Laboratories Ltd, Herts, UK 
Precision Plus Protein™ All Blue 
Standards (10-250kDa) 
Bio-Rad laboratories Ltd, Herts, UK 
PTC-100 thermal cycler Bio-Rad laboratories Ltd, Herts, UK 
Random Hexamers (RH) Amersham, Little Chalfont, UK 
RNase-free H2O Sigma-Aldrich, Poole, Dorset, UK 
RNasin® ribonuclease inhibitor Sigma-Aldrich, Poole, Dorset, UK 
Sanyo MCO-17AIC incubator Sanyo E&E Europe BV, Loughborough, UK 
siRNA buffer (5x) Thermo Scientific Dharmacon Ltd, UK 
SMARTpool siRNA against CD44 
(ON-Target plus
®
) 
Thermo Scientific Dharmacon Ltd, UK 
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Sodium azide Sigma-Aldrich, Poole, Dorset, UK 
Sodium chloride (NaCl) Sigma-Aldrich, Poole, Dorset, UK 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich, Poole, Dorset, UK 
Sodium fluoride (NaF) Sigma-Aldrich, Poole, Dorset, UK 
Sodium hydroxide (NaOH) Fisher Scientific UK Ltd, Loughborough, UK 
Sodium molybdate (Na2MoO4 )       Sigma-Aldrich, Poole, Dorset, UK 
Sodium orthovanadate (NaVO4) Sigma-Aldrich, Poole, Dorset, UK 
Solvents (acetone, chloroform, 
ethanol, formaldehyde, isopropanol 
and methanol) 
Fisher Scientific UK Ltd, Loughborough, UK 
Sterile bijou vials (5ml) Bibby Sterilin Ltd, Stone, UK 
Sterile cell culture plasticware Nunc Int, Roskilde, Denmark 
Sterile disposable serological 
pipettes (5ml, 10ml, 25ml) 
Sarstedt AG and Co, Nümbrecht, Germany 
Sterile Falcon tubes Sarstedt AG and Co, Nümbrecht, Germany 
Sterile phosphate buffered saline 
(PBS) 
Invitrogen, Paisley, UK 
Sterile syringe filters (0.2µm) Becton Dickinson (BD) UK Ltd, Oxford, UK 
Sterile syringe needles Sherwood-Davis & Geck, Gosport, Hampshire, 
UK 
Sterile syringes (BD Plastipak™, 
10ml) 
Becton Dickinson (BD) UK Ltd, Oxford, UK 
Sterile Universal Containers (30ml) Greiner Bio-One Ltd, Gloucestershire, UK 
Sub-cell® Electrophoresis System  Bio-Rad laboratories Ltd, Herts, UK 
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Sucrose Fisher Scientific UK Ltd, Loughborough, UK 
Taq DNA polymerase (BioTaq™; 
5U/µl) 
Bioline Ltd, London, UK 
Tri Reagent® RNA Isolation 
Reagent 
Sigma-Aldrich, Poole, Dorset, UK 
Tris HCl Sigma-Aldrich, Poole, Dorset, UK 
Triton X-100 Sigma-Aldrich, Poole, Dorset, UK 
Trizma (Tris) Base Sigma-Aldrich, Poole, Dorset, UK 
Tryspin/EDTA 10x solution Invitrogen, Paisley, UK 
Upper Buffer for SDS-PAGE Gels 
(Tris 0.5M, pH6.8)  
Bio-Rad laboratories Ltd, Herts, UK 
Vectashield® hard-set mounting 
medium containing DAPI nuclear 
stain 
Vector laboratories Inc, Peterborough, UK 
Western Blocking Reagent Roche Diagnostics, Mannheim,  
Germany 
X-ray film developer and fixer 
solutions (X-O-dev and X-O-fix) 
X-O-graph Imaging system, Tetbury, UK 
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2.2 CELL CULTURE 
The majority of work in this study utilised the ER-positive, hormone-sensitive wild-type 
MCF-7 cell line (‘wtMCF-7’) and its tamoxifen-resistant derivative cell line (‘Tam-R’).  
 
2.2.1 Routine Cell Culture: wtMCF-7 
2.2.1.1 Routine cell culture 
Human mammary carcinoma wtMCF-7 cells were previously donated to the breast cancer 
group by AstraZeneca Pharmaceuticals (Macclesfield, Cheshire), being originally 
obtained from the American Type Culture Collection (ATCC® Number HTB-22™). 
wtMCF-7 cells were retrieved from liquid nitrogen storage and routinely cultured in 
RPMI 1640 medium containing phenol red as an indicator of pH and supplemented with 
5% foetal calf serum (FCS), antibiotics (penicillin:100IU/ml, streptomycin:100µg/ml), 
anti-fungal agent (2.5µg/ml amphotericin B, Fungizone®) and 200nM glutamine. Cell 
cultures were maintained as monolayers in 75cm
2
 flasks (T75) at 37ºC in a humidified 
5% CO2 atmosphere using a Sanyo MCO-17AIC incubator (Sanyo E&E Europe BV, 
Loughborough, UK). The culture medium was changed at regular intervals (3-4 days). 
Culture flasks were monitored via phase-contrast microscopy (Nikon Eclipse TE200; 
Nikon UK Ltd, Kingston-upon-Thames, UK).  Cells were routinely assessed during 
culture by light microscopy and passaged once they reached 90% confluency.   
 
2.2.1.2 Cell passaging 
Cell culture medium was aspirated and the adhered cells separated using 10ml mixture of 
trypsin (0.05%) and EDTA (0.02%) in PBS. Following 3-5 minutes in the incubator to 
allow cells to detach, trypsin was neutralised by the addition of 10mls of routine culture 
medium. The cell suspension was centrifuged at 1000rpm for 5 minutes (Jouan C312, 
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Thermo Fischer Scientific Inc, MA, USA), the supernatant discarded and the cell pellet 
was resuspended uniformly in 10mls of the appropriate medium. 1/10
th 
of this uniform 
cell suspension was subsequently added to 15ml fresh medium and seeded into a T75 
flask and cultured under routine conditions described above. Cell lines were generally 
used for up to a maximum of 25 passages to avoid adverse phenotypic changes that are 
seen in higher passages. Once cells were discarded, having reached a high passage 
number, cryopreserved cells of a low passage number were revived for routine culture. 
All cell culture experiments were performed in laminar flow cabinets (Bioquell UK Ltd, 
Andover, UK) with full sterile precautions. Routine culture equipment was sterilised via 
autoclaving at 119ºC in a Denley BA852 autoclave (Thermoquest Ltd, Basingstoke, UK).  
 
2.2.2 Routine Cell Culture: Tam-R 
To explore the role of CD44 in acquired tamoxifen resistance in vitro, we used the Tam-R 
cell line. These are a tamoxifen-resistant derivative of wtMCF-7 cells used for studies 
into endocrine resistance generated by continuous exposure (6 months) of wtMCF-7 cells 
to 4-hydroxytamoxifen (4-OH-TAM, 10
-7
M in ethanol) (Knowlden, Hutcheson et al. 
2003). After an initial drop in the wtMCF-7 growth rates due to the suppressive effects of 
tamoxifen, a gradual increase in the growth rate of the remaining viable cells was 
observed indicating outgrowth of cells resistant to 4-OH-TAM. The new cell line was 
cultured in medium containing 4-OH-TAM for a further 4 months prior to original 
characterisation studies. Following retrieval from liquid nitrogen storage, Tam-R cells 
were routinely cultured in phenol-red free RPMI with 5% charcoal-stripped FCS, 
glutamine (200mM), antibiotics (penicillin:100IU/ml, streptomycin:100µg/ml) and  anti-
fungal agent (2.5µg/ml amphotericin B, Fungizone®). This medium is referred to as 
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‘W+5%’. Tam-R cell cultures in W+5% were maintained, monitored and passaged using 
the technique described for wtMCF-7 cells in Section 2.2.1.1 and 2.2.1.2.  
 
2.2.3 Preparation for Use of Cells in Experiments: wtMCF-7 and Tam-R 
Due to the potential oestrogenic stimulus arising from the phenol red indicator and steroid 
hormones within the serum, the culture conditions for wtMCF-7 cells were altered 24 
hours prior to any experiments. After washing cells 3 times with Dulbecco’s phosphate-
buffered saline (PBS), the medium was changed to the experimental medium (EM) 
containing phenol-red free RPMI with 5% charcoal-stripped FCS and glutamine 
(200mM) but lacking antibiotics or antifungals. Tam-R cells were switched over to EM 
containing 4-OH-TAM 24 hours prior to use in experiments.  
 
To ensure experimental accuracy, cells were seeded onto experimental dishes after 
determination of cell concentration and number using a Coulter Counter. Once harvested 
using trypsin/EDTA as described above, the cells were passed through a sterile 25G 
syringe needle to obtain a single cell suspension. A 100µl aliquot of this suspension was 
mixed carefully with 10mls Isoton® II and cell number determined using a Coulter™ 
Multisizer II (Beckman Coulter Ltd, High Wycombe, UK). Cell number counts were 
performed in triplicate and then averaged and multiplied by a factor of 200 to obtain a 
count of the total number of cells in the flask. Cells were then seeded at the required 
density as dictated by the experimental design in the appropriate medium. 
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2.2.4 Treatments 
The experiments in this study required use of different treatments in cultured cells these 
are listed below along with their final concentrations (Table 2.2). Full details of treatment 
concentration and duration are listed in the relevant sections of the results chapter. 
 
Table 2.2 List of treatments used in this study 
Treatment Function Concentration Manufacturer 
Gefitinib (Iressa®) Tyrosine kinase 
inhibitor 
1µM AstraZeneca, UK 
Heregulin (HRG-
β1) 
ErbB ligand 10ng/ml Sigma Ltd, Dorset, UK 
Hyaluronan (low 
molecular weight) 
CD44 ligand 200µg/ml R&D Systems, Oxford, 
UK 
Hyaluronan 
(medium molecular 
weight) 
CD44 ligand 200µg/ml R&D Systems, Oxford, 
UK 
Hyaluronan (high 
molecular weight) 
CD44 ligand 200µg/ml R&D Systems, Oxford, 
UK 
PD098059 MAPK inhibitor 50µM Alexis, Bingham, UK 
Transforming 
Growth Factor 
Alpha (TGFα) 
Growth factor 10ng/ml Sigma Ltd, Dorset, UK 
Trastuzumab 
(Herceptin®) 
Monoclonal 
Antibody against 
HER2 
100nM Roche, UK 
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2.3 GENE EXPRESSION ANALYSIS 
Gene expression in wtMCF-7 and Tam-R cells was analysed using the semi-quantitative 
reverse transcription–polymerase chain reaction (RT-PCR) technique (Saiki, Scharf et al. 
1985; Mullis, Faloona et al. 1986; Mullis and Faloona 1987). All experiments were 
conducted in a Labonco Purifier PCR Enclosure (GRI, Rayne, UK) which was rubbed 
down with 70% ethanol prior to use to minimise contamination. 
 
2.3.1  Total RNA Isolation, Quantitation and Gel electrophoresis 
Cells were seeded into 60mm dishes (5x10
5
 cells per dish), cultured until log phase 
growth was reached and total RNA extracted using TRI Reagent
 ® 
RNA Isolation Reagent 
(1ml per 10cm
2 
at room temperature). Lysates were collected using a cell scraper and 
pipetted into 1.5ml microcentrifuge tubes. Chloroform (0.2ml per 1ml TRI
 
Reagent
®
) was 
added to the lysates to achieve phase separation. Samples were then vortexed, incubated 
at room temperature (15 minutes) and centrifuged at 11,300 rpm (15 minutes at 4°C) 
using a microcentrifuge (IEC Micromax RF Microcentrifuge; Thermo Electron 
Corporation, Hampshire, UK). Isopropanol was then added to the aliquoted upper 
aqueous phase to precipitate RNA and the process repeated. RNA pellets were 
subsequently washed twice with ethanol (75% in H2O, 1ml per pellet), vortexed and 
centrifuged for 5 minutes (9000rpm at 4°C). Each pellet was then resuspended in 20µl 
RNAase-free sterile H2O.  
 
This was followed by determination of RNA concentration. 1µl RNA was dissolved in 
499µl RNAase-free H2O and the absorbance was measured at a wavelength of 260nm 
(A260) using a spectrophotometer (Cecil CE2041; Cecil Instruments, Cambridge, UK). 
RNA concentration was calculated using the following formula: RNA concentration 
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(μg/ml) = A260 x 40 x Dilution Factor. RNA quantification was then performed by 
measuring the absorbance at a wavelength of 280nm (A280). The A260/ A280 ratio was 
calculated to determine protein contamination (acceptable range = 1.8 – 2.0).  
 
Agarose gel electrophoresis was performed by resolving RNA samples on a 1% (w/v) 
agarose gel in Tris-Acetate-EDTA buffer (TAE, pH 8.3; Appendix VI) containing 
ethidium bromide (1µl of a 10g/ml solution per 100ml agarose gel). Electrophoresis of 
samples (500ng RNA dissolved in 5µl loading buffer; Appendix VI) was performed 
using a Sub-cell® Agarose Electrophoresis System linked to a power pack (Bio-Rad 
laboratories Ltd., Herts, UK) in a tank with TAE buffer at constant voltage (80V for 1 
hour). A Fotodyne 3-3002 UV transilluminator was used to visualise gels under UV light 
and photographs taken with a Polaroid GelCam camera (GRI, Rayne, UK). Good-quality 
RNA was indicated by a 28S band appearing twice as strong as the 18S band. 
 
2.3.2 Reverse Transcription 
Moloney Murine Leukaemia Virus (MMLV) reverse transcriptase enzyme was used to 
prepare complementary DNA (cDNA) using a standard protocol. 6µl of total RNA-
RNAase-free H2O solution (containing 1µg RNA) was mixed with 6µl of master mix (2µl 
of 100µM random hexamer oligonucleotides and 4µl dNTP mix comprising 0.625mM of 
dGTP, dCTP, dATP and dTTP). Samples were denatured at 65°C for 5 minutes and 
subsequently cooled at 4°C prior to addition of 8µl of RT master mix (4µl First Strand 
Buffer at 5x concentration, 2µl of 0.1M DTT, 1µl of RNasin™ RNase inhibitor and 1µl 
MMLV reverse transcriptase). Following incubation at 37°C for 50 minutes and 
inactivation, aliquotted samples were stored at -20°C until further use. 
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Amplification was performed using primers for CD44s (Forward: 5’ GAC ACA TAT 
TGT TTC AAT GCT TCA GC 3’; Reverse: 5’ GAT GCC AAG ATG ATC AGC CAT 
TCT GGA AT 3’) and β-actin (5’ GGA GCA ATG ATC TTG ATC TT 3’; Reverse: 5’ 
CCT TCC TGG GCA TGG AGT CCT 3’). 
 
2.3.3 Polymerase Chain Reaction (PCR) 
The master mix solution used for PCR contained 2µl of 100mM dNTP mix, 2.5µl of 10x 
NH4 reaction buffer, 0.625µl of 20µM forward primer, 0.625µl of 20µM reverse primer, 
0.2µl Taq polymerase enzyme, 0.75µl of 50mM MgCl2 and 17.8µl sterile RNAase-free 
H2O making up a volume of 24.5µl per reaction. This master mix solution was added to 
0.5µl cDNA and denatured at 100°C in a PTC100-thermal cycler (Bio-Rad laboratories 
Ltd, Herts, UK) with a suitable negative control for each reaction. All PCR reactions 
included primers specific for β-actin as an internal control and were performed in a semi-
quantitative manner using 27 cycles so that products were in the linear range of 
amplification (Denature 94°C, elongate 72°C and anneal 62°C).  
 
Electrophoresis of PCR cDNA products (15µl PCR product and 5µl loading buffer – 
Appendix VI) was performed as described before along with a molecular weight marker 
(Hyperladder™ IV 100-1000bp; 5µl). Visualisation of cDNA products using UV 
transillumination was carried out followed by imaging and subsequent scanning with a 
GS690 Imaging densitometer connected to a computer running Molecular Analyst version 
1.5 (both Bio-Rad Laboratories Ltd, Herts, UK).  
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2.4 ANALYSIS OF PROTEIN EXPRESSION 
Identification of cellular proteins and semi-quantitative assessment of protein expression 
was performed using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) (Towbin, Staehelin et al. 1979) and Western blotting (Laemmli 1970). Protein 
specific antibodies were used for analysis of protein expression in wtMCF-7 and Tam-R 
in basal conditions and following various treatments and modulation of experimental 
conditions. 
 
2.4.1 Cell Lysis 
Cells were seeded into 35mm, 60mm or 100mm petri dishes at an appropriate cell density 
and cultured until log-phase growth was reached. Cell confluency and viability was 
assessed using a Nikon Eclipse TE200 phase-contrast microscope (Nikon UK Ltd, 
Kingston-upon-Thames, UK). Appropriate treatments were then added according to 
experimental design and cells were continued to be cultured till experimental end point 
was reached. After this time cells were washed with ice cold PBS twice and lysed using 
lysis buffer containing protease and phosphatise inhibitors (Appendix VI). Cell material 
was collected using a cell scraper and the lysates transferred to a 1.5ml centrifuge tube 
and left on ice for 20 minutes. Lysates were then clarified by centrifugation (13,000rpm 
for 15 minutes at 4°C) and the supernatants stored at -20°C until required.  
 
2.4.2 Protein Concentration Assay 
Total soluble protein concentration in cell lysates was carried out using the Bio-Rad Dc 
Protein Assay Kit (Bio-Rad Laboratories Ltd., UK) using a modification of the original 
Lowry method (Lowry, Rosebrough et al. 1951). Initially, a BSA standard curve was 
generated by using BSA protein concentration standards ranging between 0 to 1.45 mg/ml 
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(Appendix VI) analysed at 750nm using a spectrophotometer (Cecil CE2041). 
Subsequently, lysates were diluted 1:5 in lysis buffer (final volume of 50µl in cuvette) in 
preparation for absorbance measurement. To each sample was added 250µl Reagent A 
(containing 20µl Reagent S per1ml Reagent A) and 2ml Reagent B and the solutions were 
incubated at room temperature for 5 minutes and absorbance read as previously 
described. Total soluble protein concentration in the samples was calculated using the 
BSA standard curve and the absorbance of the lysate samples.  
 
 2.4.3 SDS-PAGE Analysis 
SDS-PAGE was used to separate proteins according to size from the original whole cell 
lysates using the method originally described by Laemmli as mentioned earlier. This 
included a stacking gel (4-5% w/v) and a resolving gel (8% w/v) as described in Table 
2.3 & Table 2.4, and was performed using the Bio-Rad Mini-Protean® III apparatus 
powered by a Powerpac Basic powerpack (Bio-Rad Laboratories, UK). The Bio-Rad gel 
casting system was cleaned with ethanol and the resolving gel mixture was poured 
(leaving sufficient space for the stacking gel) into the gel cassette and overlaid with 
distilled water. The gel was then allowed to set at room temperature for at least 30 
minutes before being overlaid with the stacking gel.  
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Table 2.3 Recipe for stacking gel 
 
Composition 
 
4% gel (w/v) 
(10ml) 
 
5% gel (w/v)  
(10ml) 
 
Final 
Concentration 
Acrylamide / bis-acrylamide 
(30% solution) 
1.3ml 1.67ml 4-5% w/v 
dH20 6.1ml 5.83ml - 
Tris (0.5M, pH6.6) 2.5ml 2.5ml 125mM 
SDS (10% solution in dH20) 100µl 100µl 0.1% (w/v) 
APS (10% solution in dH20) 50µl 50µl 0.05% (w/v) 
TEMED 10µl 10µl 0.1% (v/v) 
 
 
Table 2.4 Recipe for resolving gel 
 
Composition 8% gel (w/v) for 10ml Final Concentration 
Acrylamide / bis-acrylamide 
(30% solution) 
2.7ml 8% 
H20 4.6ml - 
Tris (1.5M, pH8.8) 2.5ml 375mM 
SDS (10% solution in H20) 100µl 0.1% (w/v) 
APS (10% solution in H20) 100µl 0.1% (w/v) 
TEMED 20µl 0.2% (v/v) 
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The water overlying the gel was discarded once the gel was set and the stacking gel 
solution poured in. A 10 or 15-well comb (1.5mm width) was then inserted into the 
stacking gel solution and gel allowed to set at room temperature. The gels were 
positioned in the electrophoresis apparatus, appropriate amount of SDS-PAGE running 
buffer (Appendix VI) was added to the inner and outer reservoirs, and the combs were 
gently removed.  
 
Cell lysates were prepared for loading onto gels by mixing volumes containing 20-60µg 
protein with 3x sample loading buffer containing DTT (Appendix VI) and denatured by 
heating for 5 minutes at 100°C in a dry bath. 10µl of a molecular weight marker 
(Precision Plus All Blue Standards 10-250kDa, 10µl) was loaded alongside the 
experimental samples into the wells of the stacking gel (20-60µg/lane) to aid assessment 
of the molecular weight of the detected proteins. Electrophoresis of the gels was 
performed at a constant voltage (160V) until the samples had migrated the required 
distance down the gel. After electrophoresis, the gels were prepared for protein transfer 
by immersing the cassette in transfer buffer (Appendix VI). 
 
2.4.4 Western Blotting 
Western Blotting is the method of transferring size-fractionated proteins onto a 
nitrocellulose membrane using electrophoresis. Proteins from the SDS-PAGE gels were 
transferred to a nitrocellulose membrane using the Bio-Rad mini-Protean system 
described earlier. A ‘gel sandwich’ was created using two pieces of filter paper, two 
Teflon sponge pads and one piece Protran® nitrocellulose membrane (0.45µm pore size, 
cut to match gel size) pre-soaked in transfer buffer (30 minutes) per SDS-PAGE gel for 
assembling the transfer cassette (Figure 2.1). Following completion of SDS-PAGE 
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electrophoresis, the resolving gel was carefully removed from the cassette and placed in a 
tray containing distilled water. A 5ml pipette tip was rolled over the ‘gel-sandwich’ to 
ensure removal of any air bubbles. The cassette was then placed into the transfer 
apparatus ensuring that the membrane was adjacent to the anode. This is to ensure that the 
negatively charged or reduced proteins migrate in the appropriate direction, namely gel to 
membrane, thus reducing the risk of loss of proteins during transfer. The transfer cassette 
was placed into the transfer tank with an ice-pack and then filled with cold transfer buffer 
(4°C). The transfer process involved electrophoresis at 100V constant voltage for 60-120 
minutes (adjusted depending on the molecular size of the protein of interest). 
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Figure 2.1 Schematic representation of the Western blotting transfer cassette (‘gel
sandwich’)
A schematic representation of the Western blotting transfer cassette used during the transfer
process as described in Section 2.4.4 is depicted above. A Teflon® sponge was put onto the
black plastic wall of the transfer cassette, followed by a piece of grade 3 filter paper. The
SDS-PAGE (Sodium dodecyl sulphate polyacrylamide gel electrophoresis) gel was then
carefully placed on the filter paper taking care to keep the correct orientation and avoid
formation of air bubbles. The gel was kept wet using transfer buffer and the nitrocellulose
membrane was laid on top. The cassette was completed by putting a piece of filter paper and
then another Teflon® sponge. This ‘gel sandwich’ was then rolled with a large pipette tip to
remove any air bubbles and the cassette was closed. All components were carefully pre-
soaked in transfer buffer prior to use.
White cassette wall (positive)
Black cassette wall (negative)
Filter paper
SDS-PAGE gel
Nitrocellulose membrane
Teflon® sponge pad
Filter paper
Teflon® sponge pad
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2.4.5 Immunoprobing of Western Blots 
Following completion of transfer, the nitrocellulose membrane was washed with distilled 
water (3 x 5 minutes) and then stained with Ponceau S solution (0.1% w/v in 5% acetic 
acid) to demonstrate adequate transfer of proteins. The membrane was destained with 
TBS-Tween (TBST: 0.5% v/v Tween-20 in 1x TBS, Appendix VI) and then incubated in 
a blocking solution (Milk, 5% w/v in TBS contain 0.1% v/v Tween-20) for at least 60 
minutes at room temperature using a roller.  Subsequently, membranes were washed with 
TBST (3 x 5 minutes) and incubated under gentle agitation with the primary antibody 
according to the incubation conditions considered optimal for the antibody in question. 
The list of primary antibodies used in the experiments are listed in Table 2.5 and 
antibodies were prepared for incubation by diluting in TBST containing 5% v/v Western 
Blocking Reagent and 0.05% sodium azide (preservative).  
 
After incubating with the primary antibody, membranes were washed with TBST (3 x 10 
minutes) at room temperature and then incubated with the appropriate horseradish-
peroxidase (HRP) conjugated anti-rabbit or anti-mouse secondary antibody at room 
temperature for 60 minutes. Excess secondary antibody was carefully washed using 
TBST (3 x 10 minutes) and the protein of interest visualised with luminol/peroxide-based 
Enhanced ChemiLuminescence/ECL reagents (Supersignal™ West Dura or 
Supersignal™ West Femto) applied according to manufacturer’s instructions (500µl per 
membrane) in an auto-radiography cassette (Kricka, Schmerfeld-Pruss et al. 1991; 
Mattson and Bellehumeur 1996). Luminol is oxidised by horseradish-peroxidase (in the 
secondary antibody) in the presence of peroxide, a process which releases photons that 
can be detected on X-ray film. Exposures range from a few seconds to several hours 
depending on the signal strength. X-ray films were developed using an X-O-graph 
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compact X2 X-ray developer (X-O-Graph Imaging system, Tetbury, UK). The images 
obtained were scanned and analysed using a Bio-Rad Imaging GS-690 densitometer. 
Variation in loading was normalised using β-actin or GAPDH which are used as internal 
loading controls (Liao, Xu et al. 2000). Blots shown later in the results section are 
representative of a minimum of three separate experiments and densitometry values were 
used for semi-quantitative statistical analysis. 
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 Table 2.5 List of antibodies used during immunoprobing of Western blots  
 
Antibody Species Dilution Incubation 
conditions 
Supplier 
Primary Antibodies 
CD44 Mouse 1:2000 O/N 4°C + 
2 hours RT 
Stratech Scientific, UK 
p-MAPK 
(42/44) 
Rabbit 1:1000 O/N 4°C Cell Signaling Technology Inc, 
USA 
T-MAPK Rabbit 1:2000 O/N 4°C Cell Signaling Technology Inc, 
USA 
p-EGFR 
(1068) 
Rabbit 1:2000 2 hours RT Cell Signaling Technology Inc, 
USA 
T-EGFR Rabbit 1:2000 2 hours RT Cell Signaling Technology Inc, 
USA 
p-HER2 
(1248) 
Rabbit 1:2000 2 hours RT Invitrogen, Paisley, UK 
T-HER2 Rabbit 1:2000 2 hours RT Cell Signaling Technology Inc, 
USA 
Secondary Antibodies 
GAPDH Mouse 1:15000 1 hour RT Abcam, Cambridge, UK 
β-actin Mouse 1:20000 1 hour RT Sigma-Aldrich, Poole, Dorset, UK 
 
(Conditions: RT = Room Temperature, O/N = Overnight) 
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2.5 IMMUNOCYTOCHEMISTRY 
Immunocytochemistry (ICC) uses antibodies that target specific peptides or protein 
antigens in the cell via specific epitopes. Unlike Western blotting, ICC provides 
information about the in-situ localisation of the protein in the cell..  
 
2.5.1  Culture on Coverslips and Cell Fixation 
Cells were passaged and counted as described previously before being seeded onto 
autoclaved, sterile 3-aminopropyltriethoxysilane-coated (TESPA) coverslips at a density 
of 1 x 10
4
 cells/cm
2
 within 35mm dishes. Following a 24-hour period to allow cells to 
adhere to the coverslip, the growth medium was changed to the experimental medium 
(EM) containing appropriate treatments. At completion of the experiment, dishes 
containing the coverslips were placed on ice and transferred to a laminar flow cabinet, 
where cell fixation was performed according to the immunocytochemical assay being 
performed (Table 2.6). The details of the individual cell fixation methods used are listed 
below:  
 
1) Formal Saline: After aspirating medium from the 35mm dishes containing the 
coverslips, a 3.75% Formal Saline solution (containing 450ml tap water, 50ml 37% 
formaldehyde solution and 4.5g sodium chloride) was added to each dish (1ml per 
dish) for 10 minutes. This was followed by a 100% ethanol wash for 5 minutes and 
subsequently a phosphate-buffered saline (PBS) wash for an additional 5 minutes.  
 
2) Phenol Formal Saline: After aspirating medium from the 35mm dishes containing the  
coverslips, a 2.5% (w/v) Phenol Formal Saline solution (prepared by dissolving 
phenol in a formal saline solution) was added to each dish (1ml per dish) for 5 
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minutes. This was followed by a 100% ethanol wash for 5 minutes and subsequently a 
PBS wash for an additional 5 minutes.  
 
Once fixed, the coverslips were stored in the -20°C in sucrose storage medium 
(Appendix VI) prior to the immunocytochemical assay. 
 
2.5.2 Immunocytochemical assays 
On the day of the planned assay, stored coverslips (placed in 35mm dishes) were removed 
from the freezer and washed in PBS (2 x 5 minutes) followed by a wash with 0.02% 
Tween-PBS (5 minutes) to remove the storage medium and allow the primary antibody 
applied to be distributed evenly across the coverslip aided by the detergent effect of 
Tween. The appropriate primary antibody was then applied to the coverslips (humidified 
by suspending over a a water bath in plastic towers) and incubated (between 60 minutes 
to overnight) at room temperature or 23°C (if left overnight) depending on the specific 
assay being performed. Following incubation of the primary antibody, coverslips were 
washed again in PBS/Tween-PBS depending on the assay in question. One drop of the 
secondary antibody (Dako peroxidise-labelled EnVision
TM
, Dako Ltd., Cambridgeshire, 
UK) from the original plastic container was applied to the coverslips and incubated at 
room temperature for 60 minutes. Coverslips were washed again with PBS/Tween-PBS as 
appropriate to the assay and immunolabelled proteins were visualised with a chromagen 
(diaminobenzidine tetrahydrochloride and hydrogen peroxide substrate) for 10 minutes 
followed by counterstaining with either methyl green or 5% hematoxylin. The 
counterstain was then washed off and coverslips air dried in preparation for the 
immunostaining analysis. 
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2.5.3 Assessment of immunocytochemistry using H-score  
Final assessment of immunostaining was carried out using a microscope (Olympus BH-2) 
fitted with a dual viewing attachment to allow assessment by two independent observers 
simultaneously. Nuclear, membrane and cytoplasmic staining was assessed for CD44, 
MAPK and Ki-67 as appropriate. The intensity of immunostaining and percentage of cells 
exhibiting positive staining was estimated using a minimum evaluation of 2000 cells per 
coverslip. The data collected from these assessments is used to calculate a score that 
reflects the degree of expression of the protein of interest called the H-score (Gee, 
Robertson et al. 1994). Depending on the intensity of staining, the cells are classified into 
four groups: no staining (score = 0), low (score = 1), moderate (score = 2) and high (score 
= 3) intensity of staining respectively and a corresponding percentage value is allocated to 
each of the four groups (no staining = a, low = b, moderate = c, high =d; where, a + b + c 
+ d = 100%).  The H-score is the mathematical score derived from the following 
equation: H-score = (a * 0) + (b * 1) + (c * 2) + (d * 3) [Range = 0 - 300]. The H-score is 
used for statistical analysis of the level of protein expression between experimental 
triplicates. 
 
Specific steps were followed while creating scale bars for the immunocytochemistry 
images in an attempt to maintain uniformity and accuracy. A standardised scale 
specifically designed for use with microscopes was used for calibration of images. The 
scale was photographed at various magnifications and these images were used to 
superimpose a scale bar on images obtained at the corresponding magnifications using 
Powerpoint software. The scale bar and the original image were merged together (using 
the ‘group’ function on the Powerpoint software) before any further modifications to the 
images was performed to preserve the fidelity of the scale bar.  
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Table 2.6: Immunocytochemical assays and their corresponding fixation methods 
 
Immunocytochemical assay Fixation method 
Primary Antibodies  
CD44 Phenol Formal Saline 
p-MAPK (44/42) Formal Saline 
T-MAPK Formal Saline 
Ki-67 Formal saline 
Secondary Antibodies  
Dako  EnVision™ (Goat anti-mouse) or  
Dako  EnVision™  (Goat anti-Rabbit) 
Not diluted 
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2.6 SIRNA-MEDIATED CD44 KNOCKDOWN 
To further explore the role of CD44 in Tam-R cells an siRNA based approach was taken 
(Hannon 2002). RNA interference (RNAi) is a term to describe gene silencing by double-
stranded RNA (dsRNA) which after entering the cell is cleaved by Dicer (an RNase III–
like enzyme) into double stranded small interfering RNAs (siRNAs) usually between 21-
23 nucleotides in length (Bernstein, Caudy et al. 2001). The siRNAs then form part of a 
protein complex called the RNAi-induced silencing complex (RISC), which guides the 
siRNAs to the target RNA sequence (Nykanen, Haley et al. 2001). The siRNA duplex 
then unwinds, and the antisense strand, while still bound to RISC, directs degradation of 
the complementary mRNA sequence by a combination of endo- and exo-nucleases 
(Martinez, Patkaniowska et al. 2002). This phenomenon can be replicated, under in vitro 
conditions, in mammalian cells using synthetic, short double-stranded RNAs that mimic 
the siRNAs produced by the enzyme Dicer (Elbashir, Harborth et al. 2001). Delivery of 
siRNA into cells can be done via microinjection, electroporation or using a lipid-based 
transfection reagent. Careful early optimisation studies should be conducted in any model 
to ensure adequate transfection and knockdown as well as reduce non-specific effects 
from the various reagents used in the process. Maximum down regulation is observed in 
24-48 hours but this effect can last up to 10 days.  
 
Non-targeting (NT) and CD44-specific siRNA (CD44-siRNA), both purchased as a 
5nmol lyophilised powder, were reconstituted in 250µl of 1x siRNA buffer giving a final 
stock concentration of 20µM which was then aliquoted in 10µl volumes and stored at -
20°C. The reagents used for siRNA inhibition in this study are listed in Table 2.7. 
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Table 2.7 List of reagents used for siRNA experiments 
 
Reagent Function Company 
SMARTpool siRNA 
against CD44 (ON-
Target plus
®
)  
Knockdown of CD44 mRNA transcripts. 
Suppresses CD44 protein expression 
Thermo Scientific 
Dharmacon Ltd, UK 
ON-TARGET plus
®
 
Control Reagent  
Negative Control Thermo Scientific 
Dharmacon Ltd, UK 
DharmaFECT® 1 Lipid Transfection Reagent / Vehicle Thermo Scientific 
Dharmacon Ltd, UK 
siRNA buffer (5x) siRNA buffer used at 1x (in sterile 
RNAase free water) to resuspend siRNA 
lyophilate. 
Thermo Scientific 
Dharmacon Ltd, UK 
 
To suppress CD44 expression in TamR cells, a previously optimised in-house protocol 
was used for siRNA transfection. Briefly, Tam-R cells were seeded into 35mm dishes in 
standard medium at a cell density of 3 x 10
5 
cells per well and cultured until a confluency 
of around 50% was reached at which point the cells were considered ready for 
transfection. For all siRNA experiments, a set of controls were used to ensure accurate 
interpretation and ensure that non-specific or off-target effects of siRNA were excluded. 
This included an untreated control (C), a lipid transfection control (L) and a non-targeting 
siRNA (NT) control along with the CD44-specific siRNA (CD44-siRNA) treated sample 
making a set of 4 x 35mm dishes for each experimental arm.  
 
An appropriate amount of 5x siRNA buffer was diluted to 1x siRNA buffer using 
RNAase-free H2O in a sterile eppendorf. A pre-calculated amount of 2µM siRNA 
solution was prepared using 1x siRNA buffer and 20µM siRNA stock in a sterile 
eppendorf. In Tube A, 100µl of 2µM siRNA solution was added along with 100µl of 
91 
 
serum-free RPMI (SF-RPMI: wRPMI + 2% glutamine but no serum) to make a total 
volume of 200µl and left at room temperature for 5 minutes. In Tube B, 3.2µl of the 
DharmaFECT® 1 lipid transfection reagent was added along with 196.8µl of SF-RPMI 
making a total volume of 200µl and left for 5 minutes at room temperature. For the ‘NT’ 
dish, the NT-siRNA was used instead of the CD44-siRNA at exactly similar volumes and 
concentration. In the ‘L’ dish, no siRNA was used and the volume made up with SF-
RPMI. In the untreated control dish ‘C’, no lipid transfection reagent or siRNA was used. 
After 5 minutes, contents of tubes A & B were mixed gently (total volume: 400µl) and set 
aside for 20 minutes at room temperature to allow for lipid-micelle formation. This is 
then diluted 1:5 with 1600µl of EM (wRPMI + SFCS + 2% glutamine) to give a final 
siRNA concentration of 100nM in a volume of 2mls. The volumes of reagents were 
adjusted accordingly if higher or lower volumes were required during experiments for 
different sizes of culture vessels according to a pre-calculated table (Appendix VI). The 
medium from the 35mm dishes was then aspirated and replaced with the siRNA 
containing solution and left to incubate for 72 hours to allow adequate siRNA-induced 
CD44 inhibition. After 72 hours, the cells were considered ready for use either for lysis or 
for setting up migration, invasion and other assays. Experimental treatments were only 
added after satisfactory transfection was achieved following 72 hours of siRNA treatment 
which was the optimum duration noted in the previous in-house optimisation studies 
which was subsequently validated for this project. 
 
92 
 
2.7 CELL MIGRATION ASSAYS 
Two well-established types of migration assays were used to assess cell migration during 
the course of this study: Wound healing assay and Boyden Chamber assay. 
 
2.7.1 Wound Healing Assay 
Wound healing assay involves creation of a defined, cell-free area in a cell monolayer 
across which cells migrate and this process can be monitored in real time by microscopy 
(Rodriguez LG 2005). It has the advantage of being a relatively simple assay which 
provides real-time imaging of the migration process in two dimensions 
Cells were seeded onto 35mm plates and cultured until they reached at least 90% 
confluency.  Three parallel scratches were made in the monolayer using a fine sterile 
pipette tip (0.5-10µl white tip roducing a standard basal wound of reproducible size. To 
avoid re-seeding of detached cells, plates were rinsed with culture medium (x3) to remove 
detached cells. A permanent mark was made in the base of the plates using a green 21G 
needle to provide a reference point for wound width measurements and basal images were 
taken (Figure 2.2). Cells were cultured for 36 hours at which point the assay was stopped. 
The migration of cells into the scratched area was imaged and photographed at 10x 
magnification at 0 and 36 hours using using an Olympus BH-2 phase contrast microscope 
attached to an Olympus DP12 digital camera (Olympus Corp, UK). The linear reference 
mark at the base of the dish ensured that the same areas were photographed at 0 and 36 
hours for accurate comparison. The micrographs were analysed with Adobe Photoshop 6 
and quantification was performed by recording measurement of the distance (in arbitrary 
units) between the wound edges at 10x magnification. All experiments were performed in 
triplicate and data expressed as mean wound closure ± SD. 
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Figure 2.2 Schematic representation of a wound healing assay
Wound healing assays were used in this study to assess migratory behaviour of cells as
described in Section 2.7.1. Cells were seeded onto 35mm plates and cultured until they
reached at least 90% confluency. Three parallel scratches were made in the monolayer using
a fine sterile pipette tip (0.5–10µl white) producing a standard basal wound of reproducible
size. To avoid re-seeding of detached cells, plates were rinsed with culture medium (x3) to
remove detached cells prior to addition of treatments. A permanent mark was made in the
base of the plates using a green 21G needle to provide a reference point for wound width
measurements at 0 and 36 hours.
35mm petri dish
Wound in monolayer (1)
Wound in monolayer (2)
Reference needle line
Wound in monolayer (3)
Cell monolayer 
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2.7.2 Boyden Chamber Assay 
The Boyden Chamber assay was used to determine the role of CD44 in basal migratory 
behaviour of Tam-R cells in this study. The assay was performed in modified Boyden 
chambers (6.5mm diameter) placed in a 24-well plate. The chemo-attractant Fibronectin 
(10μg/ml in PBS; Sigma, Poole, UK) was used to coat the porous polycarbonate 
membranes (0.8µm) in the Costar Transwell
© 
inserts which were placed in 24-well plates 
containing 250µl of fibronectin solution such that the lower end of the insert membrane 
was submerged in the solution and incubated at 37°C for 2 hours. Inserts were then 
removed from the wells and placed inverted in a tissue culture hood to air dry before 
further use. The wells were then filled with 650µl medium with or without treatments and 
inserts replaced into the wells (Figure 2.3). The 24-well plate containing the inserts was 
then replaced in the incubator to equilibrate.  
 
Cells were harvested and 200µl cell suspension (50,000 cells per membrane), with or 
without treatments, was pipetted into the insert and cultured for 48 hours at 37°C. The 
supernatant was then discarded and excess non-migratory cells removed from the insert 
gently using a cotton bud. The insert was then placed into a solution of formaldehyde 
(3.7% in PBS, 10 minutes) to fix the cells and subsequently washed with PBS (1 x 2 
minutes) and stained with crystal violet (0.5% in dH2O, 20 minutes). Membranes were 
washed by immersion in PBS solution (x3) to remove excess stain and left to air dry. 
Analysis and imaging of the membranes was carried out using an Olympus BH-2 phase 
contrast microscope attached to an Olympus DP-12 digital camera. Quantification was 
performed by viewing 5 separate fields per membrane (20x magnification) and counting 
the number of cells in each field. Data were then plotted at mean cells per field ± SD for a 
minimum of 3 separate experiments, each performed in triplicate.  
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2.8 MATRIGEL
TM
 INVASION ASSAY  
Several in vitro assays have been developed to understand and elucidate the mechanisms 
by which malignant cells acquire an invasive phenotype under in vivo conditions (Shaw 
2005). Invasion assays were performed in this study using a modified version of the 
Boyden chamber assay (Albini, Iwamoto et al. 1987) to compare the invasive potential of 
wtMCF-7 and Tam-R cells basally and following CD44-siRNA knockdown.   
 
The invasion assay was carried out using special invasion chambers (6.5mm diameter 
inserts Corning Transwell
®
 inserts possessing 8µm porous membranes) placed in a 12-
well plate. 50µL of the synthetic basement membrane Matrigel™ (stock solution of 
11mg/ml diluted 1 in 3 with ice cold wRPMI) was used to coat the upper surface of the 
porous membrane of each of the inserts. The Matrigel™ was allowed to set for a 
minimum of 2 hours at 37°C and appropriate media, with or without treatments, were 
added to the well housing the insert and the plate then incubated at 37°C. The cell line of 
interest was harvested and resuspended in appropriate medium, with or without 
treatments, and 200µL of this cell suspension was added to the insert at a cell density of 
50,000 per well (Figure 2.3). Cells were then incubated for 48 hours. For CD44-siRNA 
experiments, the transfection protocol described in Section 2.6 was used prior to seeding 
siRNA-transfected cells into the Matrigel™ coated chambers .  
 
Following this, the inserts were removed from the wells, the supernatant removed and 
Matrigel™ gently wiped off from the upper surface of the membrane using a cotton bud. 
The insert was then placed into a solution of formaldehyde (3.7% in PBS, 10 minutes) to 
fix the cells and subsequently washed with PBS (1 x 2 minutes) and allowed to air dry. 
The insert membrane was then carefully excised using a scalpel blade and prepared for 
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staining by mounting it onto a glass slide, applying a fixative containing the nuclear stain 
DAPI (Vectashield®) and overlaid with a glass cover slip. The membrane mounted on the 
slide is then allowed to set overnight at 4°C. 
 
A Leica DM-IRE2 fluorescence microscope (Leica Microsystems Imaging Solutions Ltd, 
Cambridge, UK) connected to a Hamamatsu C4742-96 digital camera (Hamamatsu 
Photonics UK Ltd, Hertfordshire, UK) and a PowerMAC G5 computer (Apple Computer 
Inc, California, USA) was used to assess the membranes and count the number of cells 
that had invaded the membrane. Quantification was performed by viewing 5 separate 
fields per membrane (20x magnification) and counting the number of cells in each field. 
Data were then plotted at mean cells per field ± SD for a minimum of 3 separate 
experiments, each performed in triplicate.  
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Figure 2.3 Schematic representation of a Transwell® insert used for Boyden chamber
migration and Matrigel™ invasion assays
A schematic diagram of a Transwell® insert used during the migration and invasion assays
in this study as described in Section 2.7.2 and Section 2.8 is depicted above. The
microporous membrane was coated with either Fibronectin (migration assay) or Matrigel™
(invasion assay) prior to adding the cell suspension and medium with or without treatments.
Adapted from catalogue schematic in www.corning.com.
Transwell® insert
Microporous membrane
Outer well
Cell layers
Upper compartment
Lower compartment
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2.9 CELL GROWTH ASSAY 
Several assays have been designed to replicate cell growth in vitro in order to understand 
the mechanisms underlying this process. The growth assay used in this study is the cell 
counting assay standardised in our laboratory previously.  
 
Cell growth measurements were performed by cell counting experiments using a Coulter 
Counter. Tam-R cells were harvested using trypsinisation, as described previously, and 
seeded into a 24-well plate at a density of 30,000 cells per well containing 1ml volume. 
Each treatment was set up in triplicate in three separate wells. Appropriate treatments 
were added after 24 hours, allowing the cells to adhere to the plate during this period. For 
siRNA experiments at least 72 hours was allowed for adequate siRNA transfection. 
Following treatment, the plate was incubated at 37°C in a humidified 5% CO2 atmosphere 
for 5 days. Medium was then aspirated from a well and 1ml of Trypsin/EDTA was added 
to each well using a Finnpipette. Cells were then incubated for a further 3 to 5 minutes 
until cells were in suspension. Using a 5ml syringe and an orange 25G needle the 
suspension was passed through the syringe twice to obtain a single cell suspension and 
finally aspirated back into the syringe. 1ml of Isoton® II was added to the well and 
aspirated into the syringe. This was repeated three times making up a total syringe 
volume of 4mls. The contents of the syringe were then transferred into a counting pot 
containing a further 6mls of Isoton® II making a final volume of 10mls. The number of 
cells in each well was then determined using a Coulter counter. The count was repeated 
twice and an average count calculated for each well. This average value was multiplied 
by 20 to give the average cell number per well. The mean cell number ± SD of the counts 
from the 3 wells was subsequently calculated for each experiment performed in triplicate.  
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2.10 IMMUNOFLUORESCENCE STAINING 
Immnuoflourescence is a technique based on the pioneering work by Coons and Kaplan 
which involves the use of fluorescently-labelled antibodies to tag proteins of interest in 
live or fixed cells. This allows for subsequent antigen detection using fluorescence 
microscopy (Coons 1941). The main benefit of this procedure is that it allows for dual 
staining, where two or more separate antigens can be labelled with different fluorophores. 
Image analysis of stained samples can be used to reveal whether these proteins are co-
localised within the same cell or region of the cell. 
 
Tam-R cells were cultured in 35mm dishes on glass cover slips with W+5% until cells 
reached log phase. The medium was then aspirated and the coverslips transferred to fresh 
35mm dishes. Fixation was carried out with 3.7% formaldehyde in PBS for 15 minutes 
followed by permeabilisation with 0.2% Triton X-100 in PBS for 7 minutes. Coverslips 
were then treated with 10% normal goat serum for 30 minutes as a blocking agent 
followed by wash with PBS (x2) and treatment with antibodies diluted in PBS containing 
1% BSA as detailed in Table 2.8. Coverslips were then washed after use of Alexa Flour® 
conjugates and mounted onto microscope slides using a hard set mounting medium 
(Vectashield®, Vector Laboratories Inc, Peterborough, UK) containing the nuclear stain 
DAPI (4',6-diamidino-2-phenylindole). Cells were viewed at 63x magnification using a 
Leica DM-IRE2 inverted fluorescent microscope and images taken for further analysis. 
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Table 2.8 List of antibodies used in immunofluorescence staining 
 
Antibody Source Dilution Incubation 
conditions 
Supplier 
Primary Antibodies 
CD44 Mouse 1:1500 2 hours RT Stratech Scientific Ltd, 
Suffolk, UK  
T-HER2 Rabbit 1:100 2 hours RT Dako Ltd, Cambridgeshire, UK 
T-HER3 Rabbit 1:100 2 hours RT Santa Cruz Inc, CA, USA 
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2.11 IMMUNOPRECIPITATION 
Immunoprecipitation involves precipitating a protein antigen out of solution using an 
antibody that specifically binds to that particular protein. NT and CR44-siRNA 
transfected Tam-R cells were treated with HA for 5 minutes and cell lysates were 
obtained as described in Section 2.4 for SDS-PAGE. Lysates were centrifuged at 
12,000rpm for 15 minutes, the supernatant pipetted into a fresh eppendorf and protein 
concentration of the supernatant determined using a Bio-Rad Dc Protein Assay Kit (Bio-
Rad Laboratories Ltd, UK) using a modification of the original Lowry method (Section 
2.4.2). The protein lysate was diluted such that 500µL of the solution contained 500µg 
protein and this was then divided into two parts in two different eppendorfs. One 
eppendorf was prepared for the specific immunoprecipitating anibody and the other for a 
matching isotype control antibody. Into each eppendorf, 5µL of the appropriate antiobody 
was added (from the antibody stock tube), lids sealed with Parafilm and tubes were left in 
a rotator overnight at 4°C to allow antigen-antibody complexes to form.  
 
The following day, 20µL dye-conjugated agarose beads (EZView
TM 
Red, Sigma) were 
placed in a series of eppendorf tubes (corresponding to the number of 
immunoprecipitation samples) and washed by adding 750µL lysis buffer to each tube, 
vortexed and centrifuged at 8200rpm for 30 seconds at 4°C. Tubes were then returned to 
ice, supernatant discarded and wash repeated two more times. Cell lysates containing the 
antibody-antigen complexes were then removed from the rotator, briefly centrifuged at 
8200rpm and contents transferred to the eppendorfs containing the equilibrated 
EZView
TM
 Red beads. Eppendorf lids were sealed with Parafilm and placed again in 
rotator for 2 hours at 4°C for the antigen-antibody complexes to attach to the agarose 
beads. Following this, tubes were returned to an ice filled container, briefly centrifuged at 
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8200rpm and the supernatant discarded. Pellets were washed with 750µL lysis buffer 
(containing protease inhibitors), vortexed gently and left on ice for 5 minutes. Samples 
were then centrifuged at 8200rpm for 5 minutes at 4°C and supernatant discarded. This 
wash was repeated three times and on the final wash, attempt was made to remove as 
much supernatant as possible without discarding any beads. The next step involvesd 
eluting the antigen-antibody complexes from the beads and this was carried out by adding 
20µL lysis buffer and 20µL of 2x loading buffer (containing DTT) to each tube and 
boiling samples at 100°C for 5 minutes. Samples were then briefly vortexed and 
centrifuged again at 8200rpm for 5 minutes. At this point, samples were considered ready 
for SDS-PAGE analysis and Western blotting as described in Section 2.4.4. The Ponceau 
S stain step was avoided as only some IgG bands were usually noted and hence, was not 
considered essential. Blots were immunoprobed with the antibody of interest and detected 
using chemiluminescent reagents as described in Section 2.4.5.   
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Table 2.9 List of antibodies used in immunoprecipitation  
 
Antibody Source Dilution Incubation 
conditions 
Supplier 
CD44 Mouse 1:1500 2 hours RT Stratech Scientific Ltd, Suffolk, 
UK  
T-EGFR Rabbit 1:100 2 hours RT Cell Signaling Technology Inc, 
USA 
T-HER2 Rabbit 1:100 2 hours RT Dako Ltd, Cambridgeshire, UK 
T-HER3 Rabbit 1:100 2 hours RT Santa Cruz Inc, CA, USA 
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2.12 STATISTICAL ANALYSIS 
Direct comparisons between wtMCF-7 and Tam-R cells or between control and treatment 
effects were assessed using a Student’s t test with the Bonferroni adjustment factor. 
Student’s t test was also used to compare  differences between control and treatment 
groups where there were more than two comparison groups by testing each group 
separately. Spearman rank correlation test was used to assess whether HA effect on p-
MAPK expression was dose-dependant. A p-value of ≤ 0.05 was considered to be     
statistically significant for all experiments in this study.                    
  
 
Chapter Three 
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3.1 CHARACTERISATION OF CD44 PROTEIN EXPRESSION IN 
TAMOXIFEN-SENSITIVE AND ACQUIRED TAMOXIFEN-RESISTANT WTMCF-7 
CELLS 
Our previous observations arising from interrogation of our microarray database identified 
that CD44 was overexpressed in Tam-R compared to wtMCF-7 cells. Affymetrix® 
microarray analysis showed 1.4 fold higher expression of CD44 in Tam-R cells compared to 
wtMCF-7 cells (p-value < 0.05 on t-test, data provided courtesy of J.Gee, R. McClleland and 
L Farrow; Figure 3.1A). Our initial aim was therefore to further characterise CD44 
expression in our acquired tamoxifen–resistant (‘Tam-R’) MCF-7 cells and compare it with 
the expression in their wild-type, endocrine-sensitive wtMCF-7 counterparts. To do this we 
compared CD44 gene and protein expression between wtMCF-7 and Tam-R cells using RT-
PCR, Western blotting and immunocytochemistry. 
 
3.1.1 CD44 mRNA Expression in Tam-R Cells and wtMCF-7 Cells 
Preliminary characterisation of CD44 expression in Tam-R cells using RT-PCR revealed that 
CD44 mRNA levels were higher in Tam-R cells as compared to the wMCF-7 cells (Figure 
3.1B; data provided courtesy of C. Smith and N. Jordan). This validated our microarray 
analysis data which showed overexpression of CD44 in Tam-R cells compared to wtMCF-7 
cells. We therefore proceeded to study the protein level expression of CD44 in our Tam-R 
and wtMCF-7 cell lines using Western blotting and immunocytochemistry. 
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Figure 3.1 CD44 gene expression levels in wtMCF-7 and Tam-R cells
Affymetrix® microarray analysis was performed to evaluate CD44 expression in wtMCF-7
and Tam-R cells. Data is presented as comparative mean log intensity  SD (A). This
showed 1.4 fold upregulation of CD44 in Tam-R cells compared to wtMCF-7 cells (p-value
≤ 0.05 on t-test). CD44 mRNA expression was subsequently compared between wtMCF-7
and Tam-R cells using RT-PCR as described in Section 2.3. A higher mRNA expression of
CD44 was noted in Tam-R compared to wtMCF-7 cells (B). The representative gel in (B)
has been truncated to exclude other cell lines included in the original PCR which are not
relevant to this project. Data provided courtesy of J. Gee, R. McClleland, L. Farrow and
C. Smith.
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3.1.2 Basal CD44 Protein Expression in Tam-R cells and wtMCF-7 Cells 
For these experiments, wtMCF-7 and Tam-R cells were cultured in experimental medium 
(EM) until log-phase growth and lysed on ice using the technique described in Section 2.4. 
On Western blotting, an 85kDa protein band corresponding to the expected size of CD44 was 
noted in both wtMCF-7 and Tam-R cells but the band density was significantly higher in the 
Tam-R cells (Figure 3.2A). Semi-quantitative analysis using densitometry after normalising 
for loading using GAPDH revealed that the expression in Tam-R cells was 4.7 fold higher as 
compared to the wtMCF-7 cells suggesting that CD44 is overexpressed in Tam-R cells at the 
protein level (p-value = 0.028 on t-test; Figure 3.2B). It is important to mention at this point 
that the CD44 antibody used in this study was not specific to a particular CD44 isoform and 
likely recognises the standard and other variant isoforms of the CD44 protein.  
 
This finding was further corroborated using immunocytochemistry utilising the technique 
described in Section 2.5. Basal wtMCF-7 and Tam-R cells were cultured on glass cover slips 
until log-phase growth was reached and then fixed using 2.5% phenol (w/v) in Formal saline 
for 5 minutes followed by 100% ethanol for 5 minutes. Immunocytochemical analysis 
showed minimal CD44 expression in wtMCF-7 cells and significantly higher expression of 
CD44 in the Tam-R cells although it must be mentioned that there was difference in 
confluency between the two cell lines which can affect protein expression levels (Figure 
3.3). The expression of CD44 in Tam-R cells appeared heterogeneous with some cells 
showing quite marked overexpression compared to others. There was minimal or no 
expression noted in the cytoplasm and nucleus under basal conditions and CD44 was noted to 
be mainly localised to the cell membrane in Tam-R cells.  
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A
B
Figure 3.2 CD44 protein expression in wtMCF-7 and Tam-R cells on Western blotting
Basal wtMCF-7 and Tam-R cells were cultured in EM  4-OH-TAM (10-7M) until log-
phase growth was reached and then lysed on ice. CD44 protein expression (expected
molecular weight of 85kDa) was evaluated through Western blotting using the procedure
outlined in Section 2.4. A representative blot is shown above (A). Data was normalised
using GAPDH and presented as mean protein level  SD. CD44 expression was 4.6 fold
higher in Tam-R compared to wtMCF-7 cells (Mean protein level – wtMCF-7 100% versus
Tam-R 465  235%, n=3, p-value = 0.028 on t-test; B).
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CD44
Figure 3.3 CD44 protein expression in wtMCF-7 and Tam-R cells on immuno-
cytochemistry
Basal wtMCF-7 and Tam-R cells were cultured on glass cover slips until log-phase growth
was reached and then fixed using 2.5% phenol (w/v) in Formal saline for 5 minutes
followed by 100% ethanol for 5 minutes. CD44 expression was assessed through
immunocytochemistry using the procedure described in Section 2.5. Representative images
of CD44 expression in wtMCF-7 and Tam-R cells are shown above at 10x magnification
(A) and 20x magnification (B). CD44 was overexpressed in Tam-R compared to wtMCF-7
cells and CD44 was noted to be primarily localised to the membrane (Membrane H-score –
wtMCF-7 30 versus Tam-R 125, n=1). Scale bar = 50µm at 20x magnification and 100µm
at 10x magnification.
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wtMCF-7 Tam-R
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3.1.3 Discussion 
Significant upregulation of the CD44 gene in Tam-R cells compared to wtMCF-7 cells on 
Affymetrix® analysis was an interesting finding. The CD44 probes used during this analysis 
were not variant specific and likely detected expression of the standard form (CD44s). Our 
interest in further exploring the role of CD44 in the setting of tamoxifen resistance arose from 
published links between CD44 and breast cancer. CD44 has been shown to interact with the 
ErbB family of receptors which play an important role in breast cancer progression and have 
been implicated in poor response to endocrine therapy and endocrine resistance (Newby, 
Johnston et al. 1997; Wobus, Rangwala et al. 2002; Folgiero, Avetrani et al. 2008; Palyi-
Krekk, Barok et al. 2008). CD44 has also been shown to enhance cell migration, angiogenesis 
and metastasis in breast cancer models (Trochon, Mabilat et al. 1996; Bourguignon, 
Singleton et al. 2003). Moreover, cell models of acquired resistance show altered expression 
of various growth factor receptors that may augment the cell’s sensitivity to numerous factors 
present within the tumour microenvironment and CD44 overexpression may sensitise these 
cells to various stromal ligands (Hiscox, Jordan et al. 2006). Finally, the main stromal ligand 
of CD44 is hyaluronan which itself has been implicated in breast cancer pathogenesis. In 
light of our microarray data and, based on the above evidence that implicates CD44 in breast 
cancer progression, we hypothesised that CD44 may be implicated in influencing the 
aggressive phenotype noted in our tamoxifen-resistant Tam-R cells either directly, or by 
influencing the function of ErbB receptors. 
 
We first validated the preliminary microarray data using RT-PCR to assess CD44 expression 
at the gene level. Despite the obvious advantages of microarray analysis, this validation was 
undertaken to avoid potential pitfalls due to deficiencies inherent in this technique. For 
example, there is potential for misidentification with other variants and members of a closely-
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related gene family and possibility of statistical error due to the substantial volume of data 
generated (Murphy 2002). Subsequent validation experiments of CD44 expression at the gene 
and protein level showed significantly higher levels of CD44 in the Tam-R cells compared to 
their endocrine-sensitive wtMCF-7 counterparts. This was a novel finding in the setting of 
tamoxifen resistance although there is evidence to suggest higher CD44 expression in drug-
resistant and more invasive ER-negative cell lines compared to wtMCF-7 cells. In a mouse 
xenograft model of human breast cancer, Fitchner et al. showed that wtMCF-7 cells express 
CD44 standard at much lower levels compared to the multidrug-resistant MCF7/ADR cell 
line derived from wtMCF-7 cells (Fichtner, Dehmel et al. 1997). They also noted that CD44s 
expression in wtMCF-7 cells was much lower than more aggressive breast cancer cell lines 
such as MDA-MB435. The underlying mechanism behind CD44 upregulation in our Tam-R 
model is a potential area of further investigation. However, it is unlikely that this is an ER-
regulated phenomenon as wtMCF-7 and Tam-R cells have similar levels of ERα mRNA and 
protein (Hutcheson, Knowlden et al. 2003). It appears to be an early change in the course of 
development of tamoxifen resistance as CD44 upregulation has been detected as early as 3 
days following 4-OH-TAM treatment in wtMCF-7 cells (S. Hiscox and R. Bellerby, 
unpublished observations).  
 
On immunocytochemistry, we found that CD44 expression in the Tam-R cells was primarily 
localised to the cell membrane in a heterogenous fashion with minimal cytoplasmic and 
nuclear staining noted under basal conditions. This corresponds with the primary membrane 
localisation of CD44 noted in various studies of CD44 structure and function (Lucas, Green 
et al. 1989; Ponta, Sherman et al. 2003). Membrane associated CD44 undergoes proteolytic 
cleavage by metalloproteinases and gamma secretase causing release of the intracellular 
domain which translocates to the nucleus and influences gene transcription (Okamoto, Tsuiki 
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et al. 2002; De Falco, Tamburrino et al. 2012). It is possible that the small amount of CD44 
detected in the cytoplasm and nucleus may represent this intracellular portion of CD44. The 
other possibility is that variant forms of CD44 are also being detected during these 
experiments. Although a full discussion and delineation of the role of the variants is beyond 
the scope of this thesis, following on from this project, additional isoforms are currently 
being investigated by our group.  
 
3.1.4 Conclusion 
Based on this data, we concluded that CD44 is overexpressed at both the gene and protein 
level in acquired tamoxifen-resistant Tam-R cells compared to their endocrine-sensitive 
wtMCF-7 counterparts. We subsequently investigated the hypothesis that this overexpression 
contributes to the endogenous aggressive phenotype noted in Tam-R cells. 
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3.2 EXPLORING THE ROLE OF CD44 AS A DETERMINANT OF THE 
TAMOXIFEN-RESISTANT CELL PHENOTYPE 
CD44 upregulation has previously been associated with an aggressive phenotype in breast 
cancer cell models. For example, Li et al. have shown an increase in migratory behaviour of 
wtMCF-7 cells following transient transfection with CD44s (Li, Zha et al. 2012). Acquisition 
of tamoxifen resistance in Tam-R cells is accompanied by a dramatic and significant increase 
in invasiveness and motility when compared to wtMCF-7 cells (Hiscox, Morgan et al. 2004). 
We were keen to investigate whether CD44 overexpression played a role in this aggressive 
cellular behaviour. Thus, our main aim here was to investigate the role of CD44 in basal 
migration, invasion and growth of Tam-R cells. To do this, we used an siRNA approach to 
suppress CD44 expression.  
 
3.2.1 Optimisation of CD44-siRNA Technique  
The first step was to validate an existing siRNA protocol available in the laboratory for use in 
our study. For the initial siRNA optimisation experiments, once Tam-R cells achieved 50% 
confluence they were treated with either experimental culture medium (C), medium 
containing lipid transfection reagent (L), non-targeting siRNA (NT) or CD44-specific siRNA 
(CD44-siRNA) for 72 hours prior to lysis on ice followed by analysis of protein expression. 
Following Western blotting, a protein band corresponding to the expected CD44 molecular 
weight of 85kDa was noted in all the samples but the density was markedly reduced in the 
cells treated with CD44-siRNA (Figure 3.4A). This indicated effectiveness of the siRNA 
protocol. 
 
Validation of the CD44-siRNA technique was further confirmed using 
immunocytochemistry. Tam-R cells were cultured until they achieved 50% confluence and 
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treated with NT or CD44-siRNA for 72 hours prior to lysis on ice. Imunocytochemical 
analysis revealed clear reduction in CD44 expression levels in CD44-siRNA transfected cells 
compared to NT cells (Figure 3.4B). The siRNA method was thus noted to be effective in 
significantly reducing CD44 expression on both Western blotting and immunocytochemistry. 
Effective CD44 knockdown was confirmed in each experiment involving siRNA-mediated 
CD44 knockdown to ensure accurate interpretation of results.  
 
Having established the efficacy of the CD44-siRNA knockdown technique in Tam-R cells, 
we proceeded to elucidate the role of CD44 in basal function of Tam-R cells with respect to 
its involvement in cell migration, invasion and growth. 
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Figure 3.4 Validation of CD44-siRNA protocol in Tam-R cells
Tam-R cells were cultured in 35mm dishes until 50% confluence was reached and treated
using only culture medium (C), medium containing lipid transfection reagent (L), or
medium containing either non-targeting siRNA (NT) or CD44-specific siRNA (CD44-
siRNA) for 72 hours prior to lysis on ice. CD44 protein expression was evaluated through
Western blotting as described in Section 2.4. A representative blot is shown above (A).
Tam-R cells were subsequently cultured on glass cover slips until 50% confluence was
reached, treated as above and fixed using 2.5% phenol (w/v) in Formal saline for 5 minutes
followed by 100% ethanol for 5 minutes. CD44 expression was assessed through
immunocytochemistry as described in Section 2.5. Representative images are shown above
(B). Use of CD44-siRNA significantly reduced CD44 expression in Tam-R cells on
Western blotting (A) and immunocytochemistry (B) confirming efficacy of the CD44-
siRNA transfection protocol. Scale bar = 50µm (20x magnification).
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3.2.2 Effect of CD44 Knockdown on Migration in Tam-R Cells 
The effect of CD44 knockdown on the migratory capacity of Tam-R cells was investigated 
using wound healing assays as described in Section 2.7.1. Tam-R cells were cultured until 
50% confluence was reached and medium replaced with either NT or CD44-siRNA for 72 
hours. Wounds were then created in the cell monolayer and cells allowed to migrate for 36 
hours. Although Tam-R cells transfected with CD44-siRNA showed a trend towards reduced 
migration as evidenced by slower wound closure compared to NT cells, this difference was 
not statistically significant (p-value = 0.07 on t-test, Figure 3.5A & B).  
 
To further investigate changes in Tam-R cell migration in response to CD44 manipulation, 
Boyden chamber migration assays were performed in the presence of CD44-siRNA as 
described in Section 2.7.2. After transfecting cells with either NT or CD44-siRNA for 72 
hours, cells were harvested and seeded into the Transwell® inserts and allowed to migrate for 
a period of 48 hours. Following quantitation of the experiment, there was no statistically 
significant difference noted in the basal migratory phenotype of Tam-R cells transfected with 
CD44-siRNA compared to NT cells (p-value > 0.05/NS on t-test; Figure 3.5C). 
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Figure 3.5A Effect of CD44 knockdown on migration in Tam-R cells
Tam-R cells were cultured until 50% confluence was reached and medium replaced with
either non-targeting siRNA (NT) or CD44-specific siRNA (CD44-siRNA) for 72 hours.
Wound healing assay was then performed as described in Section 2.7.1. Representative
images are shown above (A). Results were collated after 36 hours and data presented as
mean wound closure (% of control)  SD (Mean wound closure – Control 100% versus
CD44-siRNA 90.5  17.6%, n=3, p-value = 0.07 on t-test; B). Subsequently, Tam-R cells
were set up as above and Boyden chamber migration assay was performed as described in
Section 2.7.2 by transferring cells into Transwell® inserts containing porous polycarbonate
membranes coated with fibronectin (10μg/ml). Results were collated after 48 hours and data
presented as mean cell migration (% of control)  SD (Mean cell migration – Control 100%
versus CD44-siRNA 78.2  33.7%, n=3, p-value > 0.05/NS on t-test; C). Use of CD44-
siRNA does not have a significant inhibitory effect on endogenous migration in Tam-R
cells. Scale bar = 100µm (10x magnification).
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NT
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Figure 3.5B&C Effect of CD44 knockdown on migration in Tam-R cells
Tam-R cells were cultured until 50% confluence was reached and medium replaced with
either non-targeting siRNA (NT) or CD44-specific siRNA (CD44-siRNA) for 72 hours.
Wound healing assay was then performed as described in Section 2.7.1. Representative
images are shown above (A). Results were collated after 36 hours and data presented as
mean wound closure (% of control)  SD (Mean wound closure – NT 100% versus CD44-
siRNA 90.5  17.6%, n=3, p-value = 0.07 on t-test; B). Subsequently, Tam-R cells were set
up as above and Boyden chamber migration assay was performed as described in Section
2.7.2 by transferring cells into Transwell® inserts containing porous polycarbonate
membranes coated with fibronectin (10μg/ml). Results were collated after 48 hours and data
presented as mean cell migration (% of control)  SD (Mean cell migration – NT 100%
versus CD44-siRNA 78.2  33.7%, n=3, p-value > 0.05/NS on t-test; C). Use of CD44-
siRNA does not have a significant inhibitory effect on endogenous migration in Tam-R
cells. Scale bar = 100µm (10x magnification).
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3.2.3 Effect of CD44 Knockdown on Invasion in Tam-R Cells 
The effect of CD44 knockdown on the invasive capacity of Tam-R cells was investigated 
using Matrigel™ invasion assays as described in Section 2.8. After transfecting cells with 
either NT or CD44-siRNA for 72 hours, cells were harvested and seeded into the modified 
Transwell® inserts and allowed to invade for a period of 48 hours. After quantitation of the 
experiment, there was no statistically significant change noted in the endogenous invasive 
phenotype of Tam-R cells transfected with CD44-siRNA compared to NT cells (p-value > 
0.05/NS on t-test; Figure 3.6A). We then proceeded to assess the effect of CD44 knockdown 
on growth in Tam-R cells. 
 
3.2.4 Effect of CD44 Knockdown on Growth in Tam-R Cells 
The effect of CD44 knockdown on the basal growth capacity of Tam-R cells was investigated 
using cell growth assays as described in Section 2.9. Growth assays were set up after 
transfecting cells with either NT or CD44-siRNA for 72 hours and the results were collated 
after 5 days. After quantitation of the experiment, there was no statistically significant change 
noted in the basal growth pattern of Tam-R cells transfected with CD44-siRNA compared to 
NT cells (p-value >0.05/NS on t-test; Figure 3.6B). 
 
(NB: The exact duration and degree of persistence of the effect of CD44-siRNA on CD44 
protein expression has not been specifically tested during this study.) 
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Figure 3.6 Effect of CD44 knockdown on invasion and growth in Tam-R cells
Tam-R cells were cultured in 35mm dishes and once 50% confluence was reached, the
medium was replaced with either non-targeting siRNA (NT) or CD44-specific siRNA
(CD44-siRNA) and cultured for a further 72 hours. Matrigel™ invasion assay was
performed as described in Section 2.8 by transferring cells into Transwell® inserts
containing porous polycarbonate membranes coated with Matrigel™. Results were collated
after 48 hours and data presented as mean cell invasion (% of control)  SD (Mean cell
invasion – NT 100% versus CD44-siRNA 98.2  22.7%, n=3, p-value >0.05/NS on t-test;
A). Cell growth assay was also performed on cells set up in a similar manner using the
protocol described in Section 2.9. Results were collated after 5 days and data presented as
mean cell growth (% of control)  SD (Mean cell growth – NT 100% versus CD44-siRNA
110.5  36.4%, n=3, p-value > 0.05/NS on t-test; B). There was no significant inhibitory
effect following CD44-siRNA transfection on endogenous invasion and growth in Tam-R
cells. Data provided courtesy of S. Hiscox.
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3.2.5 Discussion 
Adverse phenotypic features are commonly noted in the more aggressive breast cancers and 
include a more marked migratory phenotype, greater invasiveness and a higher growth 
capacity amongst other features. Similar observations have been made in our model of 
tamoxifen resistance where Tam-R cells show a more aggressive phenotype as compared to 
the endocrine-sensitive wtMCF-7 cells. Tam-R cells exhibit up to 200% higher growth 
capacity as compared to wtMCF-7 cells and elevated levels of MAPK has been implicated in 
driving this (Knowlden, Hutcheson et al. 2003). Furthermore, Tam-R cells in vitro grow as 
loosely packed colonies with loss of cell-cell junctions and they also exhibit altered 
morphological characteristics which resemble cells undergoing epithelial mesenchymal 
transition (EMT). Elevated Src activity has been suggested to play a role in the promotion of 
invasiveness noted in Tam-R cells (Hiscox, Morgan et al. 2006). Other researchers have also 
investigated the mechanisms underlying aggressive behaviour in resistant cell lines and have 
demonstrated suppression of the ER and ER-regulated genes and activated survival pathway 
signalling (Zhou, Capello et al. 2011; Li, Chen et al. 2013). 
 
To examine the role of CD44 overexpression on the endogenous phenotype of Tam-R cells, 
we have used siRNA for post-transcriptional knockdown of CD44 during in this study. The 
protocol was optimised for this study with assistance from Christopher Smith who had 
previously used it in a model of hormonal resistance. Our original experiments to confirm 
siRNA-mediated knockdown of CD44 included four arms: control (C), lipid (L), non-
targeting (NT) and CD44-specific siRNA (CD44-siRNA). The ‘L’ arm contained the lipid 
transfection reagent only whereas the ‘NT’ arm contained a non-targeting siRNA that was not 
specific to CD44. The main purpose of using the ‘L’ and ‘NT’ was to rule out non-specific 
effects that could affect the interpretation of results. We have demonstrated via Western 
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blotting and immunocytochemistry that transfection with NT does not have any effect on 
CD44 expression and the ‘NT’ arm has been used as the sole control arm for all further 
experiments involving CD44 siRNA. We preferred siRNA amongst other possible techniques 
for suppression of CD44 such as neutralising antibodies and short-hairpin RNAs (shRNA). 
The main advantage of using siRNA was the ease and efficiency of transfection, the stable 
quality of available reagents, minimal off-target effects and reliable suppressive effects. 
However, using siRNA has the disadvantage of having less future therapeutic potential in 
terms of drug delivery as compared to a neutralising monoclonal antibody should future 
experiments indicate potential for use as a therapeutic agent. .   
 
Our data suggests that CD44 does not play a role in the endogenous aggressive phenotype 
noted in Tam-R cells. The role of CD44 in determining the basal aggressive phenotype of 
tamoxifen-resistant wtMCF-7 cells has not been investigated by any other group previously. 
However, the role of CD44 on migration, invasion and growth has been explored in other 
models of breast cancer. For example, Ouhtit et al. transfected CD44s into wtMCF-7 cells 
and found that the resulting cell line (MCF7F-B5) had significantly higher migratory, 
invasive and growth capacity compared to the parent cell line (Ouhtit, Abd Elmageed et al. 
2007). In their doxycycline-regulated breast cancer xenograft model, CD44s induction did 
not affect the growth or local invasion of the primary tumour but promoted distant metastatic 
spread to the liver providing in vivo evidence of the role of CD44s in promoting invasion and 
metastasis.  
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3.2.6 Conclusion 
Based on our data, we concluded that despite being overexpressed in Tam-R cells, CD44 
does not appear to influence their endogenous migration, invasion or growth in vitro. We 
hypothesised that CD44 overexpression may sensitise Tam-R cells to stromal ligands such as 
HA present in the microenvironment and proceeded to investigate this further. 
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3.3 DETERMINING WHETHER CD44 OVEREXPRESSION IN TAM-R CELLS 
SENSITISES THEM TO STROMAL FACTORS 
The microenvironment is known to play an important role in breast cancer progression. We 
proceeded to investigate potential interplay between CD44 and the stroma via its interaction 
with hyaluronic acid (HA), its main ligand, and the consequent effect on signalling and 
function of Tam-R cells as a result of this interaction. Our aim was to test the hypothesis that 
Tam-R cells, which overexpress CD44, would exhibit greater sensitivity towards HA 
compared with endocrine-sensitive wtMCF-7 cells.  
 
3.3.1 Effect of HA Stimulation on MAPK Activity in Tam-R Cells  
To investigate whether CD44 overexpressing Tam-R cells were sensitised to HA, basal Tam-
R cells were cultured in experimental medium (EM) until log-phase was reached and then 
treated with five increasing concentrations of HA (0, 10, 50, 200 and 1000µg/ml) for 5 
minutes prior to lysis on ice. The initial time point of 5 minutes was chosen as it was more 
likely to demonstrate early changes in phosphorylation in downstream signalling pathways. 
TGF-α was used as a positive control as it is known to stimulate multiple signalling pathways 
in our Tam-R cell model. Analysis of activity of proteins known to be involved in CD44 
signalling (MAPK, Src and Akt) was then performed using Western blotting.  
A dual protein band at the expected phosphorylated MAPK (p-MAPK 42/44) molecular 
weight of 42/44 kDa was noted at all HA concentrations (Figure 3.7A). The intensity of the 
bands was seen to increase compared to control at HA concentrations of 50µg/ml and above 
and this increase was noted to be dose-dependant. Although a dual protein band was also 
noted at the expected molecular weight of 42/44 kDa for total MAPK (T-MAPK), there was 
no increase in intensity following HA treatment at the indicated doses. Semi-quantitative 
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analysis with densitometry after correcting for loading using β-actin and T-MAPK levels 
showed a statistically significant 2.7 fold upregulation of p-MAPK in Tam-R cells treated 
with a HA dose of 200µg/ml as compared to untreated Tam-R cells (p-value = 0.03 on t-test; 
Figure 3.7B). There was a positive correlation between the dose of HA and the resulting p-
MAPK expression indicating that this is a dose-dependant effect thereby suggesting a direct 
HA effect instead of a non-specific effect (Spearman rank correlation: Rho = +0.88). In 
contrast, no upregulation of p-MAPK signalling following HA treatment was seen in 
wtMCF-7 cells (Figure 3.8). 
 
We also investigated the effect of HA on other downstream signalling pathways known to be 
functionally relevant in CD44 signalling including Src and Akt, but did not find any 
consistent response to HA treatment (Figure 3.9). As such, in this study we have used p-
MAPK as a surrogate marker of HA stimulation in Tam-R cells. 
 
In our study we found that p-MAPK upregulation following HA treatment was noticeable at 
HA concentrations at or above 50μg/ml. However, the lowest dose that produced a 
significant, consistent and reproducible response in our cell model was 200μg/ml. This dose 
of HA has been used by other researchers in their in vitro cell models including breast cancer 
models. For example, Bourguignon et al. used a HA dose of 200μg/ml in their SP1 cell line 
based migration assays and demonstrated a HA-mediated increase in migratory phenotype 
(Bourguignon, Zhu et al. 2000). Using the lowest dose which shows consistent measurable 
results has the advantage of limiting non-specific effects of the drug. 
For the initial experiments above, medium molecular weight HA (132 kDa) was used. 
Various molecular weight forms of HA are commercially available and there is evidence in 
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the literature to suggest variable actions of HA depending on the molecular weight. We 
compared three different commercially available forms of HA in our tamoxifen-resistant 
model and found that medium molecular weight HA (average molecular weight of 132kDa) 
achieved the best p-MAPK upregulation in Tam-R cells (Figure 3.10). Low molecular 
weight HA has been reported to have an inhibitory effect on CD44 function which was an 
additional reason for favouring the 132kDa form of HA. In the BT-549 human breast cancer 
cell line and the immortalised HK-2 human renal tubular epithelial cell line, Yang et al. noted 
an inhibitory effect of low molecular weight HA on CD44 clustering (Yang, Cao et al. 2012). 
A growth inhibitory mechanism is also well described for high molecular weight hyaluronan 
(500kDa and above) which can trigger inactivation of ERM proteins (Ezrin, radixin and 
moesin) and activation of Merlin, thereby, leading to inhibition of growth and invasiveness 
(Ponta, Sherman et al. 2003). HA of an average molecular weight of 132 kDa at a dose of 
200µg/ml has, therefore, been used for all further experiments in this study unless otherwise 
specified. 
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Figure 3.7 Effect of HA on MAPK signalling in Tam-R cells
Tam-R cells were cultured in experimental medium (EM + 4-OH-TAM) until log-phase
growth was reached and treated with five different concentrations of HA (0, 10, 50, 200 and
1000µg/ml) for 5 minutes and then lysed on ice. Phosphorylated MAPK (p-MAPK) and
total MAPK (T-MAPK) expression was evaluated through Western blotting as described in
Section 2.4. A representative blot is shown above (A). Data was normalised using beta-
actin (β-actin) and presented as mean protein expression (% of control)  SD (Mean protein
expression – Control 100% versus HA ‘200µg/ml’ 273.2  93.5%, n=3, p-value = 0.03 on
t-test; B). Treatment of Tam-R cells with HA led to dose-dependent p-MAPK upregulation
in Tam-R cells (Spearman rank correlation: Rho = +0.88). TGFα was used as a positive
control.
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Figure 3.8 Effect of  HA on MAPK signalling in wtMCF-7 cells
wtMCF-7 cells were cultured in EM until log-phase growth was reached and treated with
four different concentrations of HA (0, 10, 50 and 200µg/ml) for 5 minutes and then lysed
on ice. p-MAPK and T-MAPK expression was evaluated through Western blotting as
described in Section 2.4. A representative blot is shown above. Treatment of wtMCF-7
cells with HA did not show any upregulation of p-MAPK at the indicated doses.
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Figure 3.9 Effect of HA on  Akt and Src signalling in Tam-R cells
Tam-R cells were cultured in experimental medium (EM + 4-OH-TAM) until log-phase
growth was reached and treated with five different concentrations of HA (0, 10, 50, 200 and
1000µg/ml) for 5 minutes and then lysed on ice. Akt (p-Akt and T-Akt) and Src (p-Src and
T-Src) expression was evaluated through Western blotting as described in Section 2.4.
Representative blots are shown above (A, B). Treatment of Tam-R cells with HA did not
lead to any detectable upregulation of Akt or Src at the indicated doses.
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Figure 3.10 Effect of three different types of HA on MAPK signalling in Tam-R cells
Tam-R cells were cultured in experimental medium (EM + 4-OH-TAM) until log-phase
growth was reached and then treated with three different commercially available molecular
weights of HA namely 8kDa, 132kDa and 234kDa (average molecular weight) at a
concentration of 200µg/ml for 5 minutes and then lysed on ice. p-MAPK and T-MAPK
expression was evaluated through Western blotting as described in Section 2.4. A
representative blot is shown above. The most effective p-MAPK upregulation was noted
following use of medium molecular weight HA (132kDa).
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3.3.2 Effect of CD44 Knockdown on MAPK Upregulation following HA Treatment 
We proceeded to assess whether the p-MAPK response to HA was clearly CD44-mediated or 
whether other potential mechanisms and receptors were involved in this response. Tam-R 
cells were transfected with CD44-siRNA following the standardised protocol described in 
Section 2.6 and compared with NT cells. Once log-hase growth was reached, cells were 
treated with HA for 5 minutes. No significant decrease in band density at the expected 
molecular weight for p-MAPK was noted in CD44-siRNA treated cells compared to NT cells 
(Figure 3.11A). NT cells treated with HA demonstrated a clear increase in band density at 
the expected molecular weight for p-MAPK compared to untreated cells, but this increase 
was not observed in Tam-R cells transfected with CD44-siRNA (Figure 3.11A). Semi-
quantitative analysis of densitometry values revealed that this differential response to HA 
between NT and CD44-siRNA transfected Tam-R cells was a statistically significant finding 
(p-value = 0.006 on t-test: NT – Control versus HA; Figure 3.11B). 
 
This experimental design was repeated using immunocytochemistry as well. CD44-siRNA 
transfection did not have any significant effect on the basal activity of p-MAPK in Tam-R 
cells on immunocytochemistry. NT cells treated with HA demonstrated significant 
upregulation of p-MAPK but this upregulation was not evident in CD44-siRNA transfected 
cells (Figure 3.12A). Semi-quantitative analysis using H-score showed that this differential 
response to HA between NT and CD44-siRNA transfected cells was statistically significant 
(p-value = 0.001 on t-test: NT – Control versus HA; Figure 3.12B). On 
immunocytochemistry, p-MAPK was noted to be primarily localised to the nucleus and 
cytoplasm as expected.  
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These data suggested that whilst basal MAPK signalling in Tam-R cells was not significantly 
influenced by CD44, HA treatment and thus potentially CD44 activation, resulted in 
upregulation of MAPK activity.   
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Figure 3.11 Effect of CD44 knockdown on MAPK upregulation following HA
treatment in Tam-R cells on Western blotting
Tam-R cells were cultured in 35mm dishes until 50% confluence was reached and treated
using either non-targeting siRNA (NT) or CD44-specific siRNA (CD44-siRNA) for 72
hours prior to lysis. Thereafter, medium was replaced with EM  HA (200µg/ml) for 5
minutes and p-MAPK expression evaluated through Western blotting. Representative blots
are shown above (A). Data was normalised and results presented as mean protein
expression (% of control)  SD (Mean protein expression – NT: Control 100% versus HA
209.3  22.4% [p-value = 0.006 on t-test], CD44-siRNA: Control 92.8  4.2% versus HA
103.1  15.4% [p-value > 0.05/NS on t-test], n=3; B). p-MAPK upregulation in response to
HA was significantly attenuated following CD44 knockdown.
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Figure  3.12A Effect of CD44 knockdown on MAPK upregulation following HA 
treatment in Tam-R cells on immunocytochemistry
Tam-R cells were cultured on glass cover slips until 50% confluence was reached and
transfected with non-targeting siRNA (NT) or CD44-specific siRNA (CD44-siRNA) for 72
hours. Cells were then treated with EM  HA (200µg/ml) for 5 minutes, fixed with Formal
saline and p-MAPK expression was assessed through immunocytochemistry.
Representative images are shown above (A). H-score was calculated and data presented as
mean H-score (% of control)  SD (Mean H-score – NT: Control 100% versus HA 200.9  
19.7% [p-value = 0.001 on t-test], CD44-siRNA: Control 110  42.2% versus HA 128.6  
47.6% [p-value > 0.05/NS on t-test], n=3; B). Use of CD44-siRNA significantly attenuated
p-MAPK upregulation following HA treatment. Scale bar = 50µm (20x magnification).
.
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Figure  3.12B Effect of CD44 knockdown on MAPK upregulation following HA 
treatment in Tam-R cells on immunocytochemistry
Tam-R cells were cultured on glass cover slips until 50% confluence was reached and
transfected with non-targeting siRNA (NT) or CD44-specific siRNA (CD44-siRNA) for 72
hours. Cells were then treated with EM  HA (200µg/ml) for 5 minutes, fixed with Formal
saline and p-MAPK expression was assessed through immunocytochemistry.
Representative images are shown above (A). H-score was calculated and data presented as
mean H-score (% of control)  SD (Mean H-score – NT: Control 100% versus HA 200.9  
19.7% [p-value = 0.001 on t-test], CD44-siRNA: Control 110  42.2% versus HA 128.6  
47.6% [p-value > 0.05/NS on t-test], n=3; B). Use of CD44-siRNA significantly attenuated
p-MAPK upregulation following HA treatment. Scale bar = 50µm (20x magnification).
.
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3.3.3 Effect of HA Stimulation on Growth of wtMCF-7 and Tam-R Cells 
Next, we proceeded to assess the effect of HA stimulation on the growth Tam-R cells both 
with and without CD44 knockdown. Initial experiments explored the role of CD44 in 
influencing cell growth and for this experiment, wtMCF-7 and Tam-R cells were set up in 24-
well plates as described in Section 2.9 and cell counting was performed at the end of the 
assay to determine growth rates in response to HA. There was no effect of HA treatment on 
growth of wtMCF-7 cells (p-value > 0.05/NS on t-test; Figure 3.13A). HA produced no 
growth effect on Tam-R cells (p-value > 0.05/NS; Figure 3.13B). No further experiments 
were conducted to investigate the role of CD44 on growth as there was no significant effect 
noted following treatment with HA in Tam-R cells. 
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Figure 3.13 Effect of HA treatment on growth in wtMCF-7 and Tam-R cells
wtMCF-7 and Tam-R cells were cultured in experimental medium (EM  4-OH-TAM) and
then treated with four different concentrations of HA (0, 10, 50 and 200µg/ml). Cell growth
assay was performed using the protocol described in Section 2.9. Results were collated
after 5 days and data presented as mean cell growth (% of control)  SD. Treatment of
wtMCF-7 cells with HA did not result in any effect on growth (A). Treatment of Tam-R
cells with HA did not result in any growth effect (Mean cell growth – Control 100% versus
HA‘200µg/ml’ 113.1  24.4%, n=3, p-value > 0.05/NS on t-test; B). Overall, there was no
effect of HA on growth of wtMCF-7 or Tam-R cells at the indicated doses.
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3.3.4 Effect of HA Stimulation on Migration in Tam-R and wtMCF-7 Cells 
To investigate the influence of CD44 in promoting a migratory phenotype in Tam-R cells, 
wound healing assays were set up using Tam-R cells in the presence and absence of HA. 
Tam-R cells showed a clear increase in migratory response following HA treatment 
compared to untreated cells (Figure 3.14A). Wound size was measured at 0 and 36 hours and 
results collated and expressed as mean wound closure (% of control) compared to untreated 
control. The wound closure rate of Tam-R cells treated with HA was 1.8 fold higher than 
untreated cells (p-value = 0.01 on t-test; Figure 3.14B).  
 
To assess whether this increase in the rate of wound closure was a pure migratory response 
and to examine the role of cell proliferation, Ki67 based immunocytochemical assay was 
performed in parallel on cover slips along with the standard wound healing assay. Ki67, a 
nuclear non-histone protein, is now well established as a marker for proliferation in breast 
cancer and it has been suggested that it might have a prognostic role as well (Weigel and 
Dowsett 2010). This assay did not show any clear difference in Ki67 expression in Tam-R 
cells treated with HA compared to untreated controls although it must be mentioned that a 
formal quantification was not performed (Figure 3.14C). This suggests that the difference in 
the wound closure rate following HA treatment is likely to be due to a differential migratory 
response rather than a variable rate of proliferation. Pre-treatment with an anti-proliferative 
agent such as mitomycin C would help to elucidate this further by inhibiting proliferation 
altogether. 
 
Subsequently, CD44-siRNA transfection studies were used to elucidate whether the increased 
migratory response seen in Tam-R cells was a CD44-dependant phenomenon. Wound healing 
assays were set up with NT and CD44-siRNA transfected cells in the presence and absence of 
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HA. The migratory response of Tam-R cells noted after treatment with HA was eliminated in 
CD44-siRNA transfected cells was still noted in the NT cells (Figure 3.15A). Semi-
quantitative analysis of the wound healing assay confirmed that this was a statistically 
significant finding (p-value = 0.01 on t-test: NT – Control versus HA; Figure 3.15B). This 
suggested that the HA-induced migratory response seen in Tam-R cells is mediated through 
CD44.  
 
To investigate the influence of HA on the migratory phenotype of wtMCF-7 cells, wound 
healing assays were set up using wtMCF-7 cells in the presence and absence of HA. Wound 
size was measured at 0 and 36 hours and results collated and expressed as mean wound 
closure compared to untreated control. We noted that wtMCF-7 cells did not show any 
significant difference in the rate of wound closure following treatment with HA compared to 
untreated controls (p-value = 0.13 on t-test; Figure 3.16A&B). 
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Figure 3.14A  Effect of HA treatment on migration in Tam-R cells
Tam-R cells were cultured in 35mm dishes until 90% confluence was reached and wound
healing assay performed as described in Section 2.7.1 following treatment with EM  HA
(200µg/ml). Representative images are shown above (A). Results were collated after 36
hours and data presented as mean wound closure (% of control)  SD (Mean wound closure
– Control 100% versus HA 173.5  30.9%, n=3, p-value = 0.01 on t-test; B). Cells were
also simultaneously cultured on glass coverslips, treated as above, fixed with formal saline
and immunocytochemical staining of Ki-67 performed. Representative images are shown
(C). Similar levels of Ki67 staining between the control and HA treated cells suggested that
the HA-induced response in Tam-R cells is more likely to be a differential migratory
response rather than due to a change in rate of proliferation. Scale bar = 100µm (10x
magnification).
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Figure 3.14B&C Effect of HA treatment on migration in Tam-R cells
Tam-R cells were cultured in 35mm dishes until 90% confluence was reached and wound
healing assay performed as described in Section 2.7.1 following treatment with EM  HA
(200µg/ml). Representative images are shown above (A). Results were collated after 36
hours and data presented as mean wound closure (% of control)  SD (Mean wound closure
– Control 100% versus HA 173.5  30.9%, n=3, p-value = 0.01 on t-test; B). Cells were
also simultaneously cultured on glass coverslips, treated as above, fixed with formal saline
and immunocytochemical staining for Ki-67 performed. Representative images are shown
(C). Similar levels of Ki67 staining between the control and HA treated cells suggested that
the HA-induced response in Tam-R cells is more likely to be a differential migratory
response rather than due to a change in rate of proliferation. Scale bar = 100µm (10x
magnification).
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Figure 3.15A Effect of HA treatment on migration in Tam-R cells following CD44 
knockdown
Tam-R cells were cultured in 35mm dishes until 50% confluence was reached. Cells were
then transfected with NT-siRNA (NT) or CD44-specific siRNA (CD44-siRNA) for 72 hrs
and wounds created in the monolayer as described in Section 2.7.1 followed by treatment
with EM  HA (200µg/ml). Representative images are shown above (A). Results were
collated after 36 hours and data presented as mean wound closure (% of control)  SD
(Mean wound closure – NT: Control 100% versus HA 158.5  4.2% [p-value = 0.01 on t-
test], CD44-siRNA: Control 90.5  17.6% versus HA 97.9  4.3% [p-value > 0.05/NS on t-
test], n=3; B). HA-induced migratory effect in Tam-R cells is reversed following CD44-
siRNA transfection. Cells were also simultaneously cultured on glass coverslips for CD44
immunocytochemical analysis which confirmed effective CD44 knockdown (C). Scale bar
= 100µm (10x magnification).
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Figure 3.15B&C Effect of HA treatment on migration in Tam-R cells following CD44 
knockdown
Tam-R cells were cultured in 35mm dishes until 50% confluence was reached. Cells were
then transfected with NT-siRNA (NT) or CD44-specific siRNA (CD44-siRNA) for 72 hrs
and wounds created in the monolayer as described in Section 2.7.1 followed by treatment
with EM  HA (200µg/ml). Representative images are shown above (A). Results were
collated after 36 hours and data presented as mean wound closure (% of control)  SD
(Mean wound closure – NT: Control 100% versus HA 158.5  4.2% [p-value = 0.01 on t-
test], CD44-siRNA: Control 90.5  17.6% versus HA 97.9  4.3% [p-value > 0.05/NS on t-
test], n=3; B). HA-induced migratory effect in Tam-R cells is reversed following CD44-
siRNA transfection. Cells were also simultaneously cultured on glass coverslips for CD44
immunocytochemical analysis which confirmed effective CD44 knockdown (C). Scale bar
= 100µm (10x magnification).
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Figure 3.16 Effect of HA treatment on migration in wtMCF-7 cells
wtMCF-7 were cultured in 35mm dishes until 90% confluence was reached and wounds 
created in the monolayer followed by treatment with EM  HA (200µg/ml). Representative 
images are shown above (A). Results were collated after 36 hours and data presented as 
mean wound closure (% of control)  SD (Mean wound closure – Control 100% versus HA 
113.5  12.6%, n=3, p-value = 0.13 on t-test; B). Treatment of wtMCF-7 with HA did not 
result in a clear migratory effect. Scale bar = 100µm (10x magnification). 
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3.3.5 Discussion 
The interplay between cancer cells and stromal elements in the surrounding 
microenvironment is critical in influencing tumour development and progression. In this 
study, we have investigated whether CD44 overexpression in Tam-R cells sensitises them to 
HA which is widely present in the stroma and we have used exogenous HA for experimental 
purposes. HA plays a crucial structural role in extracellular tissue and there is growing 
evidence of its role in influencing cell signalling pathways which are reported to mediate 
growth, survival, and migration of cancer cells via its interaction with its main cell-surface 
receptor, CD44 (Toole 2004; Toole and Slomiany 2008). Exogenous HA has been used by 
other groups to understand the role of CD44 in various malignancies (Bourguignon, Zhu et al. 
2000). Binding of HA to CD44 has been previously shown to alter the actin cytoskeleton 
system, through ankyrin and GTPases such as Rho, with resultant induction of cell migration 
(Bourguignon 2008). HA has also been suggested to mediate clustering of CD44 on the cell 
surface with a resultant increase in cell invasion through sequestering of  MMP9 (Peng, Su et 
al. 2007). Furthermore, various studies have shown that inhibition of HA production results 
in suppression of breast tumour development and metastasis providing further credence to the 
link between HA, CD44 and aggressive cell behaviour (Udabage, Brownlee et al. 2005; 
Hosono, Nishida et al. 2007; Urakawa, Nishida et al. 2011). These in vitro and in vivo data 
may explain why HA expression in clinical breast cancer is an independent negative 
prognostic factor for predicting survival (Auvinen, Tammi et al. 2000; Toole 2009). 
 
In our study, we noted a differential effect on Tam-R cell signalling between the different 
molecular weights of HA, an effect that has also been noted by other researchers. For 
example, in the BT549 human breast cancer cell line, Yang et al. demonstrated a strong 
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relationship between HA size and CD44 clustering in vivo and also noted that HA regulates 
cell adhesion in a manner specifically dependent on its size (Yang, Cao et al. 2012). To our 
knowledge this differential effect has not been observed in a model of tamoxifen resistance 
before. 
 
Although the dose-dependant p-MAPK upregulation following HA treatment suggested a 
direct effect, we proceeded to perform studies using CD44-siRNA to exclude the possibility 
that the HA action was being mediated via non-CD44 pathways. The main reasoning behind 
this approach was that HA is known to have another receptor which has also been shown to 
be associated with cell signalling processes. Known as CD168 or RHAMM (‘Receptor for 
Hyaluronan Acid Mediated Motility’) it was first isolated from cardiac embryonic cells and 
like CD44 also undergoes alternative splicing (Turley, Noble et al. 2002). A recent study 
showed that a HA-induced CD44, RHAMM and MAPK (ERK1/2) complex sustains a highly 
motile phenotype in the ER-negative MDA-MB-231 and Ras-MCF10A breast cancer cell 
lines (Hamilton, Fard et al. 2007). Moreover, Affymetrix® analysis showed that RHAMM 
levels are higher in Tam-R compared to wtMCF-7 cells although this was not shown to be 
statistically significant (Appendix I). Our study findings suggest  that CD44, rather than 
RHAMM, is a mediator of MAPK upregulation following HA treatment. However, due to the 
possibility of co-dependance between CD44 and RHAMM, further studies using RHAMM-
specific siRNA are required to draw a definitive conclusion. 
 
Our data suggests that HA induces a CD44-mediated upregulation of p-MAPK in Tam-R 
cells and this was a novel and exciting finding in the setting of tamoxifen resistance as 
MAPK is part of the Ras-Raf-MEK-ERK/MAPK pathway which is directly downstream to 
EGFR. MAPK signalling via EGFR-HER2 heterodimers has previously been implicated in 
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our Tam-R cells (Knowlden, Hutcheson et al. 2003). The fact that this MAPK upregulation is 
CD44 driven suggested a link between CD44 and EGFR in our Tam-R cells.  
 
Our data showed a significant CD44-mediated migratory effect of HA in Tam-R cells. 
Similar observations have been made in other breast cancer cell lines. Zohar et al. showed 
that a HA-CD44-ERM complex promotes migration of embryonic fibroblasts, activated 
macrophages, and metastatic breast cancer cells (Zohar, Suzuki et al. 2000). Bourguignon et 
al. demonstrated that HA-induced breast tumour migration in the SP1 cell line is mediated via 
CD44 where linkage between CD44v3 and Tiam1 (a guanine nucleotide exchange factor) 
leads to a cytoskeletal mediated enhancement of cell migration (Bourguignon, Zhu et al. 
2000). Kung et al. have demonstrated a pro-migratory effect of HA in breast cancer cells via 
enhanced membrane-type 1 matrix metalloproteinase expression and CD44 cleaving (Kung, 
Chen et al. 2012). Jothy et al. noted that pan-CD44 and CD44v6-specific antibodies have a 
blocking effect on cell migration in the highly metastatic Hs578T breast cancer cell line 
(Herrera-Gayol and Jothy 1999).  
 
HA-induced MAPK upregulation in our Tam-R cells raised the possibility that the enhanced 
migration may be mediated through the MAPK pathway. HA-induced phenotypic changes 
through involvement of MAPK signalling pathway in breast cancer cells has been noted 
before. For example, Fang et al. showed that when the expression vector pcDNA3.1-CD44st 
was cloned and stably transfected into wtMCF-7 cells, HA could interact with this transfected 
CD44 standard form and increase the invasion capability of wtMCF-7 cells through the 
MAPK pathway (Fang, Jiang et al. 2011). 
 
149 
 
3.3.6 Conclusion 
Based on our data, we concluded that HA induces a CD44-mediated upregulation of MAPK 
signalling and enhances the migratory behaviour of Tam-R cells. Following this observation, 
we proceeded to investigate the interplay between CD44 and ErbB family in our Tam-R cells. 
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3.4 INTERACTION BETWEEN CD44 AND ErbB RECEPTORS 
Several published studies indicate that CD44 can interact with and potentially transactivate 
receptor tyrosine kinases (RTKs), including those of the ErbB family. Our aim was to 
investigate whether CD44 interacted with ErbB receptors in Tam-R cells. To do this, we 
studied the co-localisation patterns between CD44 and ErbB receptors using 
immunoflourescence. We assessed the role of CD44 and HA on ErbB dimerisation and 
signalling in Tam-R cells using siRNA knockdown, Western blotting and 
immunoprecipitation. We also investigated the mechanism behind the HA-induced pro-
migratory effect seen in Tam-R cells especially with regard to the potential role of ErbB 
receptors.  
 
3.4.1 Co-localisation of CD44 and ErbB Receptors 
Dual immunofluorescence staining was performed to investigate whether there was co-
localisation of CD44 and ErbB receptors in Tam-R cells. Immunoflourescent staining of 
Tam-R cells grown under basal conditions revealed similar staining patterns for both CD44 
and HER2 which, when the images were merged, suggested an apparent co-localisation of 
these receptors in the membrane (Figure 3.17; data provided courtesy of C. Smith and N. 
Jordan). Of note, HER3 was found to be expressed in the nucleus as well as the membrane 
but only the membrane HER3 was found to co-localise with CD44. ErbB receptors are 
known to be present in very low levels in wtMCF-7 cells and are barely detectable using 
standard techniques as reported previously by our group (Knowlden, Hutcheson et al. 2003). 
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Figure 3.17 Co-localisation of CD44 with HER2 and HER3 in basal Tam-R cells
Tam-R cells were cultured in 35mm dishes with EM + 4-OH-TAM until log-phase growth
was reached and cells were fixed. Immunofluorescence analysis was carried out using the
method described in Section 2.10 and slides examined under an inverted fluorescence
microscope. Representative images are shown above. Immunofluorescence microscopy
revealed a largely cell-surface location of CD44 (green, A). Subsequent staining for HER2
and HER3 (red) and image overlay revealed apparent co-localisation (yellow/orange) of
these receptors in Tam-R cells (B,C). Of note, HER3 was expressed in the nucleus and the
membrane but only the membrane HER3 co-localised with CD44. Scale bar = 25µm (63x
magnification). Data provided courtesy of C. Smith and N. Jordan.
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3.4.2 Role of CD44 in Basal ErbB Signalling in Tam-R Cells 
Having noted that CD44 co-localises with HER2 and HER3 in Tam-R cells and given that 
CD44 has been linked to ErbB receptor activation in other breast cancer cell lines (Palyi-
Krekk, Barok et al. 2008), we investigated whether CD44 knockdown affects the endogenous 
activity of ErbB members 
 
Basal EGFR signalling was compared between Tam-R cells transfected with NT or CD44-
siRNA. On Western blotting, a 175kDa protein band corresponding to the expected size of 
phosphorylated EGFR (p-EGFR: Y1068) was noted in both NT and CD44-siRNA transfected 
Tam-R cells, but the band density was significantly lower in the CD44-siRNA cells (Figure 
3.18A). No similar decrease in band density was noted in total EGFR (T-EGFR) levels 
between the two groups (Figure 3.18A).  
 
Subsequently, basal HER2 signalling was compared between Tam-R cells transfected with 
NT and CD44-siRNA. On Western blotting, a 185kDa protein band corresponding to the 
expected size of p-HER2 (Y1248) was noted in both NT and CD44-siRNA transfected Tam-
R cells, but the band density was significantly lower in the CD44-siRNA cells (Figure 
3.18B). There was a small decrease in band density noted in T-HER2 levels as well between 
the two groups (Figure 3.18B). This indicates that there may be a reduction in absolute levels 
of p-HER2 in Tam-R cells following CD44 siRNA knockdown. Since HER2 phosphorylation 
is known to have important effects on downstream signalling, decrease in absolute levels of 
p-HER2 is likely to have an impact on signalling in Tam-R cells. It has previously been noted 
that CD44 knockdown using siRNA does not lead to any decrease in basal migration, 
invasion and growth (Section 3.2). Further investigation is required to understand the role 
played by CD44 in basal ErbB signalling and subsequent impact on function in Tam-R cells.  
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  Having established that CD44 co-localises with HER2 and appears to play a role in 
endogenous ErbB activation, we proceeded to investigate the impact of CD44 activation 
through HA on ErbB signalling in Tam-R cells. 
 
3.4.3 Effect of HA Stimulation on ErbB Signalling in Tam-R Cells 
We hypothesised that HA treatment of Tam-R cells would further augment ErbB signalling. 
To investigate the effect of HA treatment and determine the role of CD44 activation on ErbB 
signalling, EGFR and HER2 expression was compared between NT and CD44-siRNA 
transfected Tam-R cells in the presence or absence of HA. 
 
On Western blotting, a 175kDa protein band corresponding to the expected size of p-EGFR 
was noted in both NT and CD44-siRNA transfected Tam-R cells, but the band density was 
significantly lower in the CD44-siRNA treated cells. Moreover, following HA treatment, 
there was a clear increase in p-EGFR band density in NT cells but no corresponding change 
was noted in the CD44-siRNA transfected cells. Semi-quantitative analysis using 
densitometry after correcting for level of T-EGFR and loading showed a statistically 
significant 1.6 fold increase in p-EGFR activity following HA treatment in the NT cells 
which was not noted in the CD44-siRNA transfected cells (p-value = 0.02 on t-test; NT – 
Control versus HA Figure 3.19A&B).  
  
On Western blotting, a 185kDa protein band corresponding to the expected size of p-HER2 
was noted in both NT and CD44-siRNA transfected cells, but the band density was lower in 
the CD44-siRNA treated cells. Following HA treatment, there was a clear increase in p-
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HER2 band density in the NT cells but no corresponding change was noted in the CD44-
siRNA cells. Semi-quantitative analysis using densitometry after correcting for level of T-
HER2 and loading showed a 1.7 fold increase in p-HER2 activity following HA treatment in 
the NT cells whereas CD44-siRNA transfected cells showed attenuated response to HA with 
only a 1.4 fold increase (p-value = 0.04 on ANOVA; Figure 3.20A&B).  
155 
 
Figure 3.18 Effect of CD44 knockdown on basal EGFR and HER2 signalling in
Tam-R cells
Tam-R cells were cultured in EM + 4-OH-TAM until 50% confluence was reached and
treated using either non-targeting siRNA (NT) or CD44-specific siRNA (CD44-siRNA)
respectively for 72 hours prior to lysis on ice. EGFR and HER2 protein expression was
evaluated through Western blotting as described in Section 2.4. Representative blots are
shown above. Use of CD44-siRNA reduced basal p-EGFR expression but did not affect
T-EGFR levels (A). CD44-siRNA transfection resulted in decrease in p-HER2 and T-HER2
expression in Tam-R cells (B).
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Figure 3.19 Effect of HA and CD44 knockdown on EGFR signalling in Tam-R cells
Tam-R cells were cultured in EM + 4-OH-TAM until 50% confluence was reached and
treated using either non-targeting siRNA (NT) or CD44-specific siRNA (CD44-siRNA) for
72 hours. Thereafter, medium was replaced with EM  HA (200µg/ml) for 5 minutes and
EGFR expression evaluated through Western blotting. Representative blots are shown
above (A). Data was normalised and results presented as mean protein expression  SD (B).
CD44-siRNA knockdown resulted in significant inhibition of basal p-EGFR activity (Mean
protein expression – NT 100% versus CD44-siRNA 44.1  13.8%, n=3, p-value = 0.02 on
t-test; B). There was clear upregulation of p-EGFR expression following HA treatment but
this response was markedly attenuated in CD44-siRNA transfected cells (Mean protein
expression – NT: Control 100% versus HA 163.6  15.3% [p-value = 0.02 on t-test],
CD44-siRNA: Control 44.1  13.8% versus HA 44.6  6.6% [p-value > 0.05/NS on t-test],
n=3; B).
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Figure 3.20 Effect of HA and CD44 knockdown on HER2 signalling in Tam-R cells
Tam-R cells were cultured until they reached 50% confluence and treated using either NT
or CD44-siRNA for 72 hours. Thereafter, medium was replaced with EM  HA(200µg/ml)
for 5 minutes and HER2 expression evaluated through Western blotting. Representative
blots are shown above (A). Data was normalised and results presented as mean protein
expression  SD (B). CD44 knockdown resulted in inhibition of basal p-HER2 activity but
this was not statistically significant (Mean protein expression – NT 100% versus CD44-
siRNA 73.4  2.5%, n=3, p-value > 0.05/NS on t-test; B). There was clear upregulation of
p-HER2 expression following HA treatment but this response was attenuated in CD44-
siRNA transfected cells (Mean protein expression – NT: Control 100% versus HA 172.0  
14.1% [p-value = 0.001 on t-test], CD44-siRNA: Control 73.4  2.5% versus HA 106.6  
5.2% [p-value = 0.004 on t-test], Overall p-value = 0.04 on ANOVA n=3; B).
*
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3.4.4 Role of ErbB in HA-induced Migratory Response in Tam-R Cells 
These data suggested that HA treatment played a clear role in activation of ErbB signalling in 
Tam-R cells and this appeared to be mediated by CD44. We had previously noted in Section 
3.3.4 that HA treatment elicited a clear migratory response in Tam-R cells which was 
reversed following CD44 knockdown. In the light of our new observation indicating 
upregulation of ErbB activity following HA treatment, we hypothesised that the migratory 
response could also be mediated by ErbB members possibly via the MAPK pathway, and we 
proceeded to test this hypothesis. 
 
We performed wound healing assays to determine the role of MAPK, EGFR and HER2 
signalling in this migratory response. The effect of three different drugs, namely PD098059 
(50µM in dimethylsulfoxide), gefitinib (1µM in ethanol) and trastuzumab (100nM in dH2O) 
on migration in Tam-R cells was assessed. PD098059 is a well established MAPK inhibitor 
thought to exert its effect by binding to the inactive form of MAPK1 (Alessi, Cuenda et al. 
1995). Gefitinib (Iressa
®
) is a selective, reversible inhibitor of the tyrosine kinase domain of 
EGFR (Solomon, Hagekyriakou et al. 2003). Trastuzumab (Herceptin
®
) is a monoclonal 
antibody effective against the HER2 or neu receptor and acts by binding to the extracellular 
juxta-membrane domain of HER2 (Hudis 2007). These drugs have been used in our Tam-R 
model at the above concentrations in previous studies with proven physiological effect thus 
supporting their use at the stated concentrations in this study (Knowlden, Hutcheson et al. 
2003; Knowlden, Hutcheson et al. 2005). Use of Akt and Src inhibitors would have further 
clarified the role of Akt and Src pathways in this response and this should be explored in 
future experiments. 
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Tam-R cells were cultured in 35mm dishes until they reached 90% confluence at which point 
wound healing assays were performed along with treatment with PD098059, gefitinib and 
trastuzumab in the presence or absence of HA. Results were collated after 36 hrs and 
presented as mean wound closure (% of control) ± SD. Representative images are shown in 
Figure 3.21A.  
 
The effect of the three drugs on basal migration of Tam-R cells was first assessed. Although 
there was a trend towards reduction in migratory behaviour following treatment with all three 
drugs, in particular gefitinib, these changes were not found to be statistically significant (p-
value > 0.05/NS for all three drugs compared to untreated control; Figure 3.21A&B).  
 
Treatment of Tam-R cells with HA resulted in a statistically significant 1.7 fold increase in 
wound closure as compared to untreated cells (p-value = 0.02 on t-test; Figure 3.21C). Use 
of the MAPK inhibitor (PD098059) resulted in attenuation of the migratory response of Tam-
R cells to HA treatment (p-value > 0.05/NS on t-test; Figure 3.21C). Use of the EGFR 
inhibitor (Gefitinib) also resulted in attenuation of the migratory response (p-value > 0.05/NS 
on t-test; Figure 3.21C) as did treatment with Trastuzumab, the anti-HER2 antibody (p-value 
> 0.05/NS on t-test; Figure 3.21C). The experimental outcome suggested that the pro-
migratory response following HA treatment in Tam-R cells is mediated by CD44 via MAPK 
and the attenuation noted following treatment with drugs that target EGFR and HER2 also 
suggest involvement of the ErbB receptors in this migratory response. This however needs to 
be examined in more detail before a definitive conclusion can be reached. 
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A
Figure 3.21A Effect of PD098059, gefitinib and trastuzumab on HA-induced
migratory response in Tam-R cells
Tam-R cells were cultured in 35mm dishes until at least 90% confluence was reached and
wound healing assay performed as described in Section 2.7.1 alongside treatment with
PD098059 (50µM in dimethylsulfoxide), Gefitinib (1µM in ethanol) and Trastuzumab
(100nM in dH2O) in the presence or absence of HA (200µg/ml). Representative images are
shown above (A). Results were collated after 36 hours and data presented as mean wound
closure (% of control)  SD. There was no statistically significant decrease in basal
migration following treatment with PD098059, Gefitinib or Trastuzumab although there
was a trend towards decreased migration with Gefitinib (p-value > 0.05/NS on t-test for all
three drugs compared to control; B). Treatment of Tam-R cells with PD098059, Gefitinib
and Trastuzumab shows attenuation of HA-induced migratory response and is most marked
after treatment with PD098059 (p-values on t-test: Untreated versus HA – Control: 0.02,
PD098059: > 0.05/NS, Gefitinib: > 0.05/NS, Trastuzumab: > 0.05/NS). Scale bar = 100µm
(10x magnification).
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Figure 3.21B&C Effect of PD098059, gefitinib and trastuzumab on HA-induced
migratory response in Tam-R cells
Tam-R cells were cultured in 35mm dishes until at least 90% confluence was reached and
wound healing assay performed as described in Section 2.7.1 alongside treatment with
PD098059 (50µM in dimethylsulfoxide), Gefitinib (1µM in ethanol) and Trastuzumab
(100nM in dH2O) in the presence or absence of HA (200µg/ml). Representative images are
shown above (A). Results were collated after 36 hours and data presented as mean wound
closure (% of control)  SD. There was no statistically significant decrease in basal
migration following treatment with PD098059, Gefitinib or Trastuzumab although there
was a trend towards decreased migration with Gefitinib (p-value > 0.05/NS on t-test for all
three drugs compared to control; B). Treatment of Tam-R cells with PD098059, Gefitinib
and Trastuzumab shows attenuation of HA-induced migratory response and is most marked
after treatment with PD098059 (p-values on t-test: Untreated versus HA – Control: 0.02,
PD098059: > 0.05/NS, Gefitinib: > 0.05/NS, Trastuzumab: > 0.05/NS). Scale bar = 100µm
(10x magnification).
*
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3.4.5 Association of CD44 and ErbB Receptors in Tam-R Cells 
We noted earlier that exogenous HA can promote ErbB activation in the absence of 
exogenous ErbB ligands such as heregulin and this raised the possibility that CD44 may 
influence ErbB dimerisation either directly or indirectly. It is possible that this finding is 
somewhat confounded by the potential presence of low levels of ligands in the culture 
medium or autocrine production by the cells themselves. To investigate this, we performed 
immunoprecipitation using ErbB antibodies in the presence and absence of HA and also 
following CD44-siRNA transfection.  
 
Under basal conditions, EGFR could not be co-immunoprecipitated with CD44 but treatment 
with HA resulted in EGFR-CD44 dimerisation which was reversed by CD44-siRNA (Figure 
3.22A: IP1). Conversely, under basal conditions, CD44 and HER2 could be co-
immunoprecipitated and HA treatment did not alter this interaction which reversed following 
CD44-siRNA transfection (Figure 3.22B: IP4). EGFR-HER2 dimerisation was promoted by 
HA and this was found to be CD44-mediated as CD44-siRNA transfection reversed this 
effect (Figure 3.22B: IP6). Under basal conditions, HER3 was preferentially dimerised with 
EGFR as compared to HER2. Interestingly, HA stimulation appeared to cause HER3 to 
dimerise preferentially with HER2 instead of EGFR and this effect was reversed by CD44-
siRNA confirming that this is CD44-mediated (Figure 3.22A&B: IP2&5). These 
interactions are summarised in tabular form for clarity in Tables 3.1 and 3.2.  
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Figure 3.22A Effect of HA and CD44 knockdown on association between CD44 and
ErbB receptors
Tam-R cells were cultured in EM + 4-OH-TAM until 50% confluence was reached and
transfected with NT or CD44-siRNA for 72 hours. Thereafter, medium was replaced with
EM  HA (200µg/ml) for 5 minutes and CD44-ErbB interactions evaluated through
immunoprecipitation as described in Section 2.11. Representative blots are shown above
(A). Under basal conditions CD44-HER2 and EGFR-HER3 dimerisation was predominant.
Following HA treatment, there was alteration in ErbB dimerisation patterns with
preferential formation of CD44-EGFR and HER2-HER3 dimers which could be reversed
following CD44-siRNA transfection indicating that they are CD44-mediated. Thus, HA-
CD44 interaction can modulate ErbB dimerisation patterns. These interactions are presented
in tabular form for clarity in Table 3.1 and 3.2.
A
NT         NT + HA   CD44-siRNA   CD44-siRNA + HA
CD44 (85 kDa)
HER3 (185 kDa)
EGFR (175 kDa)
IP: EGFR
IP1
IP2
IP3
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MW
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Figure 3.22B Effect of HA and CD44 knockdown on association between CD44 and
ErbB receptors
Tam-R cells were cultured in EM + 4-OH-TAM until 50% confluence was reached and
transfected with NT or CD44-siRNA for 72 hours. Thereafter, medium was replaced with
EM  HA (200µg/ml) for 5 minutes and CD44-ErbB interactions evaluated through
immunoprecipitation as described in Section 2.11. Representative blots are shown above
(A). Under basal conditions CD44-HER2 and EGFR-HER3 dimerisation was predominant.
Following HA treatment, there was alteration in ErbB dimerisation patterns with
preferential formation of CD44-EGFR and HER2-HER3 dimers which could be reversed
following CD44-siRNA transfection indicating that they are CD44-mediated. Thus, HA-
CD44 interaction can modulate ErbB dimerisation patterns. These interactions are presented
in tabular form for clarity in Table 3.1 and 3.2.
CD44 (85 kDa)
HER3 (185 kDa)
HER2 (185 kDa)
EGFR (175 kDa)
IP: HER2
IP4
IP5
IP6
IP7
NT          NT + HA   CD44-siRNA  CD44-siRNA + HA
HER3 (185 kDa)
HER2 (185 kDa)
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225
150
225
150
225
150
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(kDa)
100
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EGFR HER2 HER3 CD44
EGFR ++  ++ +  ++ ++  + - ++
HER2 +  ++ +  + +  ++ + +
Table 3.1 Immunoprecipitation patterns between CD44 and ErbB receptors in ‘NT’ 
transfected Tam-R cells before and after treatment with HA
Table 3.2 Immunoprecipitation patterns between CD44 and ErbB receptors in ‘CD44-
siRNA’ transfected Tam-R cells before and after HA treatment
Key for Table 3.1 and 3.2
x  y = Expression level  pre  post  HA treatment
‘-’ = Minimal or absent
‘+’ = Present but low
‘++’ = High
‘+++’ = Very high
EGFR HER2 HER3 CD44
EGFR ++  ++ +  + ++ ++ --
HER2 + + +  + +  + - -
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3.4.6 Discussion 
The ErbB family represents a group of four structurally related RTKs (EGFR, HER2, HER3 
and HER4) which have all been implicated in signal transduction controlling normal cell 
growth and differentiation. Several growth factors serve as ErbB ligands and ErbB receptors 
can exist as both monomers, homodimers or heterodimers (Rubin and Yarden 2001). 
Although HER2 has no identified ligand, it is the preferred receptor for dimerisation with 
other ErbB receptors and, this initiates the most potent signal transduction pathway in the 
entire ErbB family (Rubin and Yarden 2001). The link between ErbB receptors and breast 
cancer is now well established and indeed EGFR and HER2 overexpression are associated 
with reduced sensitivity to endocrine agents and poorer prognosis (Wright, Nicholson et al. 
1992; Nicholson, McClelland et al. 1993; Nicholson, McClelland et al. 1994). Elevated levels 
of EGFR-HER2 heterodimers have been suggested to provide an autocrine growth stimulus 
in our Tam-R cells (Knowlden, Hutcheson et al. 2003). There is clear evidence of association 
between CD44 and members of the ErbB family. We were, therefore, keen to understand the 
interaction between CD44 and ErbB receptors in our model of tamoxifen resistance and test 
our hypothesis that CD44 overexpression in Tam-R cells modulates ErbB activity and 
influences phenotype.  
 
Knowlden et al. have previously noted that phosphorylated EGFR-HER2 and EGFR-HER3 
but no HER2-HER3 heterodimerisation is evident in Tam-R cells (Knowlden, Hutcheson et 
al. 2003). Previous studies have also shown that EGFR and HER2 expression are higher in 
Tam-R compared with wtMCF-7 cells but both cell lines have similar expression levels of 
HER3. We have seen on immunoflourescence that CD44 and HER2 co-localise in the 
membrane. This is further substantiated by immunoprecipitation studies where there is 
evidence of CD44-HER2 as well as EGFR-HER3 but not CD44-EGFR heterodimerisation 
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under basal conditions. Furthermore, CD44 influences expression of both phosphorylated 
EGFR and HER2 but appears to influence EGFR in a more significant fashion. Our study 
thus adds to the growing understanding of ErbB associations and signalling mechanisms in 
our Tam-R cells. Interestingly, Ghayad et al. have also noted high levels of basal EGFR-
HER3 dimerisation in their tamoxifen resistant wtMCF-7 derived cell line CL6.8 (Ghayad, 
Vendrell et al. 2009). 
 
Other researchers have also noted the importance of the ErbB receptors in their models of 
tamoxifen resistance. Block et al. reported that their wtMCF-7 derived 4-OH-TAM model of 
resistance (MCF-7-TR) displays HER2 overexpression and EGFR was overexpressed in their 
T47D-derived model of tamoxifen resistance (T47D-TR) (Block, Grundker et al. 2012). 
Ghayad et al. showed that tamoxifen resistance in two of their wtMCF-7 derived cell lines 
(CL6.7 and CL6.8) was accompanied by activation of MAPK signalling and overexpression 
of EGFR and HER2 (Ghayad, Vendrell et al. 2009). Moreover, treatment with the MAPK 
inhibitor PD098059 restored endocrine response in both cell lines.  
 
Our study findings suggest that CD44 may act as a modulator of ErbB dimerisation and 
consequently modify signalling and function in Tam-R cells. This is supported by data from 
immunoprecipitation experiments which show that HA-induced CD44 activation leads to 
leads to preferential formation of CD44-EGFR and HER2-HER3 instead of EGFR-HER3 
heterodimers. This is particularly important in view of the evidence that HER2-HER3 
heterodimerisation has been linked to heregulin-induced gefitinib resistance (Hutcheson, 
Knowlden et al. 2007). 
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We also noted during immunoflourescence that although membrane HER3 co-localises with 
CD44, HER3 is also detectable in the nucleus. Adilakshmi et al. have described a nuclear 
HER3 variant (nuc-ErbB3) that results from alternative transcription in rat primary Schwann 
cells and contains a functional nuclear homing signal sequence which can bind to chromatin 
(Adilakshmi, Ness-Myers et al. 2011). Koumakpayi et al. have reported HER3 nuclear 
localisation in prostate cancer cell lines and specimens (Koumakpayi, Diallo et al. 2006). 
Nuclear localisation of HER3 has been reported in immortalised human breast cells and 
breast cancer cell lines as well (Offterdinger, Schofer et al. 2002). The exact function of 
nuclear HER3 in our model is not clear but there is a possibility that it may be involved in 
altering cellular behaviour via a genetic mechanism and this needs to be examined further.   
 
We have previously shown that HA stimulation of CD44 overexpressing Tam-R cells 
resulted in MAPK activation and increased migration. The data here suggest that the 
migratory response is mediated via the MAPK pathway. Interestingly, Lee et al. noted that 
bacteriophage hyaluronidase, HyIP, decreased breast cancer cell migration by inhibiting 
activation of MAPK suggesting a direct role of the MAPK pathway in stimulating migration 
(Lee, Moore et al. 2010). Our data also raises the possibility that these events may occur as a 
consequence of HA/CD44-induced ErbB transactivation, possibly involving both EGFR and 
HER2. However, this needs to be investigated in more detail.  
 
The interplay between CD44, HA and ErbB receptors and the effect on migration as noted in 
this study are depicted in a schematic form in Figure 3.22.  
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Figure 3.23 Schematic diagram of interplay between CD44, HA and ErbB receptors 
and the effect on migration in Tam-R cells as noted in this study
The interplay between CD44, HA and ErbB receptors in Tam-R cells as identified in this
study is schematically depicted above. Immunoprecipitation studies have shown that CD44-
HER2 and HER3-EGFR dimerisation is predominant in Tam-R cells under basal conditions
as discussed in Section 3.4.5 (A). HA-CD44 interaction leads to changes in ErbB
dimerisation and signalling with a resultant effect on cell phenotype (B). CD44-EGFR and
HER2-HER3 dimerisation is augmented following HA treatment as discussed in Section
3.4.5. Significant increase in the migratory phenotype of Tam-R cells is noted following HA
treatment which appears to be mediated primarily via MAPK with a partial role of HER2
and EGFR as discussed in Section 3.4.4. Adapted from Linggi et al. 2006, Zoller 2011.
(NB: CD44 is known to associate with ErbB members via its transmembrane domain and
the extracellular domain in ErbB receptors is responsible for ErbB-ErbB dimerisation.)
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3.4.7 Conclusion 
CD44 is co-localised with HER2 and HER3 in Tam-R cells, influences basal ErbB signalling 
and HA-mediated CD44 activations results in alteration in ErbB dimerisation patterns.
  
 
Chapter Four 
 
Discussion 
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4.1 GENERAL DISCUSSION 
4.1.1 Resistance to Endocrine Therapy 
Use of endocrine therapy has led to definite improvement in the prognosis of breast cancer 
worldwide. However, de novo and acquired resistance to currently available endocrine agents 
continues to be a significant limiting factor in further improving outcomes. Unfortunately, 
development of resistance often presents as metastatic disease and is accompanied by several 
features that indicate a more aggressive disease pattern compared to the primary malignancy. 
The prognosis associated with disease relapse following development of acquired resistance 
to anti-hormonal therapy is very poor. As such, there has been increasing scientific interest in 
understanding and elucidating the mechanisms of acquired resistance in an effort to identify 
novel targets and therapeutic approaches that might overcome resistance. 
 
4.1.2 Use of In Vitro Models of Resistance 
Various scientific strategies have been employed in an effort to understand the pathways 
involved in resistance. Of these, in vitro cell models continue to be one of the most frequently 
used tools in the laboratory for elucidating the molecular basis for resistance. Although 
simplified compared to in vivo models, they allow a cost-effective strategy for initial 
elucidation of the mechanisms underlying therapeutic resistance. They are especially valuable 
as they lend themselves well to various manipulations at the gene and protein level, and allow 
rapid testing of novel drugs, especially with regard to their modes of action and anti-cancer 
activity. Cell models of acquired tamoxifen resistance have been developed primarily through 
use of three main ER-positive cell lines, namely, wtMCF-7, T47D and ZR75-1 which 
respond well to oestrogen stimulation as well as anti-hormonal suppression (Wong and Chen 
2012). The predominant strategy has been long-term culture of these cells in the presence of 
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anti-hormonal drugs until sustained growth is achieved despite the presence of the drug, thus, 
signalling the development of acquired resistance. Our group has developed several cell 
models based on wtMCF-7 and later T47D cells which `have been used to study signalling 
and function in the setting of endocrine resistance and these have provided some interesting 
insights into the mechanisms underlying endocrine resistance. 
 
4.1.3 Current Evidence from Cell Models 
Data from several studies modelling acquired endocrine resistance with in vitro breast cancer 
cell lines have suggested that prolonged exposure to active endocrine agents result in 
induction of growth factor mediated signalling pathways which eventually promote an 
endocrine-resistant state. Increased EGFR expression has been noted in wtMCF-7 based cell 
models of tamoxifen resistance (Ignatov, Ignatov et al. 2009). Studies from our group have 
also shown that Tam-R cells exhibit EGFR and HER2 overexpression at both mRNA and 
protein level compared with endocrine-sensitive wtMCF-7 cells (Knowlden, Hutcheson et al. 
2003). This growth factor receptor induction can be noted even in the drug responsive phase 
of the development of resistance indicating that this is an early phenomenon in the 
development of resistance. Further evidence supporting the crucial role of growth factor 
signalling in resistance comes from transfection studies whereby overexpression of growth 
factor receptors in hormone-sensitive cells have rendered them endocrine-resistant. For 
example, transfection of wtMCF7 cells with HER2 was accompanied by a pattern of 
tamoxifen-resistant tumourigenic growth (Benz, Scott et al. 1992). Another observation that 
supports this concept is that signalling pathways that are downstream to these receptors are 
also significantly upregulated following development of endocrine resistance. Elevated levels 
of phosphorylated MAPK and upregulated Src-kinase activity have been noted in models of 
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tamoxifen resistance  (Hiscox, Jiang et al. 2006; Knowlden, Jones et al. 2008; Morgan, Gee et 
al. 2009). Downregulation of negative regulators of these downstream pathways has also 
been noted. For example, expression of Caveolin-1, a negative regulator of the Ras-MAPK 
pathway which is encoded by a tumour suppressor gene, is markedly decreased as a stable 
tamoxifen-resistant phenotype develops in wtMCF-7 cells treated with 4-OH-TAM (Thomas, 
Hutcheson et al. 2009). Thus, there is reliable evidence that supports the critical role of 
growth factor receptors, especially receptor tyrosine kinases (RTKs) such as members of the 
ErbB family, in mediating signalling events that underpin the development of acquired 
resistance. 
 
Apart from inducing signalling changes, induction of growth factor receptors also contribute 
to the development of an aggressive cell phenotype accompanied by enhanced migratory 
potential and invasiveness. An eight-fold increase in basal motility has been observed by  
Zhou et al. in their model of tamoxifen-resistant wtMCF-7 cells (Zhou, Zhong et al. 2012). 
Our tamoxifen-resistant Tam-R cells also display a dramatic and significant increase in 
invasiveness and motility compared to the wild type MCF-7 cells (Hiscox, Morgan et al. 
2004). Tam-R cells also grow as loosely packed colonies with loss of cell-cell junctions and 
exhibit altered morphological characteristics which resemble cells undergoing epithelial-to-
mesenchymal transition (EMT). Similar changes in phenotype with clear features of EMT 
have also been noted by Kim et al. in their TAM-R-MCF-7 model of tamoxifen resistance 
(Kim, Choi et al. 2009). Mediators such as Src kinase have been implicated in promoting this 
aggressive phenotype noted in endocrine resistance (Hiscox, Morgan et al. 2006). 
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Knowledge of these underlying signalling and phenotypic changes has allowed identification 
of potential therapeutic targets through which endocrine resistance might be overcome along 
with suppression of the resulting aggressive cellular characteristics. Such approaches have 
met with partial success in the laboratory setting. However, although results in cell models 
have been quite encouraging, use of such strategies in the clinical setting have yielded mixed 
results. This is evident, for example, when the preclinical and clinical experience with 
gefitinib is considered. As discussed earlier, gefitinib was the first agent with selective 
activity against the tyrosine kinase domain of EGFR. There was encouraging preclinical 
evidence that supported the possibility that gefitinib would be a potent drug in the setting of 
endocrine resistance. Gefitinib was shown to improve the anti-proliferative ability of 
tamoxifen and prevent development of tamoxifen resistance in both cell and animal models 
of ER-positive breast cancer (Gee, Harper et al. 2003; Shou, Massarweh et al. 2004). 
Gefitinib was also shown to eliminate ER-HER2 cross-talk and restore tamoxifen sensitivity 
in a model of ER/HER2-positive breast cancer exhibiting de novo tamoxifen resistance 
(MCF-7/HER2-18) as well as restore tamoxifen sensitivity in a model of acquired tamoxifen 
resistance, namely T47D-TR (Shou, Massarweh et al. 2004; Block, Grundker et al. 2012). 
Furthermore, gefitinib was shown to inhibit the enhanced invasive and motile phenotype 
noted in vitro in models of acquired tamoxifen resistance (Hiscox, Morgan et al. 2004). These 
and other studies led to the initiation of several trials which sought to investigate the benefit 
of gefitinib in breast cancer including trials of gefitinib monotherapy. Interestingly, the 
results from trials evaluating gefitinib monotherapy have shown contrasting results. For 
example, whilst Gutteridge et al. found that gefitinib at a dose of 500 milligram per day was 
well tolerated with a CBR of 53.6% in tamoxifen resistant breast cancer in their phase II 
trials, Green et al. reported that gefitinib at the same dose had no clinical benefit in hormone-
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resistant advanced breast cancer (CBR 0%) in a multicentre phase II trial (Green, Francis et 
al. 2009; Gutteridge, Agrawal et al. 2010). Trials evaluating the benefit of combinational 
therapy of gefitinib with anastrozole have also reported conflicting results. For example, 
whilst Cristofanilli et al. reported that the combination of anastrozole and gefitinib is 
associated with an improvement in PFS (14.7 versus 8.4 months) over the combination of 
anastrozole and placebo in a randomised phase II trial, Carlson et al. did not find any 
additional benefit of the combination of anastrozole and gefitinib over anastrozole 
monotherapy (Cristofanilli, Valero et al. 2010; Carlson, O'Neill et al. 2012). Osborne et al. 
have noted an improved PFS in patients with ER-positive MBC receiving a combination of 
gefitinib and tamoxifen except patients who progressed or recurred following prior AI 
therapy (Osborne, Neven et al. 2011). Overall, despite encouraging preclinical data, the 
results of trials investigating gefitinib have yielded less promising results than expected. This 
illustrates the urgent need to identify further pathways that influence hormonal resistance and 
develop novel therapeutic approaches. 
 
4.1.4 CD44 – RTK Interplay 
Towards this end, we used Affymetrix® microarray analysis to screen various breast cancer 
cell models of resistance. This showed upregulation of CD44 in Tam-R cells compared to 
wtMCF-7 cells and this observation was later validated by RT-PCR studies. There is 
emerging evidence of the role of CD44-RTK interplay in influencing signalling and function 
in several malignancies including breast cancer and in the setting of endocrine resistance. 
CD44 can interact with and modulate the activity of various RTKs including Met, VEGFR-2, 
HER2 and EGFR (Singleton, Salgia et al. 2007; Tremmel, Matzke et al. 2009; Gordin, Tesio 
et al. 2010; Hatano, Shigeishi et al. 2010). We were particularly encouraged by published 
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links between CD44 and ErbB family receptors which have been shown to play an important 
role in various aspects of breast cancer progression. Overexpression of these receptors has 
also been linked with poor response to endocrine therapy (Newby, Johnston et al. 1997; 
Horiguchi, Koibuchi et al. 2005; Folgiero, Avetrani et al. 2008; Spears, Taylor et al. 2011).  
In fact, even in our Tam-R model of tamoxifen resistance, overexpression of ErbB receptors 
have been linked with an autocrine growth pathway (Knowlden, Hutcheson et al. 2003). 
 
Various mechanisms via which CD44 can influence signalling and activation of ErbB 
members have been described in breast and other tissues. One of the mechanisms implicated 
in this process involves direct interaction between CD44 and ErbB family receptors. CD44 
co-localises with ErbB receptors and has been co-immunoprecipitated with HER2 and EGFR 
in four different breast cancer cell lines namely wtMCF-7, MDA-MB-231, MDA-MB-435, 
and MDA-MB-436 (Wobus, Rangwala et al. 2002). CD44-HER2-EGFR complex formation 
has been demonstrated in cytology specimens from patients with metastatic breast cancer 
(Wobus, Rangwala et al. 2002). Another mechanism whereby CD44 transactivates ErbB 
receptors involves intracellular and extracellular intermediates. CD44-HA interaction can 
activate intracellular Src and phosphoinositide-3-kinase (PI3K) with consequent induction of 
HER2 and HER3 phosphorylation. This has been demonstrated in the TA3/St breast cancer 
cell line, where CD44-HA interaction sustains high levels of phosphorylated HER2, and 
blocking this interaction causes disruption of a complex containing HER2, CD44 and PI3K 
(Ghatak, Misra et al. 2005). CD44 can also activate ErbB receptors through extracellular or 
stromal intermediates such as the pro-form of heparin binding epidermal growth factor (HB-
EGF) which is further cleaved by matrix associated metalloproteinase 7 (MMP7) allowing 
HB-EGF to bind and activate  HER4 (Zoller 2011). 
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A further mechanism of ErbB transactivation involves HA-CD44 mediated alterations in 
ErbB dimerisation patterns and our study data supports the role of this mechanism in the 
setting of endocrine resistance. It has been shown in our Tam-R model that predominantly 
EGFR-HER2 and EGFR-HER3 heterodimers are seen basal conditions, but HER2-HER3 
heterodimers are not readily detectable (Knowlden, Hutcheson et al. 2003). Data from our 
study shows that HA-CD44 interaction induces HER2-HER3 heterodimer formation. This 
pattern of dimerisation has previously been implicated in heregulin-mediated gefitinib 
resistance in Tam-R cells (Hutcheson, Knowlden et al. 2007). Data from our study also 
shows that HA-CD44 interaction leads to preferential formation of CD44-HER2 rather than 
CD44-EGFR heterodimers noted in the basal state, a novel finding in the setting of tamoxifen 
resistance. This is particularly important as the predominant mechanism of ErbB activation 
involves dimerisation changes when activated by eleven known ligands which include 
epidermal growth factor (EGF), heparin binding EGF-like growth factor (HB-EGF), 
transforming growth factor alpha (TGF-α), Neuregulins 1-4 amongst others (Linggi and 
Carpenter 2006). The exact mechanism of alterations in ErbB dimerisation patterns noted in 
our study following HA treatment and/or CD44 knockdown in the absence of known ErbB 
ligands is not fully understood. The implications of these alterations in ErbB dimerisation 
patterns on ErbB signalling and cellular phenotype is not yet known and merits further 
investigation. 
 
CD44 has been further implicated in influencing other RTK pathways in the setting of 
endocrine resistance. Involvement of the insulin growth factor receptor, IGF-IR, in two 
models of tamoxifen resistance has been demonstrated by our group. A unidirectional IGF-
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IR/EGFR cross-talk mechanism has been found to be operational in Tam-R cells which 
directly influences EGFR signalling and cell growth. A similar mechanism has also been 
detected in T47D-R cells which is a tamoxifen-resistant cell line derived from the endocrine-
sensitive T47D cells (Knowlden, Hutcheson et al. 2005). CD44 interaction with Met has been 
noted in our wtMCF-7 derived model of fulvestrant resistance (Steve Hiscox, unpublished 
observations). Other ligands that interact with non-ErbB RTKs such as vascular endothelial 
growth factor (VEGF) and platelet-derived growth factor (PDGF) have also been associated 
with CD44 in breast cancer models. For example, significant alterations in gene and protein 
expression of apoptosis mediators such as VEGF and PDGF has been noted following 
stimulation by osteopontin, a CD44 ligand, in a murine model of breast cancer (Mi, Guo et al. 
2009).  Further investigation into the role of CD44-HA interaction on the signalling and 
function of RTKs would provide important clues to details of associated mechanisms. 
 
Data from our study shows significant overexpression of CD44 at both gene and protein level 
in the endocrine-resistant cells compared to the wild-type endocrine-sensitive cells. However, 
this does not contribute to the intrinsic adverse phenotype noted in these cells despite a 
suppressive effect of CD44 knockdown on EGFR, and to a lesser extent, HER2. The 
observations from our study have been further validated by in-house CD44s transfection 
experiments in wtMCF-7 cells showing minor induction of endogenous EGFR and HER2 
activity but no resultant change in downstream signalling or eventual cellular function 
(Appendix III; data provided courtesy of R. Bellerby). This is an interesting finding 
suggesting that mild to moderate suppression of ErbB activity does not affect basal function. 
This is somewhat surprising given that EGFR-mediated growth is considered to be the major 
mechanism accounting for the higher proliferative activity noted in Tam-R cells. One 
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possible explanation for this could be that the resistant cells manage to ‘switch’ to another 
signalling pathway that partially sustains growth despite some ErbB suppression (Sierra, 
Cepero et al. 2010). This ‘switching’ is noted long-term in most resistant cells where altered 
growth factor signalling sustains an adverse phenotype compared to the endocrine-sensitive 
cells. Another possibility is that ErbB suppression simply uncovers another signalling 
pathway that the cells routinely rely on to a lesser extent as compared to the primary ErbB 
pathway, but, is nevertheless able to sustain the adverse phenotype when partial ErbB 
suppression is seen. In fact, this highlights one of the major problems in overcoming 
resistance, namely, the ability of tumour cells to use alternative mechanisms to overcome 
anti-hormonal therapy. Breast cancer cells can overcome the ‘action’ of the drug via 
‘reactive’ mechanisms that can potentially override the growth suppressive effect of the drug. 
Some of these reactive mechanisms include oestrogen hypersensitivity via increased 
transcriptional activity of ERα, oestrogen independence, induction of growth factor signalling 
amongst others (Normanno, Di Maio et al. 2005).  
 
4.1.5 CD44 Overexpression in the Context of the Microenvironment 
The tumour microenvironment is increasingly being recognised as one of the vital elements 
of cancer development and progression. The breast microenvironment typically consists of 
the extracellular matrix (ECM) and various cell types present in the stroma such as 
fibroblasts, endothelial cells, adipocytes and immune cells along with their secretory 
products. It is now generally accepted that breast cancers sequentially progress through 
defined stages with initial epithelial hyperproliferation and progressing to in-situ, invasive 
and metastatic carcinomas and the tumour microenvironment has been shown to play an 
important role in each of these steps (Place, Jin Huh et al. 2011). There are various 
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mechanisms whereby the microenvironment influences various aspects of tumour progession. 
For example, malignant tissues contain abnormal fibroblasts which influence cancer cell 
growth and angiogenesis via secretion of factors such as stromal derived factor-1 and 
hepatocyte growth factor (Orimo, Gupta et al. 2005). One of the important mechanisms 
whereby the microenvironment impacts on cancer progression is by supplying cancer cells 
with ligands which can induce receptor activation and influence signalling and behaviour. In 
the context of our study, an important element of the breast cancer microenvironment is the 
presence of hyaluronic acid (HA). Data from our study shows that whilst CD44 
overexpression does not contribute to the endogenous aggressive phenotype seen in Tam-R 
cells, it significantly augments the cellular response to HA. This leads onto the hypothesis 
that the true implication of CD44 overexpression in tamoxifen-resistant cells is only revealed 
when the tumour microenvironment and the presence of exogenous ligands in the 
microenvironment with potential to activate CD44, such as HA, are considered. 
 
Indeed, even in the context of HA there is evidence, apart from our own data, to support the 
view that HA-CD44 interactions can have significant effects on cellular behaviour. Firstly, 
there is evidence to support that HA-CD44 interactions can promote aggressive phenotypic 
features in malignant cells. HA-CD44 interaction can alter membrane structure and promote a 
migratory phenotype by altering the actin cytoskeleton system (Bourguignon 2008). HA-
induced CD44 clustering has been shown to influence cellular invasion via accumulation of 
MMP9 at the cell surface (Peng, Su et al. 2007). Secondly, it has been shown that inhibition 
of HA activity can result in suppression of tumour progression and metastasis. For example, 
use of the HA inhibitor 4-methylumbelliferone showed clear inhibition of cell growth and 
motility in an in vivo model of breast cancer (Urakawa, Nishida et al. 2011). Thirdly, there is 
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evidence from clinical studies that show that HA expression is a strong and independent 
predictor for poor survival in breast cancer. For example, analysis of HA levels using a 
biotinylated HA-specific probe in 143 paraffin-embedded tumour samples of human breast 
carcinoma revealed that both the concentration of HA in peri-tumoural stroma and HA-
positivity in the tumour cells were strong negative predictors for overall survival (Auvinen, 
Tammi et al. 2000). Thus, it is very likely that CD44 overexpression may be of significant 
importance in an in vivo setting where HA is available in abundance. In our study, we have 
used exogenous hyaluronan to stimulate CD44 activation in Tam-R cells but validation of our 
findings in an animal model of endocrine resistance would give further valuable insights into 
the significance of CD44 overexpression in the presence of stromal ligands, and in particular, 
the presence of HA. 
 
It fact, it is possible that the degree of CD44 overexpression itself may be a poor indicator of 
drug response or prognosis until other factors in the microenvironment such as the 
concentration of stromal HA or the presence of other ligands is considered. One potential 
impact of the concentration of stromal HA could be in determining the exact phenotypic 
feature induced in the cancer cell. In other words, at certain concentrations of HA a 
proliferative phenotype may be induced whereas at other concentrations, a migratory 
phenotype may predominate. Such a differential response to ligands is seen in wound healing 
for example, where the concentration of PDGF regulates whether the mesenchymal cells 
develop a proliferative or migratory phenotype with a higher concentration favouring 
mitogenesis and proliferation (De Donatis, Comito et al. 2008). This might explain an 
interesting observation in our study which showed a profound impact of HA on migratory 
behaviour of Tam-R cells but there was little or no effect on proliferation. This could be 
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investigated further by performing growth assays in the presence of significantly higher 
concentrations of HA compared to our study. In this context, it is interesting to note that the 
primary sensors of chemoattractant ligand levels are RTKs and in particular EGFR. These act 
as signal transducers and as a relay mechanism that drives cellular decision about the final 
migration/proliferation switch (De Donatis, Ranaldi et al. 2010). Ricono et al. have 
demonstrated an EGFR-based mechanism whereby cell migration and invasion proceeds 
without any effect on primary tumour growth in an in vivo model of pancreatic 
adenocarcinoma (Ricono, Huang et al. 2009). Jeanes et al. have shown that that integrins 
exert differential control on normal human mammary epithelial cell proliferation and 
migration depending on the type of β-subunit present (Jeanes, Wang et al. 2012).  It is, 
therefore, an interesting possibility that varying concentrations of HA might have a 
differential effect on migration or proliferation and RTKs may be mediators of this process. 
This can be investigated further, for example, by determining HA concentration in tumour 
tissue and replicating those concentrations in experimental conditions in vitro. Another 
approach would be to analyse HA expression in tumour tissue, classify tumours into high- 
and low-HA groups and further assess ErbB expression levels and associated prognostic 
indices. 
 
Additional data from our group provides further evidence that lends credence to the idea that 
CD44 overexpression in tamoxifen resistance may be more relevant in the context of 
exogenous ligands present in the microenvironment. Our group has shown that CD44 
knockdown using siRNA significantly attenuates the activation of signalling and 
augmentation of cell growth, invasion and proliferation that is normally seen in Tam-R cells 
following treatment with the ErbB ligand, heregulin beta-1 (Appendix II; data provided 
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courtesy of L. Goddard and N. Jordan). Heregulins are known to be present in the tumour 
microenvironment and have been shown to influence tumour progression and spread. For 
example, breast cancer associated fibroblasts overexpress heregulin in contrast with 
fibroblasts found in benign breast tissue (Sadlonova, Bowe et al. 2009). Interestingly, a  study 
of clinical breast cancer specimens which looked at both stromal and epithelial heregulin 
expression found that only stromal heregulin levels correlated with outcome thus providing 
further evidence in support of our hypothesis  (Visscher, Sarkar et al. 1997). Overall, it 
appears likely that CD44 overexpression may be most relevant in an in vivo setting where the 
presence of ligands in the microenvironment may serve to augment cell signalling and 
behaviour via CD44-mediated pathways. 
 
 
4.1.6 Role of CD44 Isoforms 
Although the data here points to a role for CD44 in tamoxifen resistance, the fact that CD44 
may exist in several variant forms makes it challenging to understand the relative 
contribution of the different CD44 variants to the adverse phenotypic features seen in our 
model of tamoxifen resistance. Our siRNA approach used to suppress CD44 expression in 
Tam-R cells has been subsequently shown to result in knockdown of multiple CD44 isoforms 
including CD44v3 and CD44v6 (C. Smith and S.Hiscox, unpublished observations). Thus, 
there is a distinct possibility that several CD44 variants may collectively contribute to the 
HA-mediated signalling and functional changes noted in Tam-R cells, and, further work is 
ongoing in our laboratory to elucidate this in more detail. The role of variants is supported by 
studies that show variable influence of CD44s and the different variants on different aspects 
of tumour progression. For example, immunohistochemical staining of paraffin sections from 
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specimens of node-negative invasive breast carcinoma showed that CD44s appears to be a 
favourable prognostic indicator but there was no correlation between tumour progression and 
CD44v6 levels (Diaz, Zhou et al. 2005). Ma et al. also performed immunohistochemical 
analysis on primary breast cancer specimens and demonstrated that CD44v6 expression 
correlates with tumour size, nodal involvement and 5-year survival (Ma, Deng et al. 2005). 
Moreover, although the HA-binding ability is seen in all CD44 isoforms, the contribution of 
individual isoforms towards ErbB receptor dimerisation and/or activation is currently 
unknown. It is, therefore, possible that different CD44 isoforms or variants may play 
antagonistic roles.  Certain variants may contribute towards development of an aggressive 
phenotype whilst other variants may have a neutral or even an inhibitory role. There is 
published evidence that would support such a hypothesis and this includes studies which 
indicate a more significant role of CD44s over variant CD44 isoforms with regard to 
promotion of tumour proliferation and metastasis. HA stimulation of CD44s has been noted 
to mediate breast cancer cell adhesion, motility and invasion whereas HA stimulation of 
CD44 variants only regulates cell motility (Afify, Purnell et al. 2009). Induction of CD44s 
expression in wtMCF-7 cells using a tetracycline inducible system has been shown to result 
in breast tumour invasion and liver metastasis in vivo (Ouhtit, Abd Elmageed et al. 2007). 
Unfortunately, there is currently a lack of knowledge concerning the exact roles of the 
standard and CD44 isoforms with regard to their role in determining response to available 
endocrine agents in a clinical setting. This is an area where further research needs to be 
undertaken to achieve a more comprehensive understanding of the role of CD44s and variant 
isoforms. . 
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Further evidence of the potential relevance of CD44 variants clinically comes from a 
preliminary immunohistochemical study performed by our group in a series of patients with 
histologically proven breast cancer (Hiscox, Baruha et al. 2012). Tumour tissue available 
from 69 patients with breast carcinoma who received anti-hormonal therapy with tamoxifen 
at City Hospital, Nottingham was investigated using immunohistochemistry. This was 
performed on the paraffin-embedded tissue samples after staining for CD44v3 and a H-score 
between 1-300 assigned to each specimen as described in Section 2.5. Other CD44 isoforms 
were not tested. It was noted following statistical analysis that the time to disease progression 
(p-value = 0.017) and the time to death (p-value = 0.028) were both significantly lower in the 
group expressing higher CD44v3 levels (Appendix IV; data provided courtesy of N. Jordan, 
J. Gee and L. Farrow). 
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4.1.7 CD44, CSCs and Endocrine Resistance 
As discussed in Section 1.6.6, there is a current debate on the role played by breast CSCs, 
which express high levels of CD44, in promoting endocrine resistance in breast cancer 
(O'Brien, Howell et al. 2009). Breast CSCs are known to be ERα low or negative and ER 
expression is known to be the most consistent marker for response to endocrine therapy. It is 
therefore likely that breast CSCs exhibit de novo endocrine resistance. There is recent 
evidence implicating CSCs in the development of EMT and it is now widely accepted that 
development of endocrine resistance is accompanied by a transition to a mesenchymal 
phenotype with associated aggressive features (Hiscox, Jiang et al. 2006; Morel, Lievre et al. 
2008; Biddle and Mackenzie 2012). Interestingly, several mechanisms that are considered to 
be important in promoting the aggressive phenotype of breast CSCs, such as EGFR and 
HER2, are strongly implicated in endocrine resistance and are also pathways that are known 
to interact with CD44 (Farnie, Clarke et al. 2007; Duru, Fan et al. 2012). The recent evidence 
demonstrating presence of CD44-high circulating tumour cells (CTCs) with stem cell 
characteristics in patients with metastatic breast cancer makes the issue of the potential role 
of CSCs in resistance even more important in the clinical setting (Theodoropoulos, 
Polioudaki et al. 2010). Baccelli et al. noted the presence of metastasis initiating cells (MICs) 
amongst a population of CTC and furthermore demonstrated that these MICs expressed 
CD44 (Baccelli, Schneeweiss et al. 2013). Using EMT and stem cell markers including 
CD44, Barriere et al. showed that upto 39% of patients with primary breast cancer had CTCs 
with mesenchymal and stem cell properties (Barriere, Riouallon et al. 2013). Using flow 
cytometry and magnetic-activated cell separation, Wang et al. noted that nearly 19% of CTCs 
had features of CSC (Wang, Cao et al. 2012). It has also been shown that the proportion of 
CTCs with CSC features has a positive correlation with the stage of disease presentation 
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(Wang, Shi et al. 2012).  There is current debate as to the extent of the role of CSCs in 
promoting the development of resistance to endocrine agents. 
 
In fact, there is experimental evidence from cell models of tamoxifen resistance to support 
the hypothesis that tamoxifen-resistant cell lines have an enriched CSC population. In a 
model of tamoxifen resistance based on wtMCF-7 cells, tamoxifen-resistant cells showed 
enhanced mammosphere forming capacity compared to the endocrine sensitive cells, 
suggesting an increased CSC fraction in endocrine resistant cells (O'Brien, Farnie et al. 
2008). Liu et al. developed a model of acquired tamoxifen resistance from wtMCF-7 cells 
(TAMR-MCF7) and specifically investigated whether the resistant cells have stem cell 
properties (Liu, Zhang et al. 2013). They noted that their tamoxifen resistant cell line had 
enhanced mammosphere forming ability and tumourigenicity in nude mice. Moreover, their 
qPCR analysis revealed increased mRNA expression of several stem cell markers including 
SOX-2, OCT-4 and CD133 in the tamoxifen-resistant cells compared to the wild-type cells. 
They also noted significantly higher mRNA levels of Snail, vimentin and N-cadherin and 
reduced E-cadherin in the resistant cell line indicating features of EMT. Yun et al. have noted 
a link between Notch-4, which is known to play a key role in CSCs, and tamoxifen resistance 
in their model of acquired tamoxifen resistance (Yun, Pannuti et al. 2013). Whilst it appears 
quite plausible that tamoxifen-resistant cell lines have a higher proportion of cells with CSC 
characteristics, it is unclear whether the heterogeneity seen in these cell lines represents a 
population of cells derived solely from CSCs.  
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The results from our study which is based on a cell model of acquired tamoxifen resistance 
provides certain interesting insights into this. Our study results show that CD44 is 
overexpressed in acquired tamoxifen-resistant Tam-R cells compared to the tamoxifen-
sensitive wtMCF-7 cells. One possible explanation for this overexpression is that tamoxifen 
treatment of wtMCF-7 cells results in selective sparing of CSCs present in the wtMCF-7 cell 
population. This is entirely plausible as CSCs are known to have absent or low expression of 
ER and are known to be relatively resistant to chemotherapy and radiotherapy. Thus, whilst 
other ER-positive cells in the wtMCF-7 population are inhibited by tamoxifen, the CSCs may 
be inherently resistant to tamoxifen. This subselected population of CSCs may subsequently 
proliferate and lead to a heterogenous population of cells. In this context it is interesting to 
mention that there is evidence supporting the fact that CSCs can replicate the cellular 
hierarchy seen in parental tumours. Indeed, immunocytochemical analysis of CD44 
expression in Tam-R cells shows that the CD44 expression is heterogenous with some cells 
showing markedly elevated expression and others with little or no expression with a high 
proportion of cells staining positive. It is likely that most of the cells which are CD44 positive 
are not actually CSCs especially in view of the fact that upto 90% of Tam-R cells express ER 
positivity and there are similar levels of ER mRNA and protein between wtMCF-7 and Tam-
R cells (Hutcheson, Knowlden et al. 2003). To what extent these ER-positive Tam-R cells 
represent clonal populations derived from de novo tamoxifen-resistant CSCs is unclear at this 
stage. It is worthwhile discussing experimental strategies that can potentially be employed to 
explore this issue in more detail. One option would be to analyse the expression of other CSC 
markers such as CD24 and ALDH in Tam-R cells alongside CD44 using techniques such as 
immunofluorescence or immunoprecipitation. This would give an indication of the likely 
proportion of cells with CSC features amongst the heterogenous Tam-R cells. Another option 
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is to look at cells at the earliest stages of development of tamoxifen resistance such as after 4-
6 months of tamoxifen treatment of wtMCF-7 cells and compare the proportion of cells with 
CSC characteristics compared to basal wtMCF-7 cells. Cells with CSC characteristics can be 
selected from this population of cells exhibiting early tamoxifen resistance, using flow 
cytometry for example, and allowed to grow in similar conditions in parallel and features of 
cells derived can be compared with ‘normal’ Tam-R cells. One potential problem with this 
approach could be cell yield as cell numbers tend to be relatively low during this stage of 
culture of early Tam-R cells.  
 
4.1.8 Therapeutic Strategies against CD44 and HA 
Our data provides a rationale for therapeutically targeting CD44 in endocrine-resistant breast 
cancer. This is based on two main observations. Firstly, CD44 overexpression induces a 
significant migratory response in Tam-R cells in the presence of HA which is ubiquitous in 
the microenvironment in vivo. Secondly, CD44 can modulate the response of ErbB receptors 
which appear to play an important role in inducing and sustaining endocrine resistance. In 
particular, CD44 knockdown can attenuate HA-induced activation of ErbB signalling as well 
as reverse HA-induced HER2-HER3 dimerisation. Thus, CD44 knockdown in vivo may 
serve to not only reduce the responsiveness of endocrine-resistant cells to pro-migratory 
stimuli from the microenvironment, it may also attenuate ErbB-mediated augmentation of 
aggressive phenotypic features in these cells. Therapeutically targeting CD44 in this setting 
may thus serve to provide additional benefit along with current modalities of therapy. 
Although the use of CD44 as a target in breast cancer is probably not a novel idea, as far as 
we are aware our study is the first to directly implicate CD44 as a potential target in 
tamoxifen-resistant breast cancer. It is worth mentioning at this point that even if future 
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studies fail to show a direct functional relevance of CD44 overexpression in an in vivo or 
clinical setting, the finding of CD44 overexpression could still have two potential alternative 
applications, namely, as a diagnostic tool and also as a target for delivery of other known 
drugs directly to the CD44 overexpressing malignant cells. Indeed, HA has already been used 
as a carrier agent to deliver drugs to cells expressing high levels of CD44. For example, 
Cohen et al. tried a novel nanocarrier delivery system with HA for cisplatin therapy in breast 
cancer and reported improved tumour control and lower toxicity in vivo in a mouse model 
(Cohen, Cai et al. 2009).  
 
Interestingly, certain features about CD44 make it a good candidate as a feasible drug target. 
A ‘druggable’ target has been defined as a protein, peptide or nucleic acid with activity that 
can be modulated by a drug. This can consist of a small molecular weight chemical 
compound or a macromolecule, such as an antibody or a recombinant protein (Gashaw, 
Ellinghaus et al. 2012). An important feature of CD44 which lends itself well to targeting is 
the cell surface location. It is well known that a major feature that distinguishes target 
proteins which have successful drugs developed against them is their location in the cell. 
Bakheet et al. analysed the features of 148 human drug target proteins and 3573 non-drug 
targets to identify differences in their properties and noted that if a potential protein has a 
membrane location it makes them nearly twice as likely to be a successful drug target 
(Bakheet and Doig 2009). In fact, 60% of current drug targets are located at the cell surface 
(Overington, Al-Lazikani et al. 2006). CD44 also has a cytoplasmic domain which interacts 
with various intracellular signalling pathways and this allows targeting via smaller molecules 
which can cross the cell membrane. Another feature that favours CD44 is a fairly detailed 
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understanding of the three dimensional structure of the CD44 protein including details of the 
HA binding domain in humans (Teriete, Banerji et al. 2004). Moreover, reliable cell and 
tissue based assays are available against CD44 which allows monitoring of drug efficacy. 
CD44 has also been listed in the International Therapeutic Target Database 
(http://bidd.nus.edu.sg/group/ttd/ttd.asp) as a potential target.  
 
Various potential therapeutic approaches to CD44 have been examined in pre-clinical models 
and in a clinical setting. One approach that has been tried in the clinical setting is the use of a 
monoclonal antibody to target CD44. Rupp et al. reported the safety, pharmacokinetics and 
preliminary efficacy of bivatuzumab mertansine in patients with CD44v6-positive metastatic 
breast cancer in 2007 (Rupp, Schoendorf-Holland et al. 2007). Bivatuzumab mertansine is a 
tumour-activated prodrug conjugate which contains maytansinoid mertansine (DM1) linked 
to the humanised monoclonal antibody bivatuzumab, which recognises the variant domain 
(v6) of CD44v6 through disulphide bonds. DM1 is an analogue of maytansine and is a potent 
inhibitor of tubulin polymerisation causing microtubule disruption and resulting in a potent 
cytotoxic effect. Twenty-four patients were treated at eight different dose levels and 50% 
patients were noted to have disease stabilisation in the setting of heavily pre-treated 
metastatic breast cancer. However, nearly 75% patients experienced transient and mild skin 
disorders which are possibly explained by the high levels of CD44 expression present in 
normal skin. Unfortunately, due to one fatal case of toxic epidermal necrolysis (TEN) that 
occurred in another bivatuzumab study running in parallel on patients with head and neck and 
oesophageal squamous cell carcinoma, the clinical development of bivatuzumab mertansine 
was discontinued (Tijink, Buter et al. 2006). Another strategy to target CD44 is to 
competitively inhibit CD44 using proteins or peptides. This has been applied in a murine 
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model by Yu et al. who demonstrated induction of apoptosis in pulmonary metastases of 
parental TA3/St breast cancer cells with the use of soluble CD44 isoforms (Yu, Toole et al. 
1997). Inhibition of CD44 transcription or translation is an additional strategy. Salinomycin, 
an agent with potent anti-CD44 transcriptional activity, has been shown to demonstrate a 
definite anti-tumour effect in a murine model of breast cancer (Gupta, Onder et al. 2009). A 
further strategy that can be employed is to prevent CD44 activation by inhibiting HA binding 
to CD44. Small HA oligomers (6 to 20 monosaccharides) have been previously used to 
competitively inhibit HA-CD44 interaction in an in vitro model of breast cancer and this 
resulted in disassembly of CD44-HER2 complexes thus demonstrating the efficacy of this 
approach (Ghatak, Misra et al. 2005). Since the discontinuation of clinical trials on 
bivatuzumab mertansine, no other strategy has thus far been applied in a clinical setting. 
Although the fatal case of TEN was an unfortunate incident, it should not discourage from 
developing the concept of an anti-CD44 agent further. The main limitation appears to be the 
presence of CD44 in various human tissues including high levels in the skin. However, with 
further research it may be possible to clearly identify which CD44 isoforms predominate in 
various tissues. This coupled with a further understanding into the exact roles of the variants 
into various aspects of breast cancer progression may allow more specific targeting in the 
future.  
 
Another potential strategy that emerges from our data is the benefit of targeting HA directly 
in tamoxifen-resistant breast cancer. The main reasoning behind this is the evidence that HA 
can augment the migratory phenotype of Tam-R cells and also mediate CD44-ErbB 
interaction. The two primary approaches that have been tried in a pre-clinical setting include 
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enzymatic degradation of HA and reduction of HA production by inhibiting hyaluronan 
synthase (HAS).  Kerbel et al. have shown that HA degradation using hyaluronidase can 
reverse the intrinsic chemoresistance of intact murine EMT-6 mammary carcinoma spheroids 
(Kerbel, St Croix et al. 1996). Shuster et al. injected intravenous hyaluronidase into SCID 
(severe combined immunodeficiency) mice bearing xenografts of human breast carcinoma 
and noted that this was accompanied by decreased hyaluronan in the tumour specimens and a 
reduction in tumour volume of nearly 50% (Shuster, Frost et al. 2002). Inhibition of HAS 
through the use of siRNA-mediated silencing of the HAS2 gene has been shown to suppress 
the malignant phenotype of the invasive breast cancer cell line Hs578T (Li, Li et al. 2007). 
Thus, there have been some encouraging results from pre-clinical studies for the use of these 
strategies against HA but further work is needed before these can be translated into the 
clinical setting. 
 
4.2 STUDY LIMITATIONS 
Although novel and potentially exciting, the data here need to be interpreted cautiously in 
view of the study limitations. Our study uses an in vitro model of tamoxifen resistance and is 
limited by the drawbacks inherent in the use of such a model. The main limitation is that this 
study involves use of only one in vitro model of acquired tamoxifen resistance and validation 
in further models of resistance would help to further substantiate these findings and also 
potentially identify further anti-hormone specific CD44-mediated mechanisms and those 
generic to multiple forms of drug resistance. It is worth mentioning here that the importance 
of CD44 in other models of resistance is being explored through ongoing work in our 
laboratory. Indeed, overexpression of CD44 has also been noted in our Fas-R model of 
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fulvestrant (Faslodex®) resistance where it appears to stimulate migration (Rebecca Bellerby, 
unpublished observations). 
 
The use of in vivo models of acquired tamoxifen resistance would provide additional insight 
into the role of CD44 in endocrine resistance. For example, a potential strategy would be to 
establish xenografts using Tam-R cells and observe the effect of a CD44-neutralising 
antibody on the growth characteristics of the primary tumour and development of metastases. 
In vivo studies are especially important in terms of translational benefit especially if drug 
testing is being considered at a later date as these models help in determining dosage, 
pharmacodynamics and toxicity profiles.  
 
A further limitation includes the potential cross-inhibition of the siRNA technology used 
between the standard and variant forms of CD44 making it difficult to eliminate the role of 
variants in interpreting the data. Transfection studies using individual CD44 variants and 
standard form can help to identify and study the specific role of each in an in vitro setting. 
Moreover, due to resource constraints, further detailed elucidation of some of the interesting 
findings was not possible in this study but the additional experiments of interest and areas of 
potential research have been identified during the discussion in relevant sections. 
 
4.3 CONCLUSIONS 
A careful analysis of the results of this study allows the following conclusions to be reached:  
 CD44 is overexpressed at both the gene and protein level in acquired tamoxifen-resistant 
Tam-R cells compared to their endocrine-sensitive wtMCF-7 counterparts 
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 CD44 overexpression in Tam-R cells does not appear to influence their endogenous 
migration, invasion or growth 
 Overexpression of CD44 in Tam-R cells augments their sensitivity to hyaluronan with the 
resultant transactivation of ErbB members and development of a migratory phenotype 
 CD44 is co-localised with ErbB receptors in Tam-R cells and it can modulate ErbB 
dimerisation 
  
Discussion of the relevance of the results of this study in the overall context of published 
literature on endocrine resistance leads to further conclusions. Data from models of acquired 
endocrine resistance with in vitro breast cancer cell lines have established that prolonged 
exposure to active endocrine agents result in induction of growth factor mediated signalling 
pathways, especially RTKs, which contribute to the development of an aggressive cell 
phenotype accompanied by enhanced migratory potential and invasiveness which eventually 
promote an endocrine-resistant state. Knowledge of these pathways underlying signalling and 
phenotypic changes has allowed identification of potential therapeutic targets through which 
endocrine resistance might be overcome along with suppression of the resulting aggressive 
cellular characteristics. However, despite encouraging preclinical data, the results of trials 
thus far have yielded less promising results than expected. This illustrates the urgent need to 
identify further novel pathways that influence hormonal resistance and develop therapeutic 
approaches based on this understanding. Our study reveals the CD44 is overexpressed in the 
setting of tamoxifen resistance, but, the true implication of CD44 overexpression in 
tamoxifen-resistant cells is likely to be revealed only when the tumour microenvironment and 
the presence of exogenous ligands in the microenvironment with potential to activate CD44, 
such as HA, are considered. Our study also highlights the importance of CD44-ErbB 
197 
 
interplay but the implications of the alterations in ErbB dimerisation patterns on ErbB 
signalling and cellular phenotype is not yet known and merits further investigation. Although 
the data here points to a role for CD44 in tamoxifen resistance, the fact that CD44 may exist 
in several variant forms makes it challenging to understand the relative contribution of the 
different CD44 variants to the adverse phenotypic features seen in our model of tamoxifen 
resistance. Our study adds some insight into the debate on the role played by breast CSCs 
with high CD44 levels in promoting endocrine resistance in breast cancer but further 
investigation is needed prior to any definite conclusions. Our study results provide a rationale 
for targetting CD44 in tamoxifen resistance. However, this is currently of limited clinical 
relevance because of previous failure of bivatuzumab, but, identification of the predominant 
CD44 isoforms in different tissues and a development of a more detailed understanding of the 
exact roles of the variants in various aspects of breast cancer progression may allow more 
specific targetting in the future. Finally, although novel and potentially exciting, the data in 
our study needs to be interpreted cautiously in view of the study limitations.  
 
Overall, our study results support an emerging role for CD44 as a key element determining 
breast cancer progression in the setting of endocrine resistance where it may represent a 
potential therapeutic target. 
 
4.4 Future work 
To continue to explore the role of CD44 in endocrine resistance, further work needs to be 
undertaken and a consideration of the results of this study helps to identify promising future 
areas of work. The mechanisms underlying CD44 overexpression in Tam-R cells compared 
to wtMCF-7 cells can be elucidated further especially with regard to the individual 
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contributions of the different CD44 variants. In particular, the question of whether this 
overexpression is a result of subselection of CSCs needs to be explored in detail. The clinical 
implications of the CD44 overexpression noted in our preclinical model should also be 
subsequently explored in clinical specimens with particular emphasis on the prognostic 
significance of this overexpression preferably including analysis of the role of the different 
variants. Studies that compare CD44 expression before and after development of resistance 
would be particularly interesting. It would also be interesting to further explore the 
mechanisms via which HA promotes a migratory phenotype. Further investigation of this 
effect in an animal model, perhaps with the use of monoclonal antibodies, may provide 
additional supporting evidence of the merit of CD44/HA targeting in the setting of endocrine 
resistance. Another interesting area for future work is potential ability of CD44 to alter ErbB 
dimerisation patterns. This certainly merits a detailed look particularly with regard to the 
effect of these alterations on the cellular phenotype. Use of anti-ErbB agents including 
dimerisation inhibitors to explore this further may have significant translational benefit.  
 
Overall, the findings from this study need to be expanded by performing investigations in 
other models of endocrine resistance including animal models with particular emphasis on the 
role of the different variants. Translational clinical studies would also be helpful in further 
elucidating the role of CD44 in endocrine-resistant breast cancer.
  
 
 
Appendix 
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5.1 APPENDIX I: Affymetrix Analysis of RHAMM Expression in Tam-R Cells  
Affymetrix® microarray analysis was carried out to compare RHAMM gene expression 
levels between wtMCF-7 cells and Tam-R cells. Gene expression of RHAMM was noted to 
be higher in Tam-R cells compared to wtMCF-7 cells but statistical analysis using t-test 
revealed that trend was not statistically significant (p-value > 0.05/NS on t-test; Figure 
5.1A).  
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Figure 5.1 Affymetrix® microarray analysis of RHAMM expression in wtMCF-7 and
Tam-R cells
Affymetrix microarray analysis was performed using basal wtMCF-7 and Tam-R cells and
RHAMM expression evaluated in both these cell lines. Representative probeset results with
data presented as comparative mean log intensity  SD are shown above (p-value > 0.05/NS
on t-test; A). Data provided courtesy of J. Gee and L. Farrow.
RHAMM
Probe ID
207165_at
wtMCF-7 Tam-R
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5.2 APPENDIX II: CD44 Suppression Attenuates Heregulin-induced Signalling and 
Invasive Phenotype in Tam-R Cells. 
The role of stromal ligands and their effect in the setting of CD44 overexpression in Tam-R 
cells was further investigated using the ErbB ligand heregulin beta-1 (HRG-β1). Expression 
of p-EGFR and p-HER2 and associated downstream signalling components, namely p-
MAPK, p-Akt, p-Src and p-FAK, was compared between Tam-R cells transfected with 
CD44-siRNA and compared with NT-siRNA transfected Tam-R cells. Treatment of NT cells 
with HRG-β1 resulted in activation of p-EGFR and p-HER2. There was also associated 
activation of p-MAPK, p-Akt, p-Src and p-FAK (Figure 5.2A). However, in CD44-siRNA 
transfected Tam-R cells there was significant attenuation of the signalling response to HRG-
β1 (Figure 5.2A). There was a particularly marked attenuation of p-EGFR signalling.  
 
The effect of CD44 knockdown on HRG-β1 response in Tam-R cells was also investigated 
from a functional standpoint. Invasion assays were set up using Tam-R cells treated with NT-
siRNA and CD44-siRNA in the presence and absence of HRG-β1. Knockdown of CD44 
expression significantly attenuated heregulin-induced invasion in Tam-R cells (Figure 5.2 
B). 
 
Overall, CD44 suppression through CD44-siRNA significantly attenuates heregulin-induced 
signalling and invasive phenotype in Tam-R cells. 
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Figure 5.2 CD44 suppression attenuates heregulin-induced signalling and invasive 
phenotype in Tam-R cells.
Tam-R cells were treated with NT-siRNA (NT) or CD44-specific siRNA (CD44-siRNA) 
prior to treatment with the ErbB ligand, heregulin-beta1 (HRG- β1). On Western blotting, 
HRG- β1 promoted phosphorylation of EGFR and HER2 and associated downstream 
signalling pathways in NT cells but this response was significantly attenuated in CD44-
siRNA transfected cells (A). On invasion assays, there was a marked increase in cell 
invasion following HRG- β1 treatment in NT cells which was significantly attenuated in 
cells treated with CD44-siRNA (p-value < 0.05 on t-test; B). Data provided courtesy of S. 
Hiscox, N. Jordan and L. Goddard.
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5.3 APPENDIX III: Transfection of CD44s in wtMCF-7 Cells promotes HA-induced 
ErbB Activation and a Migratory Phenotype 
To further investigate the role of CD44s in breast cancer cells, CD44s was transfected into wt 
MCF-7 cells which have minimal endogenous levels of CD44. This resulted in clear CD44s 
overexpression in the transfected cells compared to basal controls (Figure 5.3A). 
 
CD44s overexpression in wtMCF-7 cells did not lead to any increase in the basal activity of 
p-EGFR and p-HER2. However, the wtMCF-7 cells which overexpressed CD44s showed a 
marked increase in p-EGFR and p-HER2 activity following treatment with HA (Figure 
5.3B). This response was not observed in basal wtMCF-7 cells treated with HA. There was 
associated downstream activation of p-MAPK following HA treatment in CD44s transfected 
wtMCF-7 cells an effect which was not noted in normal wtMCF-7 cells. 
 
The effect of HA on the migratory capacity of wtMCF7 cells overexpressing CD44 was 
subsequently investigated using wounding assays. There was no migratory response noted in 
basal wtMCF-7 cells following HA treatment and this was in clear contrast to the marked 
migratory response noted in wtMCF-7 cells overexpressing CD44 when treated with HA 
(Figure 5.3C).  
 
Overall, CD44s overexpression in wtMCF-7 cells was accompanied by a marked activation 
of ErbB signalling and migratory phenotype following treatment with the CD44 ligand HA. 
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Figure 5.3A&B Overexpression of CD44 in wtMCF-7 cells augments their response to 
HA
The standard isoform of CD44 was transiently expressed in wtMCF-7 cells, designated as
MCF-7CD (A), and their response to HA subsequently examined using Western blotting and
wounding assays. HA induced EGFR, HER2 and MAPK activity to a much greater degree
in CD44-expressing MCF-7CD cells compared to wtMCF-7 cells (B). HA treatment of
CD44-expressing MCF-7CD cells promoted a significant enhancement of their migratory
capacity (C).
CD44
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wtMCF-7 MCF-7CD
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T-EGFR
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Figure 5.3C Overexpression of CD44 in wtMCF-7 cells augments their response to HA
The standard isoform of CD44 was transiently expressed in wtMCF-7 cells, designated as
MCF-7CD (A), and their response to HA subsequently examined using Western blotting and
wounding assays. HA induced EGFR, HER2 and MAPK activity to a much greater degree
in CD44-expressing MCF-7CD cells compared to wtMCF-7 cells (B). HA treatment of
CD44-expressing MCF-7CD cells promoted a significant enhancement of their migratory
capacity (C).
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5.4 APPENDIX IV: High CD44v3 Expression is Associated with Poor Outcome in 
Breast Cancer Patients following Tamoxifen Monotherapy  
To further examine the prognostic significance of additional CD44 family members, our 
group performed preliminary analysis of CD44v3 expression in a series of ER-positive 
clinical breast cancers. Other CD44 variants were not tested during this study. Tumour tissue 
available from 69 patients with breast carcinoma who received anti-hormonal monotherapy 
with tamoxifen at City Hospital, Nottingham was investigated using immunohistochemistry 
(Figure 5.4A). This was performed on the paraffin-embedded tissue samples after staining 
for CD44v3 and a H-score between 1-300 assigned to each specimen as described in Section 
2.4. Patients were divided into two groups for statistical analysis based on the median H-
score (55): High CD44 group (H-score >55) and Low CD44 group (H-score <55). Statistical 
analysis showed that the time to disease progression (p-value = 0.017) and the time to death 
(p-value = 0.028) were both significantly lower in the group expressing higher CD44v3 
levels (Figure 5.4B, C & D). CD44v3 was not found to have independent prognostic 
significance on multivariate analysis. This preliminary study shows the potential importance 
of CD44v3 expression in determining response to endocrine therapy in patients with primary 
breast cancer.  
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Patient characteristics 
(n=69)
Values
Mean age in years (range) 54 (25-77)
Menopausal status
Premenopausal 26
Postmenopausal 43
Tumour grade 
I 5
II 25
III 39
Progression
Complete response 6
Partial response 10
Static disease 14
Progression 39
Survival
Alive 5
Cancer related death 64
Low CD44 
group 
(H score < 55)
High CD44 group
(H score >55)
p-value
Median time 
to death in 
months 
(95% CI)
49 (15.5 – 82.5) 23 (8.8 – 37.1) 0.028
Median time 
to progression 
in months 
(95% CI)
9 (1.86 – 16.1) 4 (2.5 – 5.4) 0.017
A
B
Figure 5.4A&B Higher CD44v3 expression correlates with poorer response to
endocrine therapy
Tumour tissue available from 69 patients with breast carcinoma who received anti-
hormonal therapy with tamoxifen at City Hospital, Nottingham was investigated
using immunohistochemistry (A). Patients with low CD44 expression, as defined by
a H-score <55, had longer survival (p-value = 0.028) and slower progression of
disease (p-value = 0.017) (B). Comparative Kaplan-Meier curves detailing time to
disease progression and time to death from initiation of therapy between the high
and low CD44v3 expression groups are also shown (C,D).
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Figure 5.4C&D Higher CD44v3 expression correlates with poorer response to
endocrine therapy
Tumour tissue available from 69 patients with breast carcinoma who received anti-
hormonal therapy with tamoxifen at City Hospital, Nottingham was investigated
using immunohistochemistry (A). Patients with low CD44 expression, as defined by
a H-score < 55, had longer survival (p-value = 0.028) and slower progression of
disease (p-value = 0.017) (B). Comparative Kaplan-Meier curves detailing time to
disease progression and time to death from initiation of therapy between the high
and low CD44v3 expression groups are also shown (C,D).
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5.5 Appendix V: Summary of Therapeutic Strategies against CD44 and HA 
The potential therapeutic strategies against CD44 and HA as discussed in Section 4.1.7 are 
summarised in the table below (adapted from Zoller 2011):  
 
Table 5.1 Examples of therapeutic strategies against CD44 and HA 
 
Strategy Examples demonstrating benefit from use of strategy 
Anti-CD44 strategies 
Anti-CD44 antibody Bivatuzumab induced disease stabilisation in heavily pre-treated 
metastatic breast cancer (Rupp, Schoendorf-Holland et al. 2007) 
Competitive protein or 
peptide 
Transfection with soluble CD44 isoforms resulted in induction of 
apoptosis in a murine model (Yu, Toole et al. 1997) 
CD44 transcription 
inhibition 
Loss of CD44 gene function after salinomycin use in a mouse 
model (Gupta, Onder et al. 2009) 
Anti-HA strategies 
Inhibition of binding of 
HA to ligand 
Small HA oligomers inhibit interaction with HER2, ezrin and 
hsp90 in breast cancer in vitro (Ghatak, Misra et al. 2005) 
Enzymatic degradation 
of HA 
Use of hyaluronidase reverses chemoresistance of murine EMT-6 
mammary carcinoma spheroids (Kerbel, St Croix et al. 1996) 
Inhibition of HA 
production 
Inhibition of hyaluronan synthase 2 (HAS2) suppresses the 
malignant phenotype of breast cancer cells (Li, Li et al. 2007) 
Inhibition of receptor  
dimerisation 
Pertuzumab is currently being investigated in clinical trials of 
HER2 positive metastatic breast cancer 
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5.6 Appendix VI: Composition of Buffers and Solutions Used During this Study 
The following buffers and solutions were used during this study:   
 
1. RT-PCR: The buffers and solutions used for RT-PCR are listed in Table 5.1. 
2. SDS-PAGE and Western blotting: The buffers and solutions used in SDS-PAGE and 
Western blotting are listed in Table 5.2. The composition of protease/phosphatase 
inhibitors is listed in Table 5.3 & the BSA concentration guide used for the protein assay 
is listed in Table 5.4. 
3. ICC: The solutions and buffers used during Immunocytochemistry are listed in Table 5.5.  
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Table 5.2: Composition of buffers and solutions used in RT-PCR 
Buffer 
 
Volume Composition (Final concentration) 
PCR Buffer  
(10x) 
20ml TRIS-HCl base: 4ml of 0.5M stock (100mM) 
KCl: 10ml of 1M stock (500mM) 
MgCl2: 0.3ml of 1M stock (15mM) 
Gelatine: 0.1 ml 0f 2% stock (0.01% w/v) 
H2O: 5.6ml 
Tris-Acetate-
EDTA Buffer 
(50x stock) 
1000ml TRIS base: 242g (2M) 
Glacial Acetic acid: 57.1ml (1M) 
EDTA (0.5M stock): 100ml (0.05M) 
dH2O: Sufficient colume to make up to 1000ml 
pH = 8.3 
Sample Loading 
Buffer  
10ml Sucrose: 6g (60% w/v) 
BPB: 0.025g (0.25% w/v) 
dH2O 
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Table 5.3: Composition of buffers and solutions used in SDS-PAGE and Western 
blotting 
Buffer 
 
Volume Composition (Final concentration) 
Lysis Buffer  100ml TRIS base: 0.61g (50mM) 
EDTA: 0.19g (5mM) 
NaCl: 0.87g (150mM) 
Triton X-100: 1ml (1% v/v) 
Distilled water (dH2O): 99ml 
Add protease/phosphatase inhibitors before use 
Running Buffer 
(10x stock) 
1000ml TRIS base: 30.2g (0.25M) 
Glycine: 144g (1.92M) 
SDS: 1g (0.1% w/v) 
dH2O: 1000ml 
pH = 8.3 
Dilute 10x prior to use 
Laemmli Sample 
Loading Buffer  
(3x stock) 
10ml SDS: 0.6g (6% w/v) 
Glycerol: 3ml (30% v/v) 
TRIS Base: 3.6ml of 0.5M (180mM) 
BPB: 2mg (0.02%) 
DTT: 24 mg/ml  
dH2O 
Transfer Buffer  1000ml 0.25M TRIS base: 3.03g 
1.92M glycine: 14.4g 
20% methanol: 200ml 
dH2O: 800ml 
Tris-buffered 
saline (TBS) 
1000ml TRIS Base: 1.21g (10mM) 
NaCl: 5.8g (100mM) 
dH2O: 1000ml 
TBS-Tween  Add 0.05% Tween-20 to TBS 
 
214 
 
 
Table 5.4: Protease and phosphatase inhibitors used in SDS-PAGE and Western 
blotting 
 
 
Table 5.5: Standard curve volumes used for Bio-Rad Dc Protein Assay 
BSA concentration (mg/ml) BSA (µl)(1.45mg/ml stock) Cell lysis buffer (µl) 
0.00 0.0 50.0 
0.25 8.5 41.5 
0.50 17.5 32.5 
0.75 26.0 24.0 
1.00 34.5 15.5 
1.45 50.0 0.0 
 
Name of inhibitor Solvent Stock 
concentration 
Volume in 10ml lysis 
buffer (Concentration) 
Sodium Orthovanadate dH2O 100mM 200µl (2mM) 
PMSF Isopropanolol 100mM 100µl(1mM) 
Sodium molybdate dH2O 1M 100µl (10mM) 
Sodium fluoride dH2O 2.5M 100µl(25mM) 
Phenylarsine Chloroform 20mM 10µl (20µM) 
Aprotinin dH2O 2mg/ml 40µl (8µg/ml) 
Leupeptin dH2O 5mg/ml 20µl (10µg/ml) 
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Table 5.6: Composition of buffers and solutions used in Immunocytochemistry 
Buffer 
 
Volume Composition 
Phosphate-
buffered saline 
(PBS)  
5 litres NaCl: 42.5g  
Anhydrous di-potassium hydrogen orthophosphate: 7.15g 
Potassium hydrogen orthophosphate: 1.25g 
Distilled water (dH2O): To make up 5L volume 
Sucrose storage 
medium 
250ml Sucrose: 42.8g 
Magnesium chloride: 0.33g 
PBS: 250ml (see above) 
Glycerol: 250ml 
Store in -20°C prior to use 
PBS-Tween 500ml Tween-20: 100μl (0.02% v/v) 
PBS: 500ml 
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5.7 APPENDIX VII: Calculation Table Used for siRNA Experiments 
The following calculation table was used to calculate the appropriate volumes of each of the 
reagents used for siRNA transfection studies: 
 
Table 5.7 Chart used for preparing different volumes of siRNA transfection reagents 
Desired 
volume 
(ml) 
20µM 
stock 
(µl) 
A 
siRNA 
2µM 
A 
SF-
RPMI 
(µl) 
B 
SF-
RPMI 
(µl) 
B 
Lipid 
(µl) 
Total 
volume 
A+B 
(µl) 
To 
dilute 
1:5 add 
SFCS-
medium 
Final 
volume 
(µl) 
1 5 50 50 98.4 1.6 200 800 1000 
2 10 100 100 196.8 3.2 400 1600 2000 
3 15 150 150 295.2 4.8 600 2400 3000 
4 20 200 200 393.6 6.4 800 3200 4000 
5 25 250 250 492 8 1000 4000 5000 
6 30 300 300 590.4 9.6 1200 4800 6000 
7 35 350 350 688.8 11.2 1400 5600 7000 
8 40 400 400 787.2 12.8 1600 6400 8000 
9 45 450 450 885.6 14.4 1800 7200 9000 
10 50 500 500 984 16 2000 8000 10000 
11 55 550 550 1082.4 17.6 2200 8800 11000 
12 60 600 600 1180.8 19.2 2400 9600 12000 
13 65 650 650 1279.2 20.8 2600 10400 13000 
14 70 700 700 1377.6 22.4 2800 11200 14000 
15 75 750 750 1476 24 3000 12000 15000 
16 80 800 800 1574.4 25.6 3200 12800 16000 
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